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Abstract
Although colonisation with multiresistant Burkholderia cepacia is associated with
increased morbidity and mortality in cystic fibrosis (CF) patients, little is known
about the pathogenic mechanisms underlying B. cepacia infection. The aim of this
project was to determine factors which enable B. cepacia to colonise the CF lung and
to induce the marked inflammatory response characteristic of B. cepacia
colonisation.
This project has focused on the interaction of B. cepacia with neutrophils, the
predominant immune cell in CF. As B. cepacia is resistant to neutrophil non-
oxidative killing mechanisms, respiratory burst induction by B. cepacia was
investigated using another CF pathogen, Pseudomonas aeruginosa, as a comparison.
In general, non-opsonised CF isolates of B. cepacia induced little respiratory burst
activity. By contrast, P. aeruginosa strains induced a greater range of responses,
with a subset of strains inducing considerable activity. Opsonisation with specific
immune sera increased neutrophil responses to both B. cepacia and P. aeruginosa.
Flowever, in view of the cleavage of opsonins and opsonin receptors within the CF
lung, opsonisation may have little impact on host defences to B. cepacia within the
respiratory tract.
Lipopolysaccharide (LPS) extracted from B. cepacia was shown to upregulate
neutrophil expression of complement receptor 3 (CR3) and to prime respiratory burst
responses to fMet-Leu-Phe and to whole bacteria. Significantly LPS from the major
epidemic strain of B. cepacia, ET12, increased neutrophil respiratory burst responses
to P. aeruginosa but not to the ET12 strain itself. Thus it was speculated that
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B. cepacia may establish a foothold in the P. aeruginosa-infected lung by selectively
upregulating immune responses to P. aeruginosa.
In view of the development of environmental B. cepacia as biocontrol agents,
environmental and clinical isolates were compared for potential virulence
determinants. Few obvious differences were found between CF, non-CF clinical and
environmental strains. Significantly LPS from two environmental strains of
B. cepacia primed neutrophil responses to a similar degree as LPS from CF strains of
B. cepacia. A surprising result was that an environmental B. cepacia strain was less
effectively cleared in both CF and non-CF mice than the ET12 strain.
This project has provided evidence to support the hypothesis that B. cepacia
colonisation is associated with a marked and damaging immune response in CF
patients. The avoidance of respiratory burst induction may allow B. cepacia to
survive in the hostile milieu of the CF lung, whilst increased neutrophil CR3
expression may promote increased neutrophil recruitment to the lung. Furthermore,
neutrophil priming promotes increased damage to lung tissue by activated
neutrophils. Finally, the evidence for potential pathogenicity in environmental
B. cepacia supports calls for the tighter control ofB. cepacia biocontrol programmes,
including an application presently before the US Environmental Protection Agency
to release B. cepacia in large scale agricultural trials.
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Cystic fibrosis (CF) is the commonest life-threatening, autosomal recessive condition
in Caucasian populations, with an incidence of approximately 1 in 2500 live births,
thus affecting approximately 350 children born in the UK each year (Elborn, 1994).
CF presents as a multisystem disorder of exocrine organs, including the lungs,
gastrointestinal tract, pancreas, liver, vas deferens and sweat glands. Research into
the pathophysiological mechanisms underlying the many clinical manifestations of
CF has progressed rapidly since the identification of the CF gene in 1989. Based on
present evidence, disease is known to be a consequence of a defect in a single
protein, the cystic fibrosis trans-membrane conductance regulator (CFTR), which
functions as a chloride channel on the apical surface of secretory epithelial cells
within a number of organ systems. Until recently the outlook for affected children
was poor but sophisticated treatment regimes, including physiotherapy programmes,
the aggressive use of antibiotic therapy and careful nutritional management, have led
to many patients surviving into adulthood, with, for example, an average life
expectancy of 28 years of age in 1990 (Fitzsimmons, 1993).
1.1.1 Clinical presentation of CF
The basic defect in CF results in disordered fluid and electrolyte balance in secretory
epithelia throughout the body (Elborn 1994; Noone et al, 1994; Frizzell, 1995).
Although many organ systems are affected, lung disease accounts for the greatest
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morbidity and mortality, particularly in individuals surviving infancy (Welsh and
Smith, 1993). Classically, patients produce copious amounts of thick mucous within
the bronchioles. An inability ofmuco-ciliary clearance mechanisms to remove these
secretions leads to bacterial colonisation and the blockage of small airways by plugs
of mucous. Infective exacerbations result in inflammation and damage to healthy
lung tissue, leading to the development of bronchiectasis. Thus, patients enter a
vicious circle whereby lung damage leads to bacterial colonisation and hence more
lung damage. Clinically, CF pathophysiology is associated with slow respiratory
decline punctuated by periods ofmore rapid decline associated with infective
exacerbations, followed eventually by respiratory failure and death (Elborn, 1994).
Intensive physiotherapy may clear congested airways and aggressive antibiotic
therapy can slow disease progression but ultimately, treatment is unable to prevent
decline in the majority of patients. Lung transplantation has been successful in many
patients but is not suitable, nor available, for all and is itself associated with
significant mortality (Moss, 1995).
Gastrointestinal manifestations frequently play a role in CF disease progression.
Approximately 16% patients will present at birth with gastrointestinal blockage due
to thickened intestinal secretions, a condition termed 'meconium ileus'
(Fitzsimmons, 1993). Furthermore, approximately 90% of patients will show poor
pancreatic function termed pancreatic insufficiency (PI) due to the production of
viscid secretions which block pancreatic ducts (Kubesch et al, 1993). The
subsequent lack of pancreatic enzymes leads to digestive problems and children with
CF may present with failure to thrive (Fitzsimmons, 1993). Although pancreatic
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deficiency can be treated with enzyme supplementation, patients are at risk ofbeing
clinically undernourished, compromising their resistance to respiratory infection still
further. Indeed the minority of patients who are pancreatic sufficient (PS) generally
have a less severe course of lung disease than PI patients (Kubesch et al, 1993).
Other manifestations of CF include the production of a characteristic salty sweat,
which is the basis of the 'sweat test' used to diagnose CF, and male infertility due to
blocked or absent vas deferens. In over 10% of older patients, pancreatic damage
leads to diabetes, whilst 1-2% of patients develop cirrhosis as a result of chronic
damage within the liver (Fitzsimmons, 1993). Indeed, as radical new treatments are
developed for respiratory disease, it is likely that these latter gastrointestinal
manifestations will become more important.
1.1.2 Genetic basis of CF
In 1983, Quinton described a defect in CI" secretion at the apical surface of CF
epithelial cells and proposed that aberrant chloride channel production was
responsible for the many manifestations of CF disease. By 1985, investigation of
affected and non-affected siblings in families with CF by restriction fragment length
polymorphisms identified chromosome 7 as the site of the CF gene (Tsui et al, 1985).
This breakthrough was followed by the discovery of the putative CF gene in 1989,
using the combined techniques of linkage analysis and chromosome 'walking' and
'jumping' (Rommens et al, 1989; Riordan et al, 1989; Kerem et al, 1989).
Confirmation that this was the correct gene came with the identification of a mutant
form in CF patients, with approximately 70% of CF patients showing a three base
3
pair deletion, resulting in the loss of a phenylalanine residue at position 508, termed
the AF508 mutation (Riordan et al, 1989; Kerem et al, 1989).
The CF gene spans more than 250kb and includes 27 exons, coding for the 1480
amino acid protein termed CFTR (reviewed in Frizzell, 1995). Protein production
includes extensive mRNA splicing and complex post-translational modifications,
including glycosylation within the Golgi apparatus. Although the AF508 mutation is
by far the most frequent mutant allele found in CF patients, over 400 other mutations
have been described, including deletions, nonsense mutations encoding early stop
codons, frameshift mutations, splice mutations at intron/exon boundaries affecting
mRNA processing and missense mutations resulting in substitution of single amino
acids (Welsh and Smith, 1993). Individual mutations have varying effects on CFTR
production and function (Table 1.1); for example the AF508 mutation results in a
defect in post-translational modification and intracellular protein transport;
consequently CFTR is arrested and degraded within the endoplasmic reticulum and
not expressed at the cell surface (Tsui, 1995).
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Table 1.1 Classes of CFTR mutations (adapted from Welsh and Smith, 1993)
Class Defect Result Example Frequency PI/PS
I Protein
production
Production of no or truncated
protein
G542X 3.4 PI
II Processing Failure to traffic to the
correct cellular location
AF508 67.2 PI
III Regulation Mutations in the NBD
leading to altered interactions
with ATP and decreased
channel activity
G551D 2.4 PI
IV Conduction Mutations in MSD reducing
the rate of CI" flow through
the open channel
R117H 0.8 PS
Abbreviations used: PI, pancreatic insufficient; PS, pancreatic sufficient; NBD, nucleotide binding
domain; MSD, membrane spanning domain
1.1.3 CFTR structure and function
CFTR is structurally homologous to a family of proteins termed the transport
ATPases and comprises 1480 amino acids within 15 domains (Frizzell, 1995).
Twelve transmembrane domains are arranged as 2 hydrophobic regions which form
the basis of the ion channel. The remaining domains consist of a regulatory region
(R), containing several sites for phosphorylation, and two flanking ATP-binding
regions termed the nucleotide binding domains (NBD-1, NBD-2). Activation of
CFTR depends upon phosphorylation of the R region followed by binding of ATP to
one or both of the NBD regions. The open probability of CFTR is a simple saturable
function of ATP concentration with a maximum P0 of 0.44; thus even at saturating
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concentrations of ATP, CFTR is open for less than 50% of time (Venglarik et al,
1994).
The identification of CFTR and its gene has led to several attempts to link genotype
with the varied phenotypic presentations of the disease. In one large Canadian study,
the majority of PS patients were found to express at least one missense mutation
affecting amino acids within the transmembrane regions encoding the actual chloride
channel, presumably because such mutations are associated with some residual
CFTR function (Kristidis et al, 1992). By contrast null mutations, mutations
resulting in intracellular arrest of CFTR post-translational modification, such as
AF508, and missense mutations affecting the regulatory regions of CFTR were
usually associated with the more severe PI form of disease (Table 1.1).
Homozygosity for the AF508 mutation has also been shown to correlate with more
severe respiratory disease, as assessed by measurements of respiratory function such
as forced expiratory volume in 1 min (FEV,) or by age at colonisation with the CF
pathogen P. aeruginosa (Kubesch et al, 1993). However variation between patients
is too great to allow prognosis to be predicted for any individual from a knowledge
of their genotype.
Whilst knowledge of the genetic basis of CF has increased, our understanding of the
role of CFTR within respiratory epithelia is still far from complete, and is
complicated by the observation that CFTR in the lung is mainly expressed in the
submucosal glands rather than in respiratory epithelium per se (Engelhardt et al,
1992). Studies of ion transport in normal and CF epithelia have demonstrated that
CFTR functions both as a chloride channel and as a regulatory molecule for other
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transport proteins, including the Ca2+-dependent outwardly rectifying chloride
channel (ORCC) (Noone et al, 1994; Gabriel et al, 1993). Although a limited ability
to secrete CI" ions is characteristic of CF cells, the dominant abnormality of affected
epithelia is the hyperabsorption of Na+ ions mediated via a selective sodium channel
also situated on the apical surface of the epithelial cell (Noone et al, 1994). The net
result is a flow of ions, and hence fluid, out of the respiratory tract, leading to the
production of dehydrated viscid respiratory secretions. It seems likely that CFTR
may play a regulatory role with respect to the Na+ channel as well as ORCC (Noone
et al, 1994). CFTR has also been implicated in cAMP-dependent regulation of
endocytosis and exocytosis and in the acidification of intracellular organelles during
post-translational modification processes (Cheng et al, 1990; Barasch and Al-Awqati,
1993; Dunn et al, 1994). Thus a lack of CFTR may effect cellular processes other
than ion transport; for example, sialylation and sulphation of cell surface
macromolecules is reduced in CF epithelia (Al-Awqati, 1995).
1.1.4 The microbiology of CF lung disease
A striking feature ofpulmonary infection in CF is the limited spectrum ofmicrobial
pathogens involved, although this spectrum is evolving as more effective treatment
regimes have increased the life expectancy and hence the age range of CF patients.
In the earliest microbiological study ofpost-mortem cultures of lung tissue from CF
infants, Staphylococcus aureus was the predominant colonising organism, found in
12 out of 14 CF patients (Di Sant Agnese and Anderson, 1946). Subsequently
S. aureus and Haemophilus influenzae were recognised as important CF pathogens;
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however, improved antibiotic therapy against both of these organisms facilitated the
emergence ofP. aeruginosa as a major CF pathogen. Other respiratory pathogens
have been implicated in CF, including mycobacterial species, influenza and
respiratory syncytial viruses, and the fungal pathogen, Aspergillus fumigatus (Govan
and Nelson, 1993). In recent years, several previously uncommon respiratory
organisms have also emerged, including Stenotrophomonas (Xanthomonas)
maltophilia, Alcaligenes xylosoxidans (VuThien et al, 1996; Karpati et al, 1994),
Burkholderia (Pseudomonas) cepacia (Govan and Deretic, 1996) and Burkholderia
gladioli (Wilsher et al, 1997).
P. aeruginosa in CF
Although both S. aureus and H. influenzae are associated with repeated and often
severe infective exacerbations, P. aeruginosa is generally regarded as the major CF
pathogen, responsible for the greatest morbidity and mortality amongst CF
populations. Colonisation with P. aeruginosa usually occurs after a succession of
other CF pathogens and the incidence ofP. aeruginosa increases amongst CF
patients with age (Pedersen et al, 1986; Fitzsimmons, 1993). However a recent
epidemiological study demonstrated an incidence of 21% in patients under 1 year of
age, suggesting that P. aeruginosa colonisation in younger patients may be
increasing (Fitzsimmons, 1993).
Colonisation with P. aeruginosa is characterised by the dramatic adaptation of this
versatile opportunistic pathogen to the unusual environment of the CF lung.
P. aeruginosa is initially acquired in a non-mucoid form, expressing a range of
virulence factors including pyocyanin, elastase, exotoxin A and exoenzyme S.
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However, within a few months of colonisation, mucoid variants emerge as a result of
'muc' mutations in genes regulating the production of a mannuronic acid- and
guluronic acid-rich polysaccharide termed alginate (Govan and Deretic, 1996). The
resulting constitutive production of viscous exopolysaccharide, which gels rapidly in
physiological concentrations of electrolytes, leads to biofilm formation and allows
P. aeruginosa to evade host defences by surviving as microcolonies within an
alginate matrix. Conversion to mucoidy is usually associated with the down-
regulation of exotoxin production and with a switch from smooth to rough LPS,
reflecting the metabolic demands of alginate production. Furthermore, some mucoid
variants may also contain mutations rendering them extremely sensitive to the action
of P-lactam antibiotics. Such mutations give rise to increased outer membrane
permeability and thus improve bacterial survival by promoting nutrient uptake within
the nutrient-poor environment of the alginate biofilm. Any disadvantage conferred
by increased antibiotic sensitivity is outweighed by the protective effects of alginate,
which is largely impermeable to antibiotic therapy.
Why P. aeruginosa?
The ability ofP. aeruginosa to colonise the CF lung so effectively is surprising in
view of the rarity of P. aeruginosa lung infections in non-CF individuals, including
individuals with other chronic respiratory diseases. Recent developments have shed
some light on the possible mechanisms underlying this remarkable predilection.
P. aeruginosa has been shown both to bind to tracheobronchial mucin (Ramphal et
al, 1987) and to induce enhanced production ofmucin by human goblet cells (Jian-
Dong, 1996). Coupled with the inhibition of ciliary function by the P. aeruginosa
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exoproducts pyocyanin and rhamnolipid (Kanthakamur et al, 1993; 1994), such an
upregulation of human mucin production may lead to a further increase in the
quantity and viscosity of respiratory secretions. Binding of non-mucoid
P. aeruginosa to the epithelial glycolipid asialo GM, has also been suggested as an
initial step in colonisation processes (Krivan et al, 1988). In contrast to normal
epithelial cells, which express the sialylated form of GM,, CF epithelial cells have
been shown to express primarily asialo GM, (Imundo et al, 1995), possibly through
defective intracellular acidification of the trans Golgi network and subsequent
suboptimal activity of the sialyl transferases. Finally, recent studies have
demonstrated enhanced binding ofP. aeruginosa to both exposed basement
membrane components in damaged epithelia and to the apical surface of repairing
epithelial cells (de Bentzmann et al, 1996), suggesting that damage to the CF lung
initiated by earlier pathogens may expose suitable binding sites for P. aeruginosa
and hence promote colonisation. The increased binding ofP. aeruginosa to repairing
epithelial cells has been linked to the enhanced expression of asialo GM, on these
cells, particularly in CF epithelia, where asialo GM, levels are increased still further
(Girod de Bentzmann et al, 1995).
In an innovative study, Pier et al (1996) have suggested an alternative explanation for
P. aeruginosa colonisation in the CF lung. Cultured normal respiratory cells were
found to bind and internalise P. aeruginosa via intact CFTR, expressed at the cell
surface. The authors speculate that such uptake of P. aeruginosa, followed by
epithelial cell desquamation, protects the host from colonisation. In individuals
expressing no surface CFTR, P. aeruginosa would remain adherent to
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tracheobronchial mucin and thus set up a persistent infection. Interestingly, binding
appeared to be mediated by complete LPS, with rough mutants showing diminished
internalisation. Thus the conversion of P. aeruginosa from smooth to rough forms in
vivo may contribute to P. aeruginosa survival in the CF host. Indirect evidence to
support the hypothesis that P. aeruginosa internalisation via CFTR is protective, is
provided by the observation ofP. aeruginosa colonisation at an earlier age in
individuals homozygous for the AF508 mutation (Kubesch et al, 1993), since this
mutation is associated with intracellular arrest of CFTR trafficking to the cell surface.
Further studies will be required, however, to demonstrate whether patients expressing
non-functional CFTR at the apical cell membrane are less likely to be colonised by
P. aeruginosa than patients with no surface CFTR expression.
Recent interest has also focused on the possible role of 'defensins' present in
respiratory secretions in susceptibility to both S. aureus and P. aeruginosa infection.
'Defensin' is a general term for small cationic peptides possessing antimicrobial
properties and produced in a range ofbiological systems, including phagocytic cells
and epithelial secretions. Smith et al (1996) demonstrated intrinsic anti-pseudomonal
activity in airways surface fluid (ASF) secreted by primary cultures ofnormal human
respiratory epithelial cells, but not in ASF from cultured CF respiratory epithelial
cells. Activity was dependent on the salt content in ASF and could be restored in CF
ASF by dilution in hypotonic salt solutions. Goldman et al (1997) have identified a
(3-defensin, termed human P-defensin-1 (hBD-1) in ASF from a human bronchial
xenograft in athymic mice. Following cloning of the hBD-1 gene, molecular studies
identified expression of hBD-1 throughout respiratory epithelial in both CF and non-
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CF lungs and demonstrated that hBD-1 was solely responsible for ASF anti-
pseudomonal activity. However, as in the studies of Smith et al (1996), activity was
highly dependent on salt concentration, suggesting that the hypertonic nature of ASF
in CF individuals abrogates any hBD-1 antimicrobial activity and thus predisposes
the host to infection with P. aeruginosa.
In recent years, the emergence of new CF pathogens has provoked concern amongst
patients and carers in the CF community. Of these B. cepacia, which will be
discussed in detail in sections 1.3 and 1.4, has undoubtedly had the greatest impact,
both in terms ofpathogenicity and epidemic spread within and between CF centres.
However disturbing reports have recently emerged ofpotential epidemic spread of
Stenotrophomonas maltophilia and Burkholderia gladioli, associated with serious
infections in CF patients, (Karpati et al 1994; Wilsher et al, 1997; C Doherty,
personal communication). Ominously, both of these opportunistic pathogens display
the multiresistant phenotype, characteristic of many emerging infective organisms
during the latter years of the twentieth century
1.1.5 Recent developments in CF
CF mouse models
As CF is unique to man, basic research into the physiology and pathology of CF has
been hampered by the lack of a suitable animal model. However the discovery and
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cloning of the CF gene in humans (Riordan et al, 1989) and subsequently mice (Tata
et al, 1991) has enabled the development of a number ofmurine models of CF.
Depending on the nature of the underlying mutation, considerable differences in
survival and the severity of CF-type disease are apparent in the various mouse
models. For example the UNC knock-out mice express no normal CFTR and display
a severe phenotype with less than 20% of mice surviving beyond weaning
(Snouwaert et al, 1992). By contrast, the Edinburgh CF mouse, which was
developed by insertional mutagenesis, possesses a 'leaky' mutation due to exon
skipping and aberrant splicing (Dorin et al, 1992). The resultant low level production
of CFTR (-10% wildtype levels of CFTR mRNA expression; Dorin et al, 1994) is
associated with a milder phenotype and approximately 95% ofmice survive beyond
weaning, enabling further studies to be conducted. Recently mice have been
developed to mimic human CF more closely by replacement of murine CFTR with
actual human mutations. Examples include the Cambridge AF508 mouse (Colledge
et al, 1995) containing the commonest CF mutation and the G551D mouse (Delaney
et al, 1996) containing a CF mutation associated with less severe gastrointestinal
disease in humans.
All of the CF mouse models display disturbances in CFTR-dependent chloride
channel conductance in secretory epithelia consistent with human CF. Furthermore,
histopathological abnormalities similar to changes seen in human CF have been
demonstrated in the lungs, colon and vas deferens of several mouse models (Dorin et
al, 1992; Davidson et al, 1995; Colledge et al, 1995; Snouwaert et al, 1992).
Pathological changes in the lungs are generally mild, with few mice showing overt
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symptoms of respiratory disease when housed within laboratory conditions.
However, in an important study of the Edinburgh CF mouse, Davidson et al (1995)
provided the first evidence to indicate that a CF mouse model displayed greater
susceptibility to CF pathogens than non-CF mice. Following a single exposure to
either S. aureus or B. cepacia by nebulisation, clearance was impaired in CF mice
compared to non-CF littermates. Similarly, histopathological investigation indicated
that repeated exposure to S. aureus was associated with a higher incidence of
bronchiolitis, goblet cell hyperplasia or metaplasia, and mucus retention in CF mice
than non-CF mice, whilst repeated exposure to B. cepacia was associated with a
severe bronchopneumonia in some CF mice but none of their non-CF littermates.
The Edinburgh CF mouse model, which is bred onto an outbred murine strain (MF1),
displays considerable variability in the degree of histopathological abnormalities,
particularly in response to infection (Davidson et al, 1995; Dorin et al, 1992).
Reasons for such variability could include differences in the animals' environment,
including exposure to pathogens, or variable degrees of Teakiness' with respect to
CFTR expression in CF mice. In addition, the presence of modifying genetic factors
is likely to be of major importance in determining the phenotypic presentation of CF
(Erickson, 1996). Sibling studies in human CF have demonstrated marked
differences in severity between siblings presumably carrying the same mutations and
living within similar environments (Sing et al, 1982). Recently a study of a CF
mouse model outcrossed onto two different strains ofnormal mice, demonstrated
milder phenotypic expression of CF in C57B6/J mice compared to DBA/2J mice
(Rozmahel et al, 1996). The improved phenotype of C57B6/J mice may be related to
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the higher expression of an alternative chloride channel to CFTR in these mice rather
than DBA/2J mice. Further studies of different CF mouse models crossed onto
inbred strains ofmice will provide more information on the role of genetic modifiers
in the pathogenesis of both mouse and human CF.
Gene therapy in CF
Perhaps the most exciting prospect for the successful treatment of CF is the
development of somatic cell gene therapy. Since the discovery and cloning of the CF
gene in 1989, CF research has been characterised by the speed with which gene
therapy trials have been designed and initiated (Alton and Geddes, 1997). Already a
number of phase I clinical trials have been completed, using both adenoviral and
liposomal gene vectors to deliver the CF gene to nasal epithelia in adult CF patients,
with successful transfection of the CF gene in a majority of recipients and at least
partial correction of the electrophysiological abnormalities of CF in one third of
patients. (Knowles et al, 1995; Zabner et al, 1993; Crystal et al, 1994; Caplen et al,
1995). Trials of adenovirus vectors have also included administration to the lung and
have shown expression of CFTR in bronchial epithelium following CF gene
transfection (Crystal et al, 1994); however no data is available on the functional
correction of the CF defect due to the difficulty in assaying electrophysiological
parameters in the lower respiratory tract. Several other trials have been completed or
are in progress, including a large trial of liposomal delivery currently under way in
Edinburgh.
Although early results from human gene therapy have provided much
encouragement, problems remain with current gene therapy strategies. Firstly, even
15
if CFTR can be successfully replaced in the CF lung, it may be many years before
clinical benefit can be shown in patients. At present, ethical considerations restrict
trials to adult CF patients with established lung disease, but these patients are least
likely to benefit from gene therapy. Furthermore, it is not clear how best to assess
effectiveness of treatment, particularly as normalisation of electrophysiological
measurements and CFTR expression in the lower respiratory tract may have little
bearing on lung function, bacterial colonisation and patient well-being in the
presence of pre-existing lung disease. Ultimately, trials will be needed in children
prior to bacterial colonisation and the initiation of gross lung damage. Finally, the
efficacy and toxicity of the various delivery systems will need careful monitoring.
Adenoviral vectors have already been associated with dose-dependent toxicity in CF
patients due to the generation of a cytotoxic T cell response and cytokine induction.
Such an immune response may also be associated with a decrease in the effectiveness
of gene delivery (Crystal et al, 1994). Thus, the number of successful applications of
the adenoviral vector which can be made in any one patient is limited. Since CFTR
expression is only maintained for approximately 1 -3 weeks after transfection (Caplen
et al, 1995; Crystal et al, 1994) repeated applications will be needed to induce any
clinical benefit. Research is therefore under way to develop adenoviral vectors of
low immunogenicity, allowing repeated administration of the CF gene to the
respiratory epithelium. Alternatively, improved efficiency ofnon-toxic liposomal
vectors may provide the sustainable delivery system needed for successful gene
therapy (Alton and Geddes, 1997)
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In view of the many problems outlined above, research in CF mouse models may be
of crucial importance in expediting the development of efficient, safe and clinically
effective gene delivery systems in CF patients. Already functional correction of the
CF defect in the lower respiratory tract has been demonstrated in trials of gene
therapy in CF mice (Flyde et al, 1993; Alton et al, 1993; Dorin et al, 1996).
Significantly, in one study, correction of defective chloride transport was
demonstrated after only partial correction of the genetic defect with CFTR mRNA
levels of only 5% normal (Dorin et al, 1996). Trials of different delivery systems and
regimes in CF mice may also allow greater targeting of delivery strategies in human
CF. Recent trials of fetal gene therapy have also suggested that permanent clinical
benefit can follow limited expression of CFTR by fetal mice, following
administration of adenoviral vectors in utero (). Ultimately, studies in the CF mouse
will indicate whether gene therapy can prevent the development of lung damage in
response to bacterial pathogens in CF patients. The establishment of a CF mouse
model ofbacterial colonisation with common CF pathogens will greatly aid this
research (Davidson et al, 1995; Anonymous, 1995).
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1.2 Inflammation In Cystic Fibrosis
1.2.1 CF as an inflammatory disease
Lung damage in CF is characterised by widespread destruction of the lung
parenchyma giving rise to bronchiectasis. Bacterial colonisation alone is not likely
to provoke this damage, particularly as the majority of pathogens in CF are
associated with non-invasive disease. Instead, it would appear that chronic exposure
to bacterial pathogens leads to a marked and prolonged pulmonary immune response,
resulting in inflammatory damage to the lung parenchyma. Serum indicators of
inflammation including C-reactive protein (CRP), tumour necrosis factor a (TNFa)
and neutrophil elastase are consistently increased in CF patients and can be used as a
marker for imminent or ongoing infective exacerbations (Rayner et al, 1991; Norman
et al, 1991; Glass et al, 1988; Govan and Nelson, 1993). Patient response to
antibiotic therapy is associated with a drop in CRP levels, but not necessarily in
bacterial load, suggesting that sub-lethal doses of antibiotics suppress microbial
virulence which results in a 'damping down' of the immune response (Glass et al,
1988; Govan and Nelson, 1993). Similarly the pronounced humoral response to
colonisation with P. aeruginosa does not appear to be protective, but is associated
with a poorer prognosis for patients with higher immunoglobulin levels (Pedersen et
al, 1990).
These findings indicate a correlation between immune response and clinical
condition in CF, but do not prove that the immune response per se is responsible for
the damage seen in the CF lung. P. aeruginosa, for example, is known to produce a
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range of toxins that may act directly on the lung, including elastase which may
contribute to the destruction of the lung parenchyma (Suter, 1994). However studies
using bronchoalveolar lavage (BAL) have provided evidence of an excessive local
immune response within the CF lung. Concentrations ofpro-inflammatory cytokines
including IL-1, IL-6, IL-8 and TNFa are increased in BAL fluid from CF patients
compared to healthy controls (Bonfield et al, 1995b). Konstan et al (1994) describe
an increase in phagocytic cells and immunoglobulins in BAL fluid from CF
adolescents or adults with clinically mild disease. Significantly, neutrophils
accounted for 57% of inflammatory cells in CF BAL fluid, in contrast to the
predominance of macrophages seen in healthy lungs. These findings were
particularly interesting in view of the comparatively good clinical state of these
patients, and imply that low-level inflammation is occurring continuously, even in
CF patients with mild disease. Similarly Khan et al (1995) describe an augmented
neutrophil load in infants with CF, in the absence of bacterial infection. Noah et al
(1997) compared cytokine levels in BAL fluid from children with or without CF who
were undergoing bronchoscopy. Infection in CF patients was associated with higher
levels of the pro-inflammatory cytokine IL-8 in comparison to both infected and non-
infected controls. As IL-8 is a potent chemotactic agent for neutrophils, these results
imply that increased IL-8 production in CF may account for the excessive
recruitment of neutrophils to the CF lung in response to infection. The source of
increased IL-8 production could include alveolar macrophages, respiratory epithelial
cells and neutrophils already recruited to the lung. A deficiency in the production of
the anti-inflammatory cytokine IL-10 may also augment the release of pro¬
inflammatory cytokines (Bonfield et al, 1995a). Whether such a pro-inflammatory
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state arises from the fundamental defect in CFTR function in CF remains to be
determined. However, expression of CFTR in normal macrophages and the
observation of elevated IL-8 levels in CF alveolar macrophages would indirectly
support such an hypothesis (Clement, 1996; Khan et al, 1995).
Accumulated evidence indicates that neutrophils are the predominant inflammatory
cell in the CF lung and are implicated in lung damage through the release of tissue
damaging enzymes and other substances during activation. Thus, the following
sections will provide a general overview ofneutrophil activation processes and a
critical discussion of current views on the role ofneutrophil defence mechanisms in
CF lung disease.
1.2.2 Neutrophils: an overview
Neutrophils are large granular polymorphonuclear leukocytes, constituting up to 70%
of the white blood cell population in normal blood. Their primary function is the
phagocytosis and killing of extracellular pathogens; thus neutrophils are equipped
with an impressive array ofmicrobial killing mechanisms, including proteases, acid
hydrolases, iron-binding proteins, antimicrobial agents and enzyme systems to
generate highly toxic reactive oxygen species (ROS). Neutrophil activation
processes involve numerous stages, including upregulation of surface receptors,
recruitment to inflammatory sites, binding and phagocytosis of non-opsonised and
opsonised bacteria, degranulation into phagosomes and the extracellular environment
and the initiation of the ROS-generating respiratory burst. Neutrophils, particularly
if unactivated, are short-lived cells and normally undergo apoptotic cell death and
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clearance by macrophages, thus preventing the inappropriate release of tissue-
damaging enzymes and substances into the extracellular environment (Male et al,
1996).
The complex processes underlying neutrophil recruitment to inflammatory sites and
subsequent activation are mediated by a diverse range of receptor molecules
expressed at the neutrophil cell surface. Several classes of receptor have been
described, including the 7-transmembrane domain chemokine receptors, adhesion
mediating selectins and integrins, single domain immunoglobulin receptors and a
variety of structurally unrelated receptors recognising neutrophil priming agents such
as TNFa or GM-CSF. Individual neutrophil receptors will be discussed further in
the relevant sections below.
Neutrophil granules and their constituents
Granules within the neutrophil cytoplasm act as an intracellular store for many of the
receptors, inflammatory mediators and antimicrobial systems deployed by
neutrophils during migration, phagocytosis and bacterial killing. At least 4 granule
subtypes have been identified on the basis of size, contents, density and
electrophoretic properties, but others may yet be described (Boxer and Smolen, 1988;
Borregaard et al, 1993; Sengelov et al, 1992). Degranulation, the process whereby
granules discharge their contents by fusing with the plasma membrane or a
developing phagosome, is under precise control, and can be initiated by a range of
stimuli including chemoattractants, neutrophil priming agents, bacterial products
such as lipopolysaccharide, and the phagocytosis ofbound microorganisms. Granule
fusion with the plasma membrane results in extracellular release of granule contents
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(exocytosis), as well as an upregulation of specific cell surface receptors stored
within the membrane of each granule subtype. Fusion with the phagosome results in
the release of antimicrobial compounds into the immediate vicinity of an ingested
microorganism, forming a phagolysosome.
Mobilisation of each granule subtype is regulated independently, reflecting the
diverse functions of granular constituents and the potential for harm should toxic
substances be released inappropriately (Boxer and Smolen, 1988; Borregaard et al
1993). Table 1.2 summarises the contents of the four main granule subtypes
described to date. Azurophil (primary) granules are large granules formed early in
neutrophil development. Many of the most toxic components of the neutrophil
antimicrobial armoury are stored within azurophil granules, which are mobilised late
in activation processes and fuse primarily with the phagosome to form the
phagolysosome; hence azurophil granules can be regarded as the classic lysosome.
Specific (secondary) granules are large granules which are formed later in neutrophil
development and contain a range of substances involved in neutrophil recruitment
(eg: integrins, FMLP receptors), the initiation of an inflammatory response (eg:
complement activator, monocyte chemoattractant) and antimicrobial activity (eg
lysozyme, cytochrome b558, lactoferrin). Degranulation of specific granules occurs
more readily than azurophilic granule mobilisation, and may be important in
neutrophil chemotaxis, mobilisation of inflammatory mediators, and in preparing the
neutrophil to mount an effective respiratory burst against ingested microorganisms
(Boxer and Smolen, 1988; Borregaard et al, 1993). Tertiary granules are smaller
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Table 1.2 Neutrophil granules and their constituents. (Adapted from Boxer and
Smolen, 1988; Borregaard et al, 1993).
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readily mobilisable granules containing gelatinase as well as complement receptor 3
(CR3) and receptors for formylated peptides (FMLP-R). Finally, secretory vesicles
are small endocytic vesicles characterised by latent alkaline phosphatase activity and
containing CD66, CR3, FMLP receptors and cytochrome b55g. Mobilisation of
secretory vesicles occurs early in response to low doses of chemoattractants and is
important in neutrophil recruitment to inflammatory sites (Borregaard et al, 1987;
1993; Sengelov et al, 1996).
Neutrophil recruitment
Neutrophil migration from the circulation to an inflammatory site depends upon the
co-ordinated expression of several adhesion molecules on neutrophil and endothelial
cell surfaces. Initial adherence ofneutrophils to the endothelium is mediated by
selectins which facilitate a transient 'rolling' adhesion of neutrophils along the
endothelial surface (Condliffe et al, 1996). Neutrophil arrest and firm adherence,
however, is promoted by the neutrophil (32 integrin molecules, particularly
complement receptor 3 (CR3, CD1 lb/CD18) and lymphocyte function associated
antigen 1 (LFA-1: CD1 la/CD18), which bind to members of the intercellular
adhesion molecule family (ICAM-1, ICAM-2) expressed on endothelial cells.
Adherence is followed by diapedesis between endothelial cells and migration to the
inflammatory focus.
The process of neutrophil chemotaxis is initiated by the release of chemoattractants
(chemokines) at the site of inflammation. These chemotactic factors diffuse into the
local circulation and act on both circulating neutrophils and endothelial cells to
promote neutrophil adherence. Neutrophil chemokines include small bacterially-
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derived formylated peptides, platelet activating factor (PAF), complement
component C5a and the cytokine, IL-8; all ofwhich bind to specific receptors
belonging to the 7-transmembrane-domain G-protein-linked family (Hallett and
Lloyds, 1995). Receptor occupancy and G-protein activation ultimately trigger a rise
in intracellular Ca2+ concentrations ([Ca21],), which in turn initiates actin
polymerisation and cytoskeletal rearrangements (Bokoch, 1995; Chen et al, 1996).
Alterations in endothelial cells are manifest as an increase in the expression of
selectins and ICAMs, whilst neutrophil exocytosis ofnon-azurophilic granules
results in an increased expression of several cell surface markers, including CR3.
Once adherent, neutrophil forward motion through the endothelium is facilitated by
actin polymerisation and CR3 ligand-binding primarily at the leading edge of the
neutrophil (lamellipodium), thus 'pulling' the neutrophil through the endothelium
and intercellular spaces along a chemokine concentration gradient. Simultaneously,
release of ligand-bound CR3 at the trailing edge of the neutrophil (uropod), frees the
neutrophil to move further forward. Thus, CR3 molecules undergo a cycle of
attachment at the lamellipodium and release at the uropod during neutrophil
migration. The mechanisms underlying this phenomenon are unclear but may
include conformational changes in CR3 affecting binding affinity (Diamond and
Springer, 1994). An additional explanation has been provided by the demonstration
of competitive inhibition of CR3 binding sites by the endogenous ligand, neutrophil
elastase (Cai and Wright, 1996), raising the hypothesis that increased neutrophil cell
surface neutrophil elastase following limited azurophilic degranulation triggers the
release of bound CR3 and permits the neutrophil to move forward. Released
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proteolytic enzymes, such as neutrophil elastase, may also aid neutrophil passage
between cells by digesting intercellular fibres.
Several lines of evidence suggest that upregulation of CR3 effector functions is
associated with changes in the conformational state of CR3 as well as an increase in
CR3 cell surface expression. For example, ligand-binding and non-binding forms of
CR3 can be isolated from neutrophils and treatment of the inactive form with cellular
lipids or with the monoclonal antibody KIM-127 restores ligand-binding activity
(Cai and Wright 1995; 1996; Hermanowski-Vosatka et al, 1992). Furthermore, in
purified neutrophils, stimulation with a range ofpriming agents increases CR3-
mediated binding of albumin-coated latex beads in a manner that cannot be
accounted for on the basis of increased CR3 expression alone (Condliffe et al, 1996).
Conformational changes in CR3 associated with increased activity could be induced
by derepression of a repressor protein, stimulation of an associated regulatory
protein, or through covalent modifications such as phosphorylation (Diamond and
Springer, 1994). Interestingly, a recent study has identified differential
phosphorylation of CR3 in plasma and granule membranes when stimulated with the
neutrophil agonist phorbol myristate acetate (PMA), suggesting that phosphorylation
of the CD 18 component of CR3 may be the basis of CR3 activation at the neutrophil
cell surface (Buyon et ai, 1997).
Neutrophil phagocytosis and activation
The primary function of neutrophils at an inflammatory site is to ingest and kill
extracellular pathogens and, to this end, neutrophils express a number of receptors
involved in bacterial recognition and binding. Ingestion may be triggered by either
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non-opsonised or opsonised bacteria, although opsonisation greatly enhances
phagocytosis and the subsequent deployment ofkilling mechanisms by the
neutrophil. Non-opsonic phagocytosis, however, represents an important defence
mechanism in the early stages of an infection or in inflammatory sites where levels of
opsonins are low or opsonisation is inhibited by proteolytic cleavage of opsonins and
opsonin receptors (Ofek et al, 1992; Speert, 1993; Doring 1994). Mechanisms
underlying non-opsonic phagocytosis include recognition of lectins on the bacterial
surface (lectinophagocytosis), and protein-protein interactions via an Arg-Gly-Asp
(RGD) peptide sequence (Ofek et al, 1992). Neutrophil lectinophagocytosis of a
range of bacterial species has been described, including type 1-and type P-fimbriated
E. coli, Neisseria gonorrhoeae, Actinomyces naeslundii, and Staphylococcus
saprophyticus. Interestingly, type-1 fimbriated E. coli have been shown to bind to
components of the (32 integrin family, including CR3, demonstrating that neutrophil
receptors may play a dual role by facilitating both opsono- and lectinophagocytosis.
Indeed CR3 has also been implicated in the RGD amino acid sequence-mediated
uptake ofBordetella pertussis and Leishmania donovani by macrophages. Ligand-
binding to CR3 alone induces little or no respiratory burst activity (Ofek et al, 1992;
Berton et al, 1992; Gadd et al, 1994), a phenomenon exploited by both these
intracellular pathogens, which gain entry to macrophages via CR3 without triggering
ROS generation and hence microbial killing (Falkow et al, 1992). It is therefore
possible that other pathogens may similarly evade neutrophil-mediated killing by
binding to CR3 alone, triggering phagocytosis and exocytosis but not respiratory
burst activity.
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Opsonisation of microorganisms with antibody and complement increases both the
efficiency ofphagocytosis and the initiation of the appropriate killing mechanisms.
Neutrophil opsonin receptors include Fc receptors for the Fc region of
immunoglobulin G molecules, and complement receptors recognising various
activated forms of the complement component C3. Both medium affinity FcyRII
(CD32) and low affinity FcyRIII (CD 16) are found on neutrophils, although levels of
FcyRII (10,000 - 20,000 per neutrophil) are much lower than levels of FcyRIII
(100,000 - 300,000 per neutrophil) (Cohen, 1994). High affinity FcyRI may also be
expressed by neutrophils following incubation with the pro-inflammatory cytokine
interferon y (IFNy) (Gadd et al, 1996). Complement receptors include CR1 (CD35)
which recognises the C3b form of complement component C3 and CR3 which
recognises particles coated with the iC3b form of C3. An opsonised bacterium
binding to FcyR and complement receptors on the surface of the neutrophil is
engulfed by a 'zippering' motion, as progressive receptor binding pulls the plasma
membrane around the bacterium until a phagosome is formed. Simultaneous
degranulation of azurophil and specific granules in the vicinity of the phagosome
results in phagolysosome formation, ROS generation, and increased cell surface
expression of complement receptors, thus improving the efficiency ofbacterial
engulfment and initiating bacterial killing (Cohen, 1994).
The relative contributions of the various FcyR and complement receptors to
phagocytosis and respiratory burst induction remains unclear. Cross-linking of CR3
alone induces an increase in [Ca2+]i; triggering a variety ofneutrophil responses,
including phagocytosis, but not a substantial respiratory burst (Petersen et al, 1993;
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Berton et al, 1992; Gadd et al, 1994). However FcyR-induced respiratory burst
responses are enhanced by the presence of activated complement. Studies have
shown the moderate affinity FcyRII to be a more effective trigger for phagocytosis
and respiratory burst induction than the low affinity FcyRIII (Cohen, 1994; Edwards,
1995), and the latter was traditionally regarded as playing a subsidiary role in
enhancing FcyRII functions and ingesting large immune complexes. However, cross-
linking of either FcyRII and FcyRIII can independently lead to tyrosine
phosphorylation and an elevation in [Ca2+]i5 both ofwhich are features of neutrophil
activation processes (Edwards, 1995). Interestingly, interactions of FcyRIII with (32
integrins appear to be particularly important in FcyRIII-mediated neutrophil
activation (Edwards, 1995; Petty and Todd, 1996). The form of FcyRIII expressed in
neutrophils (FcyRIIIB) lacks a transmembrane domain but is anchored to
glycosylphosphatidylinositol (GPI) within the plasma membrane (Edwards, 1995;
Petty and Todd, 1996). Consequently another molecule must be involved in
signalling from activated FcyRIIIB molecules. Co-capping studies have
demonstrated the close proximity ofFcyRIIIB and CR3 in neutrophil plasma
membranes and transfection studies in non-haematopoietic cells have indicated that
CR3 is necessary for FcyRIIIB-mediated phagocytosis to occur. Coupled with
studies of CR3 interactions with other GPI-linked neutrophil markers, these results
suggest that the transmembrane CR3 molecule may function as a relay for signals
generated by GPI-linked receptors (Petty and Todd, 1996).
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Respiratory burst activity and ROS generation
Respiratory burst activity in phagocytic cells, manifest as an increase in oxygen
consumption which is independent ofmitochondrial activity, is the initiating event in
the generation of ROS, which are necessary for the effective killing of many bacterial
species. At the molecular level, ROS formation depends upon the transfer of
electrons from molecular oxygen to H20 via a series of intermediaries ofvarying
toxicity (Fig 1.1, also reviewed in Miller and Britigan, 1997; Karnovsky, 1994).
Respiratory burst activity is initiated by the assembly and activation of the enzyme
NADPH oxidase, which catalyses the transfer of a single electron to molecular
oxygen to form the superoxide anion, 02\ Individuals with an inherited defect in any
one of several of the components of the NADPH oxidase enzyme complex are unable
to mount an appropriate respiratory burst in response to phagocytic cell activation,
and consequently suffer from recurrent life-threatening infections with catalase
positive bacteria, including S. aureus and B. cepacia. The failure of neutrophils to
clear the infection promotes macrophage recruitment and granuloma formation;
hence the syndrome is termed chronic granulomatous disease (CGD) (Dinauer,
1992).
The central component of the NADPH oxidase system is a flavicytochrome complex
entitled cytochrome b558, b559 or b.245 and consisting of a 91 kDa glycoprotein, gp91-
phox, and a 22 kDa protein, p21-phox (Deleo and Quinn, 1996; Wientjes et al, 1997).
In resting cells, cytochrome b558 is found predominantly within the membrane of
specific granules, although approximately 10% is expressed within the plasma
membrane. A further component, the GTP-binding protein, RaplA, is also found
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within the plasma and specific granule membranes in association with cytochrome
b558. Cytosolic components ofNADPH oxidase include a further GTP-binding
protein, Rac, and a complex of three proteins, p47-phox, p67-phox and p40-phox.
On phagocytic cell activation, specific granules are translocated to the plasma
membrane, leading to an increase in cytochrome b558 at the cell surface. Cytosolic
components are also translocated to the plasma membrane and associate with the
cytochrome b558 component to form the completed enzyme. In particular,
phosphorylation of the p47 component induces conformational changes in the
p47/p67/p40 complex which in turn permit binding to the cytochrome b558
component, and hence NADPH oxidase assembly. GTP-binding proteins appear to
play a regulatory role, particularly in enzyme activation where GDP-GTP exchange
may function as an on-off switch. Activated NADPH oxidase catalyses the
transformation ofNADPH to NADP and H+ with the release of a single electron and
hence the generation of 02" from 02.
Once formed 02" is rapidly dismuted to H202 either spontaneously or through the
action of superoxide dismutase (SOD) (Fig 1.1; Miller and Britigan, 1996). agents.
Neutrophils, unlike monocytes/macrophages, contain a further enzyme,
myeloperoxidase (MPO), which converts H202 to hypochlorous ion (OC1), a potent
anti-bacterial agent. A variety of reactions between 02", H202 and OC1" lead to the
formation of the highly reactive oxygen species, singlet oxygen ( 02('Ag)) and
hydroxyl radical (-OH ), both of which are short lived and highly potent oxidising
agents. Cytotoxic chloramines and tyrosyl radicals are generated via an MPO-

















Fig 1.1 Respiratory burst induction and the production of reactive oxygen species in
neutrophils. Solid lines: pro-oxidant reactions; dashed lines: antioxidant reactions.
ROS shown in red.
released by macrophages or epithelial cells, to produce toxic peroxynitrites. In view
of the toxicity of the many oxygen species generated during a respiratory burst,
several regulatory mechanisms exist to prevent damage to host tissues, whilst
maximising the effectiveness ofbacterial killing. NADPH oxidase is stored
primarily in specific granules and assembled at the plasma membrane which is then
incorporated into the phagosome during phagocytosis. By contrast MPO is contained
within azurophil granules and is released into the phagosome during phagolysosome
formation via the fusion of azurophil granules. Thus highly active ROS are primarily
generated within the immediate environment of the ingested microorganisms.
However some leakage of ROS to the extracellular environment is inevitable and
may be considerable in instances of frustrated phagocytosis or if neutrophils are
killed and undergo lysis. Since H202 formation is pivotal in the formation of most
ROS, neutrophils also contain mechanisms to remove excess H202, including the
enzyme catalase which converts H202 to water and oxygen, and the enzyme system
glutathione reductase / peroxidase which converts H202 to water. Extracellular anti¬
oxidant molecules such as ascorbic acid (vitamin C), a-tocopherol (vitamin E), P-
carotene and sulphydrls also play a role in protection from oxidative damage via
released ROS (Brown and Kelly, 1994b).
Neutrophil priming
In vitro, neutrophil responses to any given stimulus can be modulated by prior
exposure to a wide range of inflammatory mediators. Such agents do not trigger a
respiratory burst in themselves but 'prime' the neutrophil so that a subsequent
respiratory burst is of a greater magnitude. Many substances have been demonstrated
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to prime neutrophils, including cytokines such as IL-8, platelet activating factor
(PAF), insulin-like growth factor 1 (IGF-1), granulocyte/macrophage-colony
stimulating factor (GM-CSF) and TNFa (Hallet and Lloyds, 1995; Condliffe et al,
1996; Bjerknes and Aarskog, 1995; Wozniak et al, 1993; Daniels et al, 1994) or
bacterially derived substances, such as LPS (Bohmer et al, 1992; Condliffe et al,
1996). Although the role ofpriming in vivo is less clear, the observation that many
priming agents are also potent chemoattractants suggests that neutrophils are primed
for more effective bacterial killing as they move along a chemokine gradient towards
the inflammatory focus. Priming is also associated with degranulation of non-
azurophilic granules and subsequent increased expression of complement receptors at
the cell surface (Bjerknes and Aarskog, 1995; Condliffe et al, 1996), again preparing
the neutrophil for more effective bacterial phagocytosis and killing.
LPS preparations from a range ofbacterial species (Aida et al, 1995; Heiman et al,
1990; Karlsson et al, 1995; Kharazmi et al, 1991) have been shown to prime
neutrophil respiratory burst responses in vitro. LPS is avidly bound by the serum
protein, LPS-binding protein (LBP). Thus, in the presence of serum, LPS interacts
with phagocytic cells as LPS-LBP complexes, which bind to a GPI-linked protein,
CD 14, expressed predominantly on monocyte/macrophages but also at lower levels
on neutrophils. Along with other GPI-linked receptors, CD 14 probably requires
cross-linking with CR3 or other receptors to induce intracellular signalling and
neutrophil priming (Petty and Todd, 1996). LPS can also bind to neutrophils and
induce priming in the absence of serum and hence LBP, although the concentrations
of LPS required to induce a level ofpriming equivalent to that induced in the
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presence of serum, are generally much greater (Luchi and Munford, 1993; Lynn et al,
1991; I Dransfield, personal communication). In the absence of LBP, putative LPS
receptors include a 70-80 kDa molecule (Hailing et al, 1992; Jacques, 1996) and CR3
(Wright et al, 1989), but not CD 14 (Luchi and Munford, 1993). Surprisingly,
however, expression of functional CD 14 does appear to be necessary for neutrophil
priming to occur under these circumstances (Lynn et al, 1991).
Cellular mechanisms controlling neutrophil priming and activation
The potential toxicity ofneutrophil defence mechanisms is matched by several
regulatory systems controlling the many neutrophil effector functions. The
complexity of such regulatory networks is reflected in the fact that one agonist can
have many different effects upon neutrophil function depending on both the
concentration of the stimulus and on the activation state of the neutrophil. For
example at low concentrations, the formylated peptide, fMet-Leu-Phe (FMLP), is a
potent stimulator ofneutrophil chemotaxis and primes neutrophils for later
respiratory burst responses. However at high concentrations, FMLP itselfwill
induce a respiratory burst in unprimed neutrophils (Hallett and Lloyds, 1995; Jaconi
et al, 1993). Neutrophil activation state is also important, since primed neutrophils
will produce a respiratory burst in response to concentrations ofFMLP that do not
trigger respiratory burst induction in unprimed neutrophils (Condliffe et al, 1996).
Many investigators have attempted to unravel the complex regulatory webs
controlling neutrophil functions, and considerable progress has been made. Diverse
neutrophil effector functions, including adhesion, chemotaxis, priming,
degranulation, and respiratory burst induction are dependent upon an increase in
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[Ca2+]j transients (Jaconi et al, 1993; Hallett and Lloyds, 1995). Different patterns of
[Ca2+]; release may dictate the nature of the neutrophil responses induced. For
example, low concentrations of FMLP, which are associated with chemotaxis, induce
a sustained increase in [Ca2+]i transients, whilst high concentrations of FMLP, which
are associated with the arrest of cell movement and the activation of degranulation,
induce a single elevation of [Ca2+]( which rapidly returns to baseline levels (Jaconi et
al, 1993). Additional mechanisms involved in neutrophil regulatory pathways
include both serine/threonine and tyrosine phosphorylation of intracellular proteins
(Bokoch, 1995).
The biochemical pathways underlying changes in [Ca2+]j and protein phosphorylation
following receptor activation have been studied most fully in relation to the 7-
transmembrane G-protein linked family of chemokine receptors (Bokoch, 1995). G
proteins, which are heterotrimeric GTP-binding proteins comprising a, [i and y
subunits, dissociate on activation, releasing Ga and Qf3y components. In the
classical model of intracellular signalling (illustrated in Fig 1.2), Gj3y activates
phospholipase C which breaks down phosphatidylinositol 4,5-biphosphate (PIP2) to
form the second messengers inositol triphosphate (IP3) and diacylglycerol (DAG).
IP3 mobilises intracellular Ca2+ stores and hence induces an increase in [Ca2+]j which,
along with DAG, activates protein kinase C (PKC) and initiates intracellular
phosphorylation reactions (Bokoch, 1995; Worthen et al, 1994). Activation of
phospholipases D (PLD) and A2 (PLA2) also occur as downstream events of G-
protein activation, triggering the formation of phosphatidic acid (PA) and arachidonic
acid (AA) respectively. PA is further degraded to DAG, whilst AA is metabolised to
36
produce a range of eicosanoid inflammatory mediators. In addition, both PA and AA
have been linked to NADPH oxidase activation (Edwards, 1995; Jones et al, 1996)
and hence respiratory burst induction.
Fig 1.2. Classical pathway of chemokine receptor signalling in neutrophils. Binding
of chemokine (CK) to a specific 7-transmembrane domain linked receptor (CTxR)
triggers G protein dissociation into Ga and Qf5y components and a cascade of events
leading to cell activation. PLC, phospholipase C; PLD, phospholipase D; PLA2,
phospholipase A2; PIP2, phosphatidyl inositol-4,5-biphosphate; IP3, inositol
triphosphate; DAG, diacylglycerol; PKC, protein kinase C; AA, arachidonic acid;
PA, phosphatidic acid. (Adapted from Bokoch, 1995)
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Recently, several alternative regulatory networks have been described involving a
number of tyrosine kinases, mainly of the Src family, and low molecular weight
GTPases of the Ras family (reviewed in Bokoch, 1995). Tyrosine kinase activation
triggers GDP/GTP exchange on Ras, which in turn activates the Ras-dependent
kinases, Raf and MAP/ERK kinase kinase (MEKK-1; Fig 1.3). Both Raf and
MEKK-1 activate MAP/ERK kinase (MEK-1 and MEK-2), which subsequently
activates a serine/threonine kinase termed mitogen activated protein kinase (p42/p44
MAPK), triggering a range of cellular events including activation ofphospholipase
A2, cytoskeletal rearrangements, and activation of other serine/threonine kinases
(Bokoch, 1995; Nick et al, 1997). Src tyrosine kinases also function in association
with Ras to activate phosphatidylinositol 3-kinase (PI3K) which converts PIP2 to
phosphatidylinositol triphosphate (PIP3). PIP3 formation is associated with
cytoskeletal rearrangements, whilst inhibition of PI3K blocks chemoattractant
stimulation ofNADPH oxidase activity, suggesting that PIP3 may have a role in both
of these processes (Bokoch, 1995).
Other less well-characterised signalling pathways have been described in neutrophils,
including a novel form of PI3K activated by G/?y (Bokoch, 1995) and a 38 kD MAP
kinase (p38 MAPK) activated by a distinct pathway from the p42/p44 MAPK (Nick
et al, 1997). Stimulation of FMLP and PAF receptors induces differential activation
of p38 MAPK and p42/p44 MAPK, which in turn produces distinct effects on
neutrophil activation processes (Nick et al, 1997). Similarly, the two IL-8 receptors
expressed by neutrophils, IL-8R1 and IL-8R2, induce different effects, with both
triggering an increase in [Ca2+]j and exocytosis, whilst only IL-8R1 triggers
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cPLA2
Fig 1.3. Chemokine receptor Ras-dependent signalling pathways. Nonreceptor
tyrosine kinases of the Src family (Tyr kinases), activated by G protein components,
trigger activation of the small GTPase, Ras. Subsequent stimulation of the
serine/threonine kinase Raf, kinases of the MAPK cascade, and PI3K lead to various
effects upon neutrophil activation processes. MAPK, mitogen-activated protein
kinase (ERK); MEK, MAPK/ERK kinase; MEKK, MEK kinase; PI3K,
phosphatidylinositol 3-kinase; PIP3 phosphatidylinositol triphosphate. (Adapted from
Bokoch, 1995; Nick et al, 1997)
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respiratory burst activity and PLD activation (Jones et al, 1996). Thus neutrophil
responses to an individual chemokine may be 'fine-tuned' by the selective
upregulation of distinct intracellular signalling pathways, perhaps mediated by the
coupling of G proteins with distinct a subunits to individual chemokine receptors
(Gierschik et al, 1989).
The role of kinase activation and changes in [Ca2+]j in neutrophil priming remains
unclear. However, a recent review has suggested that tyrosine phosphorylation may
be the major mechanism underlying priming activity (Hallett and Lloyds, 1995).
Evidence in support of this hypothesis includes a number of observations: 1. changes
in [Ca2+]j following neutrophil stimulation are identical in unprimed and primed
neutrophils, despite greater 02" production in the latter, suggesting that priming does
not function by facilitating greater release of intracellular Ca2+ stores (Lloyds and
Hallett, 1994); 2. receptors for agents such as TNFa or GM-CSF, which prime but do
not activate neutrophils, do not trigger a rise in intracellular [Ca21 ]; but do increase
intracellular tyrosine phosphorylation (Hallett and Lloyds, 1995); 3. tyrosine kinase
activation occurs in response to primers and agonists at concentrations too low to
trigger a rise in [Ca2+]; (Lloyds et al, 1995; McColl et al, 1991); 4. neutrophil priming
can be manipulated experimentally by inhibition or activation of tyrosine kinases and
phosphatases (Lloyds and Hallett, 1994). The kinetics of tyrosine phosphorylation
on neutrophil stimulation are much slower than those of an increase in [Ca2+];,
providing a model to explain the dose-dependent effects of several neutrophil
agonists upon neutrophil priming and activation (Hallett and Lloyds, 1995). In this
model, high agonist concentrations induce a rapid rise in [Ca2+]; and NADPH oxidase
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activation initiating a modest respiratory burst. Low agonist concentrations,
however, fail to induce a rise in [Ca2+];, but do initiate tyrosine phosphorylation,
which in turn primes any subsequent activation ofNADPH oxidase for a greater
respiratory burst.
1.2.3 Neutrophil-mediated damage in the CF lung
As the predominant immune cell within the CF lung, neutrophils are regarded as
major contributors to inflammatory damage in CF patients. Given the increased
levels ofpro-inflammatory cytokines and bacterial products such as LPS in the CF
lung, conditions would seem ideal for priming and activation ofneutrophil responses.
Furthermore, exposure to colonising bacteria provides a constant stimulus for
neutrophil activation, as demonstrated by the 'frustrated phagocytosis' model of
neutrophil/mucoid P. aeruginosa (MPA) interactions (Govan and Glass, 1990;
Govan and Deretic, 1996). In this model, antibodies to alginate and other
pseudomonal antigens trigger neutrophil attempts to engulf large microcolonies of
MPA within alginate biofilms. In the absence of effective phagosome formation,
neutrophil granule exocytosis releases tissue-damaging substances into the
extracellular environment, thus promoting further lung damage and continuing
neutrophil activation.
Interest in neutrophil-mediated lung damage in CF has focused on two main areas;
first, the generation of toxic ROS, and second, the release of proteolytic enzymes
such as neutrophil elastase. Both will be discussed in the following sections.
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ROS-mediated damage
The antimicrobial action of ROS are essential to the control of many bacterial
pathogens, but, ifpresent in excess, can provoke considerable damage to host tissues.
Damage may be induced directly via cytotoxic reactions involving oxidation and
peroxidation of proteins or lipids, or indirectly by the upregulation of pro¬
inflammatory cytokines and the inactivation of anti-inflammatory molecules such as
the serine protease inhibitor, a,-antitrypsin (reviewed in Miller and Britigan, 1996).
In CF, the observation of elevated plasma concentrations of oxidised lipids, proteins
and DNA suggests the presence of an oxidant/antioxidant imbalance favouring the
presence of excess ROS at inflammatory sites. Significantly, increased plasma levels
of oxidation products correlate with reduced lung function, implying that oxidative
tissue damage contributes to CF lung disease (Brown and Kelly, 1994a; Brown et al,
1995). Although it has been suggested that deficiencies in antioxidant vitamins such
as a-tocopherol and ascorbic acid may contribute to oxidative stress, studies have
indicated that antioxidant levels in CF children fall within normal ranges, reflecting
the good nutritional management now provided in CF clinics (Brown and Kelly,
1994b; Vaisman et al, 1994). However a deficiency of the antioxidant glutathione
has been demonstrated both systemically and in the airways lining fluid of CF
patients (Roum et al, 1993).
Increased production of oxidant molecules by activated phagocytic cells may also
contribute to an oxidant/antioxidant imbalance in CF. For example sputum
concentrations of extracellular MPO are elevated in CF patients and correlate with
the severity of lung disease (Regelmann et al, 1995). Furthermore, studies measuring
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neutrophil luminol-enhanced chemiluminescence (LCL), which is myeloperoxidase-
dependent, have shown increased neutrophil LCL activity in CF patients compared to
healthy controls (Vaisman et al, 1994; Roberts and Stiehm, 1989). These findings
were confirmed in a recent publication directly demonstrating increased
myeloperoxidase activity and chloramine release, but not increased production of Of
or H,02 in neutrophils from CF patients (Witko-Sarsat et al, 1996). Interestingly,
asymptomatic CF heterozygotes also showed increased intracellular MPO activity,
and, for both groups, MPO activity could be returned to control levels by amiloride-
dependent inhibition of sodium/proton antiport activity. These results imply that
increased MPO activity in CF is not solely a consequence of neutrophil priming or
activation, but reflects a fundamental defect in the regulation of intracellular pH
and/or ionic concentrations.
The proposed oxidant/antioxidant imbalance in CF has prompted calls to introduce
antioxidant therapy in CF patients, including the use of recombinant SOD (Koyama
et al, 1992), selenium (Sies, 1987), the glutathione precursor N-acetylcysteine (Leff
et al, 1993) and catalase (Thibeault et al, 1991). However, it is still unclear how
much tissue damage in CF can be attributed to oxidative processes. For example,
levels of the oxidant species NO and H202 in exhaled air are increased in asthmatic
children but not in CF patients or healthy controls (Dotsch et al, 1996; Worlitzsch et
al, 1998). Both sputum, which largely consists of DNA, and pseudomonal alginate
are powerful scavengers of oxygen radicals and may therefore remove ROS from the
respiratory epithelium before damage can occur. In addition, the sequestration of the
highly cationic enzyme MPO by negatively charged DNA within sputum may favour
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the generation of ROS away from the epithelial cell surface, thus providing further
protection against oxidative damage.
Proteolytic enzymes
Neutrophils contain both metalloproteinases and serine proteases which may be
involved in inflammatory damage in CF patients. Most interest has focused on the
role of serine proteinases, and particularly neutrophil elastase, which is capable of
digesting elastin and fibronectin within the lung parenchyma, inducing a loss of lung
elasticity and thus promoting the development of bronchiectasis (Doring and Bellon,
1996). Within the normal lung, free elastase activity is inhibited by the presence of
a,-proteinase inhibitor (a,-PI) which forms an inactive complex with neutrophil
elastase (NEAP). An imbalance of elastase/antiproteinase inhibitor is believed to be
present within the CF lung, mediated by the inactivation of arPI by a range of
substances, including neutrophil elastase itself (Doring, 1994), P. aeruginosa elastase
(Suter, 1994) and MPO-derived oxidants (Miller and Britigan, 1996). Free
neutrophil elastase may have a number ofpotentially detrimental effects in CF lung
disease, including epithelial cell toxicity, degradation of the lung extracellular
matrix, promotion ofmucus hypersecretion and inhibition ofmucociliary transport,
induction of IL-8 and other neutrophil chemotactic factors, and interference with
phagocytosis by degradation of immunoglobulin and CR1 (Vender 1996; Doring
1994). In addition, neutrophil elastase may impair surfactant function by degrading
surfactant proteins (Liau et al, 1996). Consequently, antiproteinase supplementation
has been proposed as a potential therapy in CF patients (Vender, 1996; Doring and
Bellon, 1996). Although some trials of aerosolised a,-PI in CF patients have
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demonstrated decreased concentrations of free neutrophil elastase in both sputum and
airway lining fluid, not all have been successful and further work is required to
improve delivery systems for a,-PI before a definite therapeutic benefit can be
demonstrated (Doring and Bellon, 1996). As a caveat, disruption ofphagocytosis
and the cleavage of T lymphocyte receptors such as CD2, CD4, and CD8 by the
serine proteinases neutrophil elastase and cathepsin G, may downregulate immune
responses, and so protect lung tissue from further inflammatory damage (Doring et
al, 1995). Thus a cycle of acute inflammation followed by serine protease-mediated
immune downregulation may contribute to the typical pattern of intermittent
infective exacerbations on a background of chronic inflammation seen in CF patients.
1.3 BURKHOLDERIA CEPACIA
1.3.1 Background
Burkholderia cepacia was first described as the cause of sour skin in onions in 1950
by Burkholder, who termed the organism Pseudomonas cepacia (Latin: cepia =
onion) (Burkholder, 1950). Subsequently, B. cepacia was cultured from both clinical
and environmental sources and appeared in the literature under various names,
including eugonic oxidiser 1 (EO-1), P. kingii and P. multivorans. The latter name
reflects the characteristic nutritional versatility of B. cepacia, which can metabolise a
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wide variety of substrates and is even capable ofutilising penicillin G as a sole
carbon source (Beckman and Lessie, 1979).
As an environmental, non-fermentative, Gram-negative bacillus ofhigh G-C content,
B. cepacia was originally included in the genus Pseudomonas. The genomic
heterogeneity of the phenotypically-diverse pseudomonads was confirmed by RNA-
DNA hybridisation studies with five major groupings identified; RNA Group I
included the type strain, P. aeruginosa, whilst RNA Group II included P. cepacia
(Palleroni, 1984). In the early 1990's, the RNA group II pseudomonads were
transferred to a new genus, Burkholderia, with B. cepacia as the type strain
(Yabuuchi et al, 1992). Other members of the Burkholderia genus include
B. pseudomallei, B. mallei, B. gladioli, B. caryophilli, (Yabuuchi et al, 1992),
B. plantarii, B. glumae, B. vandii, (Urakami et al, 1994), B. cocovenenans (Zhao et
al, 1995) and B. vietnamiensis (Gillis et al, 1995). Although members of the
Burkholderia genus are typically environmental organisms and phytopathogens,
several species have been associated with human disease. Most notably,
B. pseudomallei is the causative agent ofmelioidosis, an often lethal infection which
may present as septicaemia with multi-system abscess formation or as a chronic
pneumonic illness resembling tuberculosis. B. mallei is associated with glanders, a
predominantly respiratory disease of horses and occasionally man. Since the early
1980's, B. cepacia has been increasingly recognised as a human pathogen,
particularly amongst CF patients.
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1.3.2 Clinical impact ofB. cepacia
Reports of B. cepacia infection in non-CF patients have typically been associated
with immunocompromised individuals treated within intensive therapy units. In
many instances, outbreaks ofB. cepacia infection have been traced to contaminated
aqueous or antiseptic solutions (Craven et al, 1981; Sobel et al, 1982; Rapkin et al,
1976) or to contaminated equipment (Takigawa et al, 1993; Poe et al, 1977;
Berkelman et al, 1982; Gelbart, 1976), reflecting the organisms innate resistance to
many commonly used disinfectants. Sites of infection have included the lungs
(Maningo and Watanakunakorn, 1995; Takigawa et al, 1993; Poe et al, 1977) urinary
tract (Levey et al, 1981; Sobel et al, 1982), and soft tissues (Basset, 1970), as well as
bacteraemia (Henderson et al, 1988; Berkelman et al, 1981; Craven et al, 1981) and
septic shock (Brauner et al, 1985; Thong and Tay, 1975; Phillips and Eyken, 1971).
Lung infection has been associated with contaminated nebulisers (Poe et al, 1977),
including an outbreak affecting 36 patients in a Japanese hospital (Takigawa et al,
1993). In contrast to these opportunistic infections, B. cepacia has been described as
a pathogen in apparently immunocompetent individuals, including a report of
macerated hyperkeratotic foot lesions or 'foot rot' amongst troops training in swamps
in northern Florida (Taplin et al 1971), two reports ofbacteraemic pneumonia in
previously healthy children (Wong et al, 1991; Pujol et al, 1992) and a recent report
of otitis media and cerebellar abscess formation in a UK offshore oil worker (Hobson
et al, 1995). Serious infections with B. cepacia, particularly affecting the lower
respiratory tract, are also a feature of CGD (Lacy et al, 1993; O'Neil et al, 1986).
However, the greatest impact of B. cepacia has been as a major pathogen within the
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CF community, where the increasing prevalence of B. cepacia within CF clinics,
associated with the emergence of transmissible 'epidemic' lineages, has led to the
introduction of segregation for colonised patients in both European and North
American clinics. The role ofB. cepacia in CF will be discussed in detail in section
1.4.
1.3.3 Characteristics and identification of B. cepacia
B. cepacia is a motile non-spore-forming, aerobic bacillus, with a G-C content of 66-
67% and typically catalase- and oxidase-positive. Various non-fluorescent pigments
may be produced and poly-P-hydroxyalkanoates can be accumulated as reserve
materials. Optimal growth occurs at 30°C (Palleroni, 1984). The characteristic
nutritional versatility and adaptability ofB. cepacia has been attributed to its unusual
genetic structure. B. cepacia possesses an exceptionally large genome with
approximately 8 megabase pairs, contained within multiple replicons (Cheng and
Lessie, 1994; Rodley et al, 1995). Using multilocus linkage disequilibrium analysis,
Wise et al (1995) demonstrated a high degree of variability in a clonally-derived
natural population ofB. cepacia, which suggested an unusually high rate of
recombination of B. cepacia relative to binary fission. Furthermore, B. cepacia has
been shown to contain multiple insertion sequences (IS) (Rodley et al, 1995;
Scordilis et al, 1987). Indeed migration of IS within the B. cepacia genome has been
proposed as a mechanism to account for the phenotypic variability seen in B. cepacia
infections, particularly in terms of changing antibiotic sensitivity patterns during
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treatment (Hobson et al, 1995; Pitt et al, 1996; Larsen et al, 1993; Scordilis et al,
1987).
In the clinical setting, isolation and identification ofB. cepacia has been greatly
improved by the introduction of selective media and the use of commercial multitest
systems (Gilligan, 1991; Pitt and Govan, 1993). However, accurate identification of
B. cepacia is still problematic, particularly as other bacteria may grow on selective
media and commercial test systems do not accurately identify all B. cepacia isolates
(Kiska et al, 1996; Leff et al, 1995). Recent studies have identified further
difficulties, by demonstrating the extreme diversity ofbacterial isolates currently
identified as B. cepacia by standard laboratory tests. Analysis ofwhole cell fatty
acids as fatty acid methyl esters (FAME) by gas chromatography led Simpson et al
(1994) to speculate that epidemic strains of B. cepacia, associated with outbreaks
amongst CF patients, may actually be hybrids of B. cepacia and other members of
the Burkholderia genus, including the phytopathogen B. gladioli and the potent
intracellular pathogen B. pseudomallei. Taxonomic studies have also shown that
strains currently identified as B. cepacia on the basis of standard laboratory tests,
actually consist of at least 5 distinct species or 'genomovars' (Govan et al, 1996;
Vandamme, 1995). Isolates were grouped according to polyacrylamide gel
electrophoresis of whole cell proteins and DNA-DNA hybridisation studies. By
convention, new species identified in such a manner are referred to as 'genomovars'
until reliable phenotypic markers are found for species identification (Ursing et al,
1995). Thus, for example, genomovar V isolates have been identified as the new
species, B. vietnamiensis on the basis of nitrogen-fixing ability (Gillis et al, 1995),
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whilst genomovar II isolates have recently been proposed as the new species,
B. multivorans (Vandamme et al, 1997).
1.3.4 Biotechnological exploitation ofB. cepacia
Although originally identified as a phytopathogen, B. cepacia is currently being
developed as an agent of biocontrol and bioremediation for agricultural use. The
nutritional adaptability of B. cepacia makes it an attractive prospect for the
'neutralisation' of land contaminated by industrial wastes or herbicides (Bhat et al,
1994; Havel and Reineke, 1993; Folsom et al, 1990; Krumme et al, 1993). For
example, B. cepacia has been shown to degrade the defoliant 2,4,5-
trichlorophenoxyacetic acid (2,4,5-T; 'agent orange') at a rate up to 20,000 times
greater than other degradative bacteria (Kilbane et al, 1982; Folsom et al, 1990).
Furthermore, like many soil organisms, B. cepacia produces a range of antimicrobial
compounds which enable it to compete for limited nutrients within the soil micro-
environment. Agricultural microbiologists are investigating the use of B. cepacia in
the control of a wide range of plant pathogens, including Rhizoctonia solani,
Fusarium monoliforme, Sarocladium oryzae, Pyricularia oryzae, Verticillium
dahliae, Sclerotium rolfsii, Pythium ultimum and Pseudomonas solanacearum
(Homma et al, 1989; Aoki et al 1991; Fridlender et al, 1993; Rosales et al, 1995).
The commercial release of B. cepacia in biocontrol programmes, involving either
crop spraying or seed treatment, remains controversial, particularly as the
mechanisms underlying B. cepacia pathogenicity are unclear. Bevivino et al (1994)
compared two clinical and two environmental strains for a range of characteristics
50
associated with environmental organisms or human pathogens. Although the clinical
strains were found to bind more effectively to urinary epithelial cells than the
environmental strains, the limited number of strains involved and choice of
'virulence determinants' restricts the usefulness of this study in determining the
safety of environmental B. cepacia isolates. In an earlier study, Gonzalez and
Vidaver (1979) were able to differentiate clinical and environmental isolates on the
basis ofphytopathogenicity tests but found no difference in mouse lethality between
the two groups. Gessner and Mortensen (1990) compared a larger panel of CF, non-
CF clinical and environmental B. cepacia strains for a range ofpotential virulence
factors but found few obvious differences between the two groups. Recent
taxonomic analyses have indicated that most environmental isolates, including the
B. cepacia type strain ATCC25416, are genomovar I isolates. The observation that
isolates of genomovars I and IV are less frequently found in CF than genomovar II
and III isolates is perhaps relevant to the choice ofB. cepacia strains for development
in biocontrol programmes. However pro-inflammatory activity induced by a
genomovar I strain has been demonstrated in a study of monocyte TNF-a induction
by bacterial lipopolysaccharide (Shaw et al, 1995a). Thus, controversy still
surrounds the human hazards associated with the commercial use ofB. cepacia;
indeed, a recent application to release an environmental B. cepacia strain in a large
scale agricultural programme in the USA has been vigorously opposed by clinicians
and medical microbiologists involved in the care of CF patients. Further
understanding of B. cepacia acquisition and pathogenicity is necessary to enable an
adequate assessment of the 'safety' of any B. cepacia strain proposed for release.
1.4 Burkholderia cepacia In Cystic Fibrosis
1.4.1 Background
Culture ofB. cepacia from a CF patient was first reported in the early 1970's as part
of a large survey of B. cepacia in US hospitals (Ederer and Matsen, 1972). Several
years later, Rosenstein and Hall (1980) reported a severe case of B. cepacia infection
in a 17-year old female CF patient. Infection was characterised by acute pneumonia
and septicaemia, a pattern of disease not seen with other CF pathogens. In the mid
1980's, an increase in B. cepacia prevalence within North American CF clinics was
reported; significantly, a number ofpatients developed septicaemia as a consequence
ofB. cepacia infection. (Isles et al, 1984; Thomassen et al, 1985). In the UK, rapid
pulmonary deterioration and fatal B. cepacia septicaemia in a CF patient was first
reported in 1986 (Glass and Govan, 1986). However, by the early 1990's, an
increase in B. cepacia prevalence equivalent to that seen in North American CF
centres was observed in UK clinics (Govan et al, 1993; Smith et al, 1993).
B. cepacia colonisation in both North American and European CF centres has
provoked concern for several reasons (Govan et al, 1996). The organism is innately
resistant to available antibiotics and hence extremely difficult to treat. Colonisation
is also associated with a poorer clinical outcome for most patients who acquire the
organism, particularly those who succumb to the characteristic pneumonia and
septicaemia described in early reports; the so-called 'cepacia syndrome'. Finally,
there is compelling evidence that the increasing incidence of colonisation in some
centres results from direct patient-to-patient transmission of B. cepacia. As fears of
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B. cepacia acquisition have grown, segregation of colonised and non-colonised CF
patients has been introduced in many centres worldwide. National CF organisations
also introduced measures to prevent B. cepacia acquisition, including hygiene
guidelines for hospitals, patients and carers, and a ban on summer camps and similar
social events for CF patients (ACFA, 1993; Bingen et al, 1993; Pegues et al, 1994).
The psychological, social and financial implications of these infection control
measures for patients and carers have been considerable, particularly as patients may
feel they have become social outcasts as a consequence of colonisation (Govan and
Deretic, 1996). Reinfection of transplanted lungs with B. cepacia, and the spread of
B. cepacia in transplant centres has even led to the inclusion ofB. cepacia infection
as a contra-indication to transplantation in some centres (Noyes et al, 1994; Snell et
al, 1993).
1.4.2 B. cepacia and transmissibility
During the 1980's, the emergence ofB. cepacia in CF was characterised by
dramatically different prevalence figures at individual clinics. Possible explanations
for such regional variation included difficulties in the isolation ofB. cepacia from
sputum specimens (Tablan et al, 1987). However, with the widespread introduction
of improved cultural techniques (Gilligan, 1991), laboratory proficiency alone could
not account for the observed differences in prevalence. Alternative explanations
were the improved life expectancy of CF patients, with corresponding changes in the
pattern of respiratory disease, or selective pressure caused by increased antibiotic
use, in particular the introduction of nebulised colimycin for early treatment of
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P. aeruginosa colonisation. Early studies attributed the increased B. cepacia
prevalence to nosocomial acquisition, particularly from contaminated equipment
(Isles et al, 1984; Thomassen et al, 1985). However growing suspicion that direct or
indirect patient-to-patient transmission was responsible for new cases increased
pressure to introduce cohorting of colonised patients. With the advent of molecular
typing in the early 1990's, several studies indicated the existence of distinct
B. cepacia lineages within CF centres (LiPuma et al, 1988; 1990; Govan et al, 1993;
Smith et al, 1993). In addition, collection of detailed epidemiological data provided
compelling evidence of direct patient-to-patient transmission of B. cepacia and
validated the unpopular segregation policies introduced by CF centres and
organisations. Table 1.2, which summarises studies ofB. cepacia epidemiology,
demonstrates the weight of evidence supporting the epidemic spread ofB. cepacia
within at least some CF centres.
Highly transmissible B. cepacia lineages
Epidemiological data from numerous studies indicated that some strains of
B. cepacia were associated with epidemic spread within CF clinics whilst others
remained restricted to individual patients. In a large outbreak ofB. cepacia infection
in Edinburgh and Manchester CF centres, genomic fingerprinting by pulsed field gel
electrophoresis (PFGE) and extensive epidemiological investigation of patient
contacts, demonstrated the spread of at least two epidemic strains of B. cepacia
between patients (Govan et al, 1993). In both centres, transmission occurred mainly
through social contact both within and outwith the hospital setting. Similarly, inter¬
regional spread of the so-called Edinburgh epidemic strain followed contacts at
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Table 1.2a. Publications supporting person-to-person transmission ofB. cepacia.
Publication Comments
Isles et al 1984 Seminal paper: noted rising incidence ofB. cepacia and
cepacia syndrome in Toronto
Thomassen et al 1985 Rising B. cepacia incidence in US clinics
Thomassen et al 1986 Fall in incidence post segregation
Lipuma et al 1988 Prevalence of one ribotype in individual clinics
Lipuma et al 1990 Ribotyping demonstrates person-to person spread between
two patients at a CF camp
Anderson et al 1991 Nosocomial outbreak
Millar-Jones et al 1992 UK nosocomial outbreak
Govan et al 1993 PFGE: person-to-person spread through social contact in
and between two UK CF centres
Smith et al 1993 Further UK outbreak with transmission in clinical and
social settings
Bingen et al 1993 International consensus confirming B. cepacia
transmissibility
Corkill et al 1994 Highlights transmission particularly at UK CF events
Pegues et al 1994 Demonstration of transmission at US CF camps
Johnson et al 1994 Intercontinental spread of Edinburgh/Toronto strain ET12
Lipuma et al 1994 ? Inapparent transmission from culture negative patient
Ryley et al 1995 Further UK outbreak
Sun et al 1995 Cable pili demonstrated on intercontinental strain (ET12)
Revets and Lauwers Prevalent strain in Belgian clinic
1995
Whiteford et al 1995 Outbreak in UK Paediatric clinic
Pitt et al 1996 Strain ET12 prevalent in UK clinics: accounting for 38%
cases
Cazzola et al 1996 Variable transmission in an Italian clinic
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Table 1.2b. Publications with no evidence ofperson-to-person transmission of
B. cepacia.
Publication Comment
Glass and Govan 1986 No transmission of pathogenic strain between siblings
Hardy et al 1986 No transmission to uncolonised patients during
hospitalisation
Taylor 1994 No transmission in UK unit prior to segregation
Steinbach et al 1995 No transmission in large CF unit despite no segregation of
hospitalised patients
national CF events. Further epidemiological studies using the PFGE typing method
have now demonstrated the spread of this strain throughout many centres in the UK
(Pitt et al, 1996) whilst a large study involving multilocus enzyme electrophoresis
and ribotyping has demonstrated the presence of this B. cepacia lineage, termed
electrophoretic type 12 (ET12), in both UK and North American CF centres (Johnson
et al, 1994). Indeed it is now believed that the ET12 lineage originated in Toronto,
Canada before spread to the UK at international CF camps during the mid 1980's.
Throughout the rest of this thesis, the Edinburgh/Toronto epidemic strain will be
referred to as the ET12 lineage.
A number of studies have provided additional evidence that not all B. cepacia strains
are equally transmissible. For example, in the Edinburgh outbreak, one patient who
was colonised with two B. cepacia strains, only transmitted one, the ET12 lineage, to
his CF girlfriend (Govan et al, 1993). Furthermore evidence from studies of CF
siblings indicates that not all strains will spread from sibling to sibling despite the
close proximity of these patients (Glass and Govan, 1986; Cazzola et al, 1996). The
occurrence of sporadic new cases of colonisation with genetically distinct B. cepacia
in clinics where strict segregation measures have been applied, suggests that
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environmental reservoirs may also be an important source of infection (Govan and
Deretic, 1996). For patients acquiring such strains, segregation is particularly
controversial as transmissibility has not been demonstrated. However to classify
such strains as non-transmissible on the basis of current knowledge is difficult.
Notably, a recent study has identified transmission of a B. cepacia lineage to
5 patients, 6 years after the index case was originally colonised (Mahenthiralingam et
al, 1997). Consequently research has focused on identifying bacterial markers that
might enable the identification of highly transmissible strains before transmission
occurs. A greater understanding of such factors will not only allow the development
of more rational segregation policies but may provide a basis for the development of
an anti-5. cepacia vaccine.
B. cepacia transmissibility markers
Studies of B. cepacia ET12 demonstrated its enhanced adhesion to respiratory mucin
mediated by a 22kDa protein (Sajjan et al, 1992; Sajjan and Forstner 1992; Sajjan
and Forstner, 1993)) present on giant intertwined fibres expressed at the bacterial cell
surface, the so-called 'cable pili' (Sajjan et al 1995). Sajjan et al (1995) identified
the gene encoding cable pili, termed cblA, in isolates of the ET12 lineage, but
extensive analyses failed to find cblA in representatives of other epidemic B. cepacia
lineages, suggesting that other transmissibility factors exist (Sun et al, 1996).
However one 'non-transmissible' isolate from a CF patient in Mississippi was found
to contain a variant of the cblA gene. Interestingly, this strain has now been
implicated in a large outbreak involving over 200 non-CF patients in an intensive
therapy unit, possibly through transmission from the original CF host (R. Goldstein,
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personal communication). Further studies have identified enhanced adhesion of
variants of the ET12 strain deficient in cable pili, to the cell surface glycolipid,
globotriosylceramide (Sylvester et al, 1996). The authors speculate that increased
expression of this glycolipid in response to pro-inflammatory cytokines may promote
adhesion of B. cepacia to the CF lung. Using randomly amplified PCR,
Mahenthiralingam et al (1997) have identified a novel genomic marker termed
'Burkholderia cepacia epidemic strain marker' (BCESM). Significantly, BCESM
was identified in all representatives of genetically distinct epidemic lineages tested,
including the ET12 clone. The absence of BCESM in apparently non-transmissible
clones suggests that it may provide a useful marker for transmissibility. Further
studies are ongoing to identify the role of the putative EsmR protein encoded on the
1.4 kb BCESM DNA.
1.4.3 Is B. cepacia a pathogen in CF?
Whilst the existence of highly transmissible B. cepacia lineages has now been widely
accepted, the pathogenicity ofB. cepacia is still controversial, particularly in CF
centres where B. cepacia colonisation has not been associated with poor clinical
outcome. Some clinicians believe B. cepacia to be merely a marker ofpre-existing
lung disease, or indeed, CF itself, rather than a pathogen in its own right, and thus
question the need to maintain current segregation protocols (Revets and Lauwers,
1995; Conway et al, 1995). However other centres have experienced the rapid
deterioration ofpreviously well patients on acquisition of B. cepacia, consistent with
a major pathogenic role for this organism (Govan et al, 1993). Furthermore, in
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several case-controlled studies, B. cepacia colonisation has been associated with
accelerated respiratory decline and increased mortality (Whiteford et al, 1995; Muhdi
et al, 1996; Tablan et al, 1985; Lewin et al, 1990; Brown et al, 1993). In one study
(Muhdi et al, 1996), retrospective analysis found no difference between colonised
and non-colonised patients in lung function or hospital visits in the 24 months prior
to B. cepacia acquisition, providing strong evidence that B. cepacia acquisition was
not merely a marker of existing lung disease.
Further evidence for the pathogenic potential ofB. cepacia in CF comes from studies
in the Edinburgh CF mouse (Davidson et al, 1995). Following repeated exposure of
mice to B. cepacia J2315, an ET12 isolate, by nebulisation, histological examination
of lungs revealed more severe histopathological changes in CF mice than in their
non-CF littermates. Pathological changes were consistent with a severe
bronchopneumonia in the CF mice and were analogous to the clinical outcome of
B. cepacia infection in some CF patients.
Although there is an inclination to link B. cepacia transmissibility with
pathogenicity, this view is unfounded on the basis of the available evidence. On the
one hand, apparently non-transmissible strains have caused cepacia syndrome (Glass
and Govan, 1986) whilst on the other, epidemic lineages have not been universally
associated with a poor clinical outcome (Revets and Lauwers, 1995; Whiteford et al,
1995). Even within patients colonised with the same epidemic strain, clinical
outcomes can be widely variable, ranging from asymptomatic colonisation to
fulminant cepacia syndrome (Isles et al, 1984; Govan et al, 1993). Possible
explanations for the variable outcome of B. cepacia colonisation include differences
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in strain virulence (Govan et al, 1996), the underlying severity of CF disease (Tablan
et al, 1985; Lewin et al, 1990; Brown et al, 1993) host immune response (Shaw et al,
1995a), gender (Thomassen et al, 1985; Govan et al, 1993), age at colonisation
(Whiteford et al, 1995) and the effect of co-colonising respiratory pathogens (Shaw
et al, 1995b).
Genomovar status andpathogenicity
Recently, attempts have been made to link B. cepacia genomovar status with both
transmissibility and pathogenicity in CF. Comparison of genomovar data for a panel
of B. cepacia isolates found examples of genomovars I to IV and B. vietnamiensis
amongst CF isolates (Govan et al, 1996). Flowever, genomovars II and III were
associated more frequently with CF than other genomovars and included examples of
known epidemic lineages, including the ET12 lineage which belongs to genomovar
III. Strains associated with severe disease and cepacia syndrome in CF belonged
predominantly to genomovar III. One patient who was colonised with a genomovar I
strain subsequently died, but it was not clear whether B. cepacia had contributed to
his death. A survey ofBelgian CF patients identified genomovars II, III and IV
amongst 12 B. cepacia-colonised patients but no genomovar I isolates (Revets et al,
1996). PFGE patterns revealed transmission of one genomovar III strain between 4
CF patients within a clinic but not of two other genomovar III strains. Other isolates
were unique, apart from one genomovar IV strain detected in two patients from
another clinic. It may be relevant to note that of the 12 patients, only one individual
who was colonised with the transmissible genomovar III strain, displayed a
deterioration on acquisition ofB. cepacia and died 5 years after first B. cepacia
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culture. In conclusion, present knowledge suggests that genomovar III strains are
associated with pathogenicity in CF. However further microbiological and
epidemiological studies are required to validate this important association.
1.4.4 B. cepacia cell surface structures
The outer surface of Gram-negative microbes is characterised by two lipid bilayers,
the cytoplasmic and outer membranes, located on either side of a thin peptidoglycan
wall. LPS is expressed on the outer membrane and consists of a hydrophobic anchor
region termed lipid A, embedded in the outer membrane and linked by core
oligosaccharide to the hydrophilic O antigen region made up of repeating
oligosaccharide units, extending into the surrounding environment of the bacterium.
LPS may be complete, i.e. expressing O antigen, in which case it is referred to as
'smooth', or lacking in O antigen, in which case it is referred to as 'rough'. Outer
membrane proteins (OMPs) are also expressed at the cell surface and include
transmembrane structures involved in signalling, nutrient uptake and secretion
processes, or proteins expressed only on the inner or outer surface of the membrane
involved in bacterial signalling and adhesion. Production of extracellular
polysaccharide may give rise to capsule formation around the organism. Other
appendages, in particular pili and flagella may be present on the surface of the
bacterium.
Several researchers have investigated various aspects of the B. cepacia outer surface
including LPS structure, OMP profiles, extracellular polysaccharide production and
expression ofpili or flagella. The potential role of B. cepacia pili in adhesion and
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transmissibility has already been discussed in section 1.4.2. Exopolysaccharide
production, OMP expression and LPS structure will be discussed below.
Exopolysaccharide production
Given the importance of alginate production in the pathogenesis of P. aeruginosa
infection in CF (Govan and Deretic, 1996), attempts have been made to identify
alginate production in B. cepacia strains. To date, production of an alginate-like
polysaccharide, containing 72% guluronic acid, has been reported in a single strain
only (Straus et al, 1989). In another study, a pivotal gene in the alginate biosynthesis
pathway termed algD, was not found in any of 10 B. cepacia isolates (Nelson et al,
1994). Other studies have identified non-alginate heteropolysaccharide production in
some B. cepacia strains but no correlation has been found with colonisation or
virulence in CF (Allison and Goldsborough, 1994; Sage et al, 1990; Nelson et al,
1994). Furthermore, unlike P. aeruginosa, isolation ofmucoid B. cepacia variants
amongst CF patients is rare and has not been associated with severe disease (Govan
and Deretic, 1996).
Outer membrane protein expression
Researchers have identified various OMP profiles in B. cepacia strains. Aronoff and
Stern (1988) identified 5 major OMP comprising OMP A (56kDa), OMP B (38kDa),
OMP C (37kDa), OMP D (28kDa) and OMP E (21kDa). Anwar et al (1983)
described major OMPs at 40kDa, 36kDa, 24.5kDa, 17kDa and 14.5kDa. An 81kDa
OMP has also been described (Parr et al, 1987; Gotoh et al, 1994), which dissociates
into 36kDa and 27kDa components, probably corresponding to the C and D proteins
of Aronoff and Stern and the 36kDa and 24.5kDa proteins of Anwar et al. Nutrient
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depletion has been associated with changes in OMP profiles, including the induction
of a 66kDa OMP under conditions of iron depletion (Anwar et al, 1983).
Considerable phenotypic variability in the OMP expression of clonally related
isolates may also occur. For example, in the study of Larsen et al (1993), up to
5 OMP profiles were observed from clonal isolates derived from one colonised CF
patient.
Several studies have reported an association between OMP expression and antibiotic
resistance in B. cepacia infection (Parr et al, 1987; Moore and Hancock, 1986;
Aronoff, 1988). Many hydrophilic antibiotics, including P-lactams, depend on the
presence of suitable transmembrane protein channels termed 'porins', to diffuse
across the bacterial outer membrane. Parr et al (1987) demonstrated that the 81kDa
complex referred to earlier forms an unusually small porin channel in lipid bilayers,
through which p-laclam antibiotics would be unable to pass. Antibodies to both the
36kDa (OMP C) and the 27kDa (OMP D) OMPs of this complex have been
demonstrated in the serum ofB. cepacia-colonised patients, demonstrating that both
molecules are expressed in vivo and may be involved in antibiotic resistance
(Aronoff and Stern, 1988). Changes in OMP profiles may also be important in the
development of resistance to other antimicrobial compounds, particularly in vivo
where dramatic variation in antibiotic resistance patterns can be observed even within
clonal isolates from individual patients (Corkill et al, 1994a; Larsen et al, 1993;
Hobson et al, 1995; Pitt et al, 1996)
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Lipopolysaccharide
Bacterial lipopolysaccharide is a potent inflammatory molecule and thus a major
virulence factor in many infectious diseases. As biological activity is highly
dependent on LPS structure, several researchers have investigated the nature of
B. cepacia LPS. Strains of B. cepacia may produce rough or smooth LPS, although a
predominance of strains producing rough LPS have been noted in CF patients,
particularly amongst highly transmissible lineages (Nelson et al, 1994; Butler et al,
1994b; Simpson et al, 1994). Unlike P. aeruginosa, there is no evidence to suggest
that B. cepacia initially colonises CF lungs in a smooth form before changing to a
rough form (Nelson et al, 1994). However antibody to B. cepacia O-antigen has
been demonstrated in serum from patients colonised with apparently rough
B. cepacia strains (Lacy et al; 1995; Shaw, 1995). These observations suggest that
B. cepacia may undergo phenotypic variation in vivo, expressing O-antigen under
certain situations not yet reproduced in the laboratory. Butler et al (1994)
demonstrated serum sensitivity of rough B. cepacia isolates despite the ability of the
strains involved to cause septicaemia in CF patients. It is tempting to speculate that
this observation may be due to transient expression of smooth LPS in bacteraemic
B. cepacia. However comparison ofblood culture and sputum isolates ofB. cepacia
shows no difference in LPS expression.
Chemical analyses and studies of antibody responses have indicated that the structure
of B. cepacia core LPS is markedly different from that of P. aeruginosa LPS (Nelson
et al, 1993; Lacy et al, 1995; Manniello et al, 1979). In an earlier study LPS from
several strains of B. cepacia was found to contain less phosphorus but more heptose
64
than P. aeruginosa LPS (Manniello et al, 1979). The presence of 3-deoxy-D-manno-
2-octulosonic acid (KDO) has been linked to LPS toxicity, but several studies have
reported little or no detectable KDO in B. cepacia LPS (Manniello et al, 1979; Shaw
et al, 1995a). Straus et al (1990) demonstrated the presence of KDO in only 1 out of
6 B. cepacia strains using standard assay conditions but were able to detect KDO in
all strains using a modified assay procedure. They concluded that KDO in
B. cepacia LPS may be altered by substitution at a carbon position, thus rendering
the molecule undetectable under normal assay conditions. Simultaneous studies of
mouse lethality, however, demonstrated no difference in toxicity, suggesting that the
form of KDO present had no impact on LPS biological activity.
Although LPS is a major bacterial virulence determinant, studies of the biological
activity ofB. cepacia LPS are limited. The toxicity of an extracellular compound of
LPS, carbohydrate and protein in a mouse model appeared to be related to the LPS
content of the compound. (Straus et al, 1989). As discussed in section 1.4.7, Shaw et
al (1995a) have shown LPS from a range of B. cepacia strains to be efficient inducers
of the pro-inflammatory cytokine TNF-a from human monocytes. In this study,
neither LPS O-antigen expression nor content ofphosphorus and KDO correlated
with cytokine-inducing activity.
1.4.5 Production of extracellular virulence factors by B. cepacia
B. cepacia produce a range of extracellular compounds including protease, lipase,
gelatinase, haemolysin, catalase and siderophores (Nelson et al, 1994; Govan and
Deretic, 1996). No definitive role has been found for any of these substances in CF,
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although the production of catalase is linked to the ability of B. cepacia to cause
infection in CGD.
Protease, lipase and haemolysin production
A 34kDa proteinase sharing antigenic similarities with P. aeruginosa elastase and
cleaving gelatin and collagen has been isolated from B. cepacia (McKevitt et al,
1989). Intratracheal instillation of the purified protease into rat lungs was associated
with the development ofbronchopneumonia. Despite these findings, the observation
that many CF strains of B. cepacia do not produce any proteolytic activity, would
suggest that protease production is not a major virulence determinant in B. cepacia
infection of the CF lung (Govan and Deretic, 1996).
Lipase and haemolysin production by B. cepacia is also highly strain dependent.
Haemolytic activity is found in a minority of clinical strains (McKevitt and Woods,
1984; Nakazawa et al, 1987; Gessner and Mortensen, 1990), although in one study,
investigation of activity on a panel of erythrocytes from various species found 40%
of strains to be haemolytic against at least one form of erythrocyte (Vasil et al, 1990).
By contrast, lipase activity, including the production of phospholipase C (PLC), is
found in over 60% of B. cepacia isolates (McKevitt and Woods, 1984; Gessner and
Mortensen, 1990). Purified B. cepacia lipase (MW 25,000) demonstrated no toxicity
for either mice or HeLa cells (Lonon et al, 1988) but in a later study this same lipase
was found to disrupt rat alveolar macrophage phagocytosis in a dose-dependent
manner, suggesting a possible role for lipase in human infection (Straus et al, 1992).
However, as many CF isolates of B. cepacia do not possess lipolytic activity,
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production of lipase may play only a minor role in B. cepacia infection (Govan and
Deretic, 1996).
Unlike P. aeruginosa, PLC activity in B. cepacia does not correlate with haemolytic
activity, although a heat-labile haemolysin with PLC and sphingomyelinase activities
has been described (Vasil et al, 1990). Thus although haemolytic strains of
B. cepacia display PLC activity, many strains positive for PLC do not express
haemolytic activity (Nelson et al, 1994). Studies of PLC have revealed the complex
nature of PLC regulation and expression in B. cepacia. In particular, a gene probe
directed to the B. cepacia PLC gene was found to bind to restricted DNA in a highly
variable manner (Vasil et al, 1990). One possible explanation for this finding is
migration of insertion sequences (IS) within the B. cepacia genome. Multiple IS
have been found within the B. cepacia genome and are believed to be involved in the
activation or inactivation of gene expression (Scordilis et al, 1987). The variability
in the expression of haemolytic and PLC activity and the observation of conversion
of a haemolysin-positive strain to a haemolysin-negative mutant following DNA
rearrangements (Vasil et al, 1990) would support this hypothesis.
Abe and Nakazawa (1993) described the production of a novel compound displaying
haemolytic and antifungal activity, by a clinical isolate ofB. cepacia. This
substance, termed cepalycin, was a small non-proteinaceous heat-resistant compound
which was demonstrated to form pores within erythrocyte membranes as determined
by electronmicroscopy. Haemolytic activity was inhibited by sterols. Recently
Hutchison et al (1998) have described a haemolysin extracted from a representative
isolate of B. cepacia ET12 displaying many properties similar to cepalycin.
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Biochemically the haemolysin behaves as a classical lipopeptide. Haemolytic
activity follows pore formation in the erythrocyte membrane and is inhibitable by
sterols. Biological assays have indicated a possible clinical role for this substance
which induces neutrophil apoptosis at low concentrations and neutrophil
degranulation at higher concentrations. As the haemolysin is only expressed in
conditions of high oxygen tension, the authors speculate that the most likely role for
this molecule is in the initial establishment of infection in the CF lung.
Gessner and Mortensen (1990) compared 98 CF and 21 control (environmental and
non-CF clinical) isolates of B. cepacia for a wide range of potential virulence factors.
Significant differences included greater catalase production, ornithine decarboxylase
activity and a haemolytic activity amongst CF strains, whilst control strains were
more likely to display nitrate reduction, urea hydrolysis, xanthine hydrolysis, valine
aminopeptidase activity, C14 lipase activity, p haemolysis and alginase and trypsin
activity. However, the role of any of these factors in pathogenesis remains unclear.
Siderophore production
The production of iron-binding siderophores enables bacteria to compete with host
proteins for limited iron resources and is thus associated with virulence. B. cepacia
produces at least three iron-binding siderophores, termed cepabactin, azurechelin and
pyochelin, the latter being chemically unrelated to the P. aeruginosa siderophore of
the same name (Sokol, 1986; Bukovits et al, 1982; Sokol et al, 1992; Meyer et al,
1989). To date, a definitive role for any of the B. cepacia siderophores in CF has not
been demonstrated. Sokol (1986) reported increased morbidity and mortality in CF
patients colonised with pyochelin-producing strains but half of all CF isolates
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investigated were pyochelin-negative. Administration of exogenous pyochelin
enhanced the virulence of non-pyochelin producing B. cepacia in a rat model of
chronic pulmonary B. cepacia infection (Sokol and Woods, 1988), suggesting that
pyochelin may aid B. cepacia dissemination through the lungs. A role for
azurechelin in pathogenesis has also been suggested following the observation of
azurechelin production in 88% of clinical isolates of B. cepacia (Sokol et al, 1992).
1.4.6 B. cepacia and intracellularity
Several puzzling clinical and scientific observations have led to speculation that
B. cepacia may survive and grow within pulmonary phagocytes or respiratory
epithelial cells: first, clinical resistance to antimicrobial therapy despite
demonstration of in vitro susceptibility; second, culture of serum sensitive isolates in
bacteraemic infection (Butler et al, 1994a); third, chronic pulmonary colonisation
despite a pronounced antibody response (Nelson et al, 1993); fourth, the close
taxonomic relationship between B. cepacia and the highly virulent intracellular
pathogen, Burkholderia pseudomallei (Palleroni, 1984; Pruksachartvuthi et al, 1991).
To date, however, the scientific evidence for intracellular survival or growth of
B. cepacia is not convincing. Studies of intracellularity in bacterial pathogens can be
difficult and in the case of B. cepacia are further complicated by the organism's
innate resistance to antibiotics, including aminoglycosides, which are commonly
used in intracellular assays to kill extracellular organisms. In a short abstract, Burns
(1992) reported the observation of B. cepacia within CF post-mortem respiratory
epithelial cells by electronmicroscopy. No further evidence was presented until 1996
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when the same authors reported that B. cepacia ET12 invaded cultured respiratory
epithelial cells to a greater extent than an apparently non-transmissible CF strain of
B. cepacia (Burns et al, 1996). Other researchers have also demonstrated low level
in vitro invasion of respiratory epithelial cells by the ET12 lineage (Tipper et al,
1995) but the role of epithelial invasion in vivo remains unclear. As a caveat, the
demonstration of the intracellular survival and growth ofB. cepacia within amoeba
raises the possibility that free-living protozoa may act as an environmental reservoir
from which CF patients could acquire the organism (Landers et al, 1995).
1.4.7 The immune response to B. cepacia infection in CF
Humoral immune responses
In CF patients, colonisation with B. cepacia is associated with a pronounced and
specific humoral response, including raised serum IgG and IgA and sputum TgA titres
against B. cepacia lipopolysaccharide (LPS) and outer membrane components
(OMP) (Nelson et al, 1993; Aronoff et al, 1991). Anti-5. cepacia antibodies have
also been detected in non-colonised CF patients, and particularly in patients
colonised with P. aeruginosa (Nelson et al, 1993; Aronoff and Stern, 1988). Studies
using pre-absorbed sera have failed to demonstrate an appreciable degree of cross-
reactivity between the two species, either for OMP or LPS components (Nelson et al,
1993; Lacy et al, 1995) suggesting that the response to P. aeruginosa is not the
source of pre-colonisation anti-5. cepacia antibody. Generally, levels of anti-
B. cepacia immunoglobulin in non-colonised patients are low but the demonstration
of substantially raised titres in a subset ofpatients may reflect prior exposure to
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B. cepacia where an appropriate antibody response has prevented the occurrence of
chronic colonisation. The role of antibody once B. cepacia is established in the CF
lung is unclear; for example, clinical outcome is independent of the magnitude of
anti-5. cepacia responses (Nelson et al, 1993). Measurement ofhumoral responses
to B. cepacia core LPS amongst B. cepacia-colonised patients has demonstrated
variable IgG subclass expression with a predominance of IgG2 and IgG3, leading the
investigators to speculate that the poor clinical outcome in some colonised patients
may be due to an inappropriate IgG subclass response (Butler et al, 1994b). A recent
study by Burnie et al (1995), using immunoblotting techniques, suggested that IgG
antibodies against a 30 kDa OMP, presumptively identified as the major
immunodominant porin OMP D (Aronoff and Stern, 1988, Parr et al, 1987), are
associated with a better prognosis in colonised patients. If these results are
confirmed, it raises the possibility of using this OMP as a target for immunotherapy.
The association ofB. cepacia with CGD (O'Neil et al, 1986; Lacy et al, 1993) and
the role ofneutrophils as the predominant immune effector cell in the CF lung
(Konstan et al, 1994) have led to speculation that the interaction between B. cepacia
and neutrophils may be important in the evasion of host defences by this organism.
Speert et al (1994) demonstrated that unlike P. aeruginosa, B. cepacia is resistant to
non-oxidative neutrophil killing mechanisms; hence the role of B. cepacia in CGD.
Evasion of the normal neutrophil oxidative burst, through the avoidance of
opsonisation with specific immunoglobulin, would aid the survival of B. cepacia in
the presence of a pronounced immune response. Such a situation can be postulated
within the CF lung, where normal opsonisation processes are disrupted by proteolytic
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cleavage of complement receptors and immunoglobulin molecules (Doring, 1994;
Suter, 1994), neutralising the humoral immune response to B. cepacia and enabling
the organism to persist despite the high neutrophil presence. This hypothesis,
however, does not explain the ability of rough, O antigen-deficient, serum-sensitive
B. cepacia to cause invasive pneumonitis and septicaemia in patients with elevated
anti-5. cepacia immunoglobulin titres (Butler et al, 1994a).
Inflammatory damage
Recently, increasing evidence has indicated that host immune responses are
important in the pathogenesis of B. cepacia infection. A UK multicentre study has
shown that levels of the inflammatory markers, C-reactive protein and neutrophil
elastase al-antiproteinase complex, are significantly higher during B. cepacia-
associated exacerbations than in exacerbations due to P. aeruginosa. Aggressive
antibiotic treatment with the most active agents available did not eliminate
B. cepacia but in most cases was associated with a decline in inflammatory markers
to pre-exacerbation levels (Elborn et al, 1994). In addition, anecdotal evidence
indicates that patients who exhibit rapid pulmonary decline and pronounced
inflammatory symptoms, but do not respond to antibiotic therapy, nevertheless
respond to treatment with commercial preparations of immunoglobulin (Govan et al,
1996). The relative absence of B. cepacia antibodies in healthy humans (Nelson et
al, 1993), from whom these immunoglobulins are obtained, suggests that such
preparations contain potentially useful anti-inflammatory activity.
Shaw et al (1995a) have demonstrated that LPS from clinical and environmental
isolates of B. cepacia induces pro-inflammatory cytokines, including the major
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cytokine TNFa, to a level ten times that induced by P. aeruginosa LPS and matching
the inflammatory power ofEscherichia coli endotoxin (Shaw, 1995; Shaw et al,
1995a). The mechanism involved in B. cepacia cytokine stimulation is unclear but is
independent of CD 14 receptors. Of interest, induction of TNFa by B. cepacia LPS
was reduced in the presence of P. aeruginosa LPS which suggests that the diversity
of clinical outcomes in patients colonised with B. cepacia may in part be influenced
by the presence or absence ofP. aeruginosa and other CF pathogens (Shaw et al,
1995a; b).
The pro-inflammatory effect of B. cepacia has also been shown in studies by
Palffeyman et al (1997) who demonstrated the induction of the cytokine IL-8 in a
respiratory epithelial cell line by supernatants from B. cepacia culture. Since
purified LPS induced little or no IL-8 production by epithelial cells, activity did not
appear to be related to the presence ofLPS in the culture supernatants. As IL-8 is a
potent chemotactic agent for neutrophils, these results suggest that B. cepacia may
increase neutrophil recruitment, with a resulting increase in the inflammatory burden
within the CF lung.
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Chapter 2 Methods
2.1 Materials And Equipment
2.1.1 Bacterial strains
Strains used in this thesis are from the collection ofDr John Govan (CFL, Dept of
Medical Microbiology, Edinburgh University) and are described in Table 2.1.
Information regarding pulsed field gel electrophoresis patterns and genomovar status
was provided by Mrs C Doherty (CFL) and Dr P Vandamme (University of Gent,
Belgium) respectively. Phenol water extracts of LPS from strains P. aeruginosa
PAOl and C1250, and B. cepacia J2540, J2505 and CI504, were provided by Dr D
Shaw and from E. coli 018K- by Dr D Delahooke, (MPRL, Dept. of Medical
Microbiology, Edinburgh University). B. cepacia haemolysin was provided by Dr M
Hutchison (CFL).
2.1.2 Serum and antibodies
Serum from CF patients was provided by the adult CF clinic at the Western General
Hospital, Edinburgh. Serum was extracted from clotted blood samples after
overnight storage at 4°C. RBC were removed by centrifugation and samples stored at
-20°C before use. Heat-inactivated sera were prepared by incubation of serum at
56°C for 1 hour before use. Pooled human serum and pooled human AB+ serum
were provided by the Scottish Blood Transfusion Service, (SEBTS, Royal Infirmary
Edinburgh).
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C1394 Manchester epidemic strain III




C1576 Glasgow epidemic strain II
C1579 Glasgow epidemic strain II






J2315 ET12 lineage (Edinburgh, index case) III
J415 non-epidemic III
Non-CF clinical
CI 962 Cerebellar abscess II
J2352 Neonatal infection III
J2503 ATCC 25608, Wound infection I, III, IV
J2505 ATCC 17762, UTI I, III, IV
J2660 ITU infection III
J2684 Pneumonia
Environmental
J2395 Soil (pot plant, respiratory unit) II
J2504 ATCC 29424, Soil
J2511 ATCC 17616, Soil
J2540 RBGE, Soil I
J2552 RBGE, Soil I
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Table 2.1b Other strains used in this thesis
Pseudomonas aeruginosa
A15 non-mucoid CF strain
A593 non-mucoid CF strain
A603 non-mucoid CF strain
A605 non-mucoid CF strain
A607 non-mucoid CF strain
A609 non-mucoid CF strain
CI 249 non-mucoid CF strain
C1250 mucoid CF strain (isogenic CI249)
H228 non-mucoid CF strain
H230 non-mucoid CF strain
J1385 non-mucoid CF strain




J2563 haemolytic clinical isolate
For flow cytometry, murine monoclonal antibodies conjugated to FITC were
provided by Serotec Ltd (Kidlington, Oxford, UK) including control IgGl and anti-
human CD1 lb.
2.1.3 Mice
Wild-type and CF mice were provided by Prof D. Porteous, MRC HGU, WGH
Edinburgh. Mice were housed either in standard conditions or in a specific pathogen
free environment as stated in the results section. Background colonisation of the
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respiratory tract was investigated in a range ofmurine strains, including MF1,
C57/B16, CI29 and the Edinburgh transgenic CF mouse (Dorin et al, 1992).
Clearance of B. cepacia J2315 was initially investigated in Swiss mice. In all other
experiments, mice used were from breeding programmes involving heterozygotes of
the Edinburgh transgenic CF mouse (CFHGU/+ : h/+; Dorin et al, 1992) and the UNC
knockout mouse (CF^A-: u/+; Snouwaert et al, 1992). Non-CF mice were
therefore wildtype (+/+) or heterozygotes (h/+ or u/+), whilst CF mice were
compound heterozygotes (h/u) or homozygotes (h/h or u/u).
2.1.4 Chemicals and media
Solutions
Unless otherwise stated, all solutions were sterilised by autoclaving at 121°C/15psi
for 15 min. Saline solutions were prepared at both 0.85% and 0.9% (w/v) in distilled
water. Phosphate buffered saline (PBS) was prepared using one PBS tablets (Oxoid,
Basingstoke, Hants) per 100 ml distilled water. Pyrogen-ffee water (pfH20) was
obtained using a Milli-Q Reagent Grade Water system (Millipore Corporation,
Molshiem, France). Pre-sterilised Hanks balanced salt solution with Ca2+ and Mg2+
but without phenol red (HBSS) was obtained from Sigma (Sigma-Aldrich Coy. Ltd.,
Poole, Dorset). For neutrophil incubations, HBSS was modified by addition of 0.1%
(w/v) glucose from a filter-sterilised stock solution of 50% (w/v) glucose (mHBSS).
Bacteriological media
Unless otherwise stated media were provided by Oxoid. All media were sterilised by
autoclaving at 121°C/15psi for 15 min except skimmed milk which was autoclaved
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for only 5 min and Malka medium which was prepared from sterile stock solutions.
Nutrient agar: Columbia agar base, 39 g/L.
Tryptone soya agar (TSA): Tryptone soya agar, 40 g/L.
Blood agar: Columbia agar base, 39 g/L, with 5% sterile horse blood
(E-0 Laboratories, Bonnybridge, Falkirk) added after autoclaving, when the agar has
cooled to 50°C.
Cepacia agar (CEP): Cepacia agar (MAST Diagnostics Ltd., Bootle, UK), 32.5 g/L.
Add one Selectatab (MAST) per 100 ml agar after autoclaving, when the agar has
cooled to 50°C. This gives a final antibiotic concentration of 300 U/ml polymixin
and 100 pg/ml ticarcillin.
Pseudomonas isolation agar (PIA): Pseudomonas isolation agar (Difco
Laboratories, Michigan, USA) 45 g/L with 2% (v/v) glycerol (BDH, Merck Ltd.,
Dorset, UK), added prior to autoclaving.
Skimmed milk: Skimmed milk powder, 10% (w/v).
Nutrient broth (NYB): Oxoid broth No 2, 25 g/L, with 0.5% (w/v) yeast extract
(Difco) added prior to autoclaving.
Malka medium stock solutions: All stock solutions were prepared with sterile
pfH20 in clean sterile glassware (Table 2.2). All chemicals were Analar grade,
supplied by BDE1 (Merck Ltd, Dorset, UK).
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Table 2.2 Malka Medium stock solutions
Solution Recipe
A NajHPC^ (7.34 g/100 ml) and KH2P04 (3.24 g/100 ml). pH adjusted to
7.2. Stored over 3-5 ml chloroform.
B MgS04.7H20 (20.5 g/100 ml). Stored over 3-5 ml chloroform.
C 50% (w/v) glucose. Filter sterilised.
D FeS04.7H20 (0.183 g/100 ml). Add 1 drop of concentrated H2S04 or HC1.
E (NH4)2S04 (5 g/100 ml). Stored over chloroform.
Malka medium (MMFe+): Add 20 ml A, 20 ml B, 5 ml C, 1 ml D, and 20 ml E to
934 ml sterile pfH20 in a sterile clean glass container. For iron-deficient Malka
medium (MMFe ) omit solution D.
Chemicals
All chemicals were Analar grade, provided by BDFI unless otherwise stated.
Luminol (5-amino-2,3-dihydro-l,4-phthalazinedione; Sigma) and lucigenin (bis-N-
methylacridinium nitrate; Sigma) were stored as 0.1 M stock solutions in dimethyl
sulphoxide (DMSO) at -20°C. Other stock solutions included fMet-Leu-Phe (FMLP;
Sigma), stored as a 10"3 M solution in DMSO at-20°C, and phorbol 12-myristate 13-
acetate (PMA, Sigma), stored as a 1 mg/ml solution in distilled water at -20°C.
Solutions for flow cytometry, including FACS Lysing Solution and CellFix, were
supplied by Becton-Dickinson (Cowley, Oxford). Dihydrorhodamine (DHR) was
supplied by Cambridge Biosciences, Cambridge, UK and was stored as a 10 mg/ml
stock solution in DMSO at -20°C in the dark.
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2.1.5 Equipment
Chemiluminescence experiments were carried out using a LabSystems Luminometer
(Labsystems, Life Sciences International UK Ltd, Basingstoke, Hants), in the
laboratory of Dr GR Barclay, SEBTS. Flow cytometric analyses were conducted
using a Becton Dickinson FACSort, also in the laboratory of Dr Barclay. Other
items of equipment are described within the relevant section.
2.2 General Bacteriological Methods
2.2.1 Storage, recovery and growth of bacteria
Bacteria were stored in skimmed milk at -70°C and were recovered by streaking onto
nutrient agar or TSA. Bacterial cultures were maintained on the bench by weekly
passage on CEP for B. cepacia or PIA for P. aeruginosa, but were replenished from
frozen stores at 1-2 monthly intervals. For the majority of experiments bacteria were
grown overnight in NYB at 37°C with orbital incubation at 140 rpm. Unless
otherwise stated, bacterial cultures were standardised spectrophotometrically to a
concentration of 1 x 109 cfu/ml using an OD590 of 1.0.
2.2.2 Extracellular products ofB. cepacia isolates
Lecithinase test agar was prepared using standard TSA with 0.11% (w/v) CaCl2 and
5% (w/v) egg yolk powder (Oxoid). Protease test agar was prepared as follows.
9.25 g of Brain, Heart Infusion powder (Oxoid) was dissolved in 25 ml of distilled
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water and dialysed against 500 ml distilled water for 18h at 4°C. The resultant
dialysate was combined with 3% bacteriological agar and 3% skimmed milk before
sterilisation. Elastase test agar was prepared similarly except that skimmed milk was
omitted and 1% UV-sterilised Elastin Congo Red stain was added to the medium at
50°C after autoclaving. Haemolysis was tested using blood agar with 5% horse or
human blood.
For all media, bacterial strains were tested as follows. Bacteria were grown
overnight in NYB and diluted 1 in 10 before use. Plates were inoculated using a
multipoint inoculator (A400 Multipoint Inoculator, Denley, Billingshurst, Surrey)
and incubated at 30°C and 37°C. Plates were assessed after 24h and 48h, with a zone
of clearing around bacterial growth being a positive result.
Catalase testing was carried out in a bacteriological safety cabinet using 30% H202
solution. Bacteria were grown overnight on either nutrient or cepacia medium.
Using sterile wooden sticks, a small sample ofbacterial growth was smeared onto a
glass slide and 1 to 2 drops of H202 solution added using a glass Pasteur pipette,
before covering with a glass coverslip. Catalase activity was determined by bubbling
of the bacterial culture. Activity was either brisk on the basis of immediate bubbling
or slow on the basis of obvious bubbling only occurring after the addition of the glass
coverslip.
2.2.3 Growth in iron-rich and iron-deficient media
Iron-rich and iron-deficient Malka media (MMFe+ and MMFe" respectively) were
prepared as described as in section 2.1.4. For selected experiments apotransferrin
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(Sigma; stock solution: 10 mg/ml in pfH20) was added to MMFe+ and MMFe" to
give a final concentration of 200 pg/ml (MMFe+TF and MMFeTF). Bacteria were
grown overnight in NYB at 37°C with orbital incubation at 140 rpm. After
centrifugation at 2500 x g for 10 min, bacteria were resuspended in PBS and
standardised spectrophotometrically to give a concentration of 5 x 10s cfu/ml using
an OD525 of 0.43. Bacteria were further diluted in PBS to 5 x 106 cfu/ml. 100 pi
amounts of the 5 x 108 cfu/ml suspension or the 5 x 106 cfu/ml suspension were
added to 10 ml aliquots of the appropriate Malka medium in sterile glass universals,
giving inoculum sizes of 5 x 106 cfu/ml and 5 x 104 cfu/ml respectively. Cultures
were grown for up to 5 days at 37°C, with orbital incubation, and aliquots removed at
intervals for serial dilution and counting of viable bacteria.
2.2.4 Extraction of outer membrane proteins
Bacteria were grown up in at least a 500 ml volume in NYB over a 48h period, in
either shaking culture in air or static culture in air + 5% C02. Cells were washed
twice in PBS at 10,000 x g ( Sorvall, RC-5B centrifuge, Dupont UK Ltd., Stevenage,
Flerts.) before resuspension in 10-20 ml PBS in a glass universal. Samples were
sonicated at an amplitude of 10 pm for 6 x 30s pulses (Microson, Ultrasonic Cell
Disrupter, Heat-Systems-Ultrasonic Inc., NY, USA). For each 10 ml of sample, 1 ml
7% Sarkosyl was added and the cell debris spun out at 10,000 x g for 15 min. The
supernatant was removed and spun again to ensure complete removal of cell debris.
Outer membrane proteins were precipitated by ultracentrifugation at 50,000 x g for
1 hour (Sorvall ultracentrifuge-OTD65B, Dupont UK Ltd.). After resuspension in
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pfH20 a further ultracentrifugation step was carried out. Finally the samples were
resuspended in 2 ml pfH20 and stored in 200 pi aliquots at -20°C. Protein
concentration was determined using the method of Lowry et al (1951), with bovine
serum albumin (BSA) as the protein standard.
2.2.5 Phenol water extraction of lipopolysaccharide
LPS extracts were prepared according to a modified aqueous phenol method of
Westphal and Luderitz (1954) as described in Hancock and Poxton (1988). Bacteria
were grown for 48 hours in a orbital incubator (140 rpm) at 37°C in NYB and washed
twice in PBS at 10,000 x g (Sorvall RC-5B), before resuspension in PBS and
lyophilisation over 48 hours (Edwards Modylo freeze dryer, Edwards High Vacuum
Ltd., Surrey, UK). Dry cells were resuspended (2% w/v) in pfH20 and softened for
1 hour at 60°C, before addition of an equal volume of 90% phenol, pre-warmed to
60°C. The aqueous phenol mixture was incubated at 60°C for 15 min, with shaking,
before cooling on ice. Extracts were transferred to centrifuge tubes and spun at
13,000 x g for 20 min to ensure phase separation. The LPS rich upper aqueous layer
was removed and dialysed overnight against running tap water, before 4 hours further
dialysis against pfH20, with 3-4 changes of water. The resulting dialysate was
lyophilised and resuspended in pfH20 at a concentration of 2 mg/ml. Samples were
sonicated at an amplitude of 10 pm for three to eight 30s pulses to ensure adequate
solubilisation. All samples were stored at -20°C.
LPS purity was confirmed using the method of Bradford (1976) to determine protein
content. Briefly, Bradford's reagent was prepared by dissolving 100 mg Coomassie
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brilliant blue R-250 (Biorad, Hemel Hempstead, Herts.) in 50 ml 95% (v/v) ethanol.
To this was added 100 ml of 85% (w/v) phosphoric acid and the resulting mixture
made up to a volume of 1L in pfH20. Standard solutions of BSA in pfH20 were
prepared as a series of 1 in 10 dilutions from 2 mg/ml to 2 ng/ml. One part standard
or LPS solution was diluted with 4 parts Bradfords reagent and kept at room
temperature for at least 2 min before reading of the OD595. Protein content of LPS
samples was derived using a standard curve of OD595 against protein content prepared
from results for the BSA standards.
2.2.6 SDS-PAGE gel analysis of OMP and LPS extractions
Solutions
OMP and LPS preparations were separated on polyacrylamide gels using the buffer
system of Laemmli (1970). The following solutions were used:
Double strength sample buffer: 0.125M Tris-HCl, 4% (w/v) sodium
dodecylsulphate (SDS), 20% (v/v) glycerol, 2% (v/v) 2-mercaptoethanol, 0.002%
(w/v) bromophenol blue; pH 6.8.
Double strength separating buffer: 0.75M Tris-HCl, 0.2% (w/v) SDS; pH 8.8.
Double strength stacking buffer: 0.25M Tris-HCl, 0.2% (w/v) SDS; pH 6.8.
Acrylamide: 40% (w/v) acrylamide consisting of lOOg acrylamide and 2.7g
methylene bis acrylamide.
Electrode buffer: 0.025M Tris, 0.192M glycine, 0.1% (w/v) SDS; pH 8.3.
84
LPSpreparations
LPS samples (1 mg/ml) were prepared for polyacrylamide gel electrophoresis
(PAGE) as follows: 100 pi LPS was mixed with 100 pi double strength sample
buffer and 50 pi proteinase K solution (Sigma, 2.5 mg/ml in pfH20). Samples were
incubated for 2 hours at 37°C before storage at -20°C. Immediately prior to loading
samples were thawed at room temperature and boiled for 10 min.
OMP preparations
200 pi of each OMP sample was mixed with 200 pi double strength sample buffer.
Standards were prepared from a stock solution of 2 mg/ml protein standards (Sigma)
in single strength sample buffer, by diluting one part standard solution to three parts
single strength sample buffer. Both OMP preparations and standards were boiled for
2-5 min prior to loading onto the gel.
SDS Polyacrylamide gel electrophoresis
LPS preparations were run on a 14% separating gel, whilst OMP preparations were
run on a 12% separating gel. Table 2.3 summarises the preparation of stacking and
separating gels. All gels were degassed prior to addition of TEMED and APS.
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Table 2.3 Preparation ofpolyacrylamide gels
Reagent Stacking gel Separating gel
4% 12% 14%
pfH20 3.5 ml 5.2 ml 3.45 ml
Separating buffer - 17.5 ml 17.5 ml
Stacking buffer 5.0 ml - -
40% Acrylamide 1.0 ml 10.5 ml 12.25 ml
TEMED (NNN'N'-tetramethyl-
1,2-diaminoethane)
20 pi 50 pi 50 pi
Ammonium persulphate
(APS; 15 mg/ml)
0.5 ml 1.75 ml 1.75 ml
The separating gel was poured and overlaid with water-saturated butan-2-ol until set.
After removal of the butan-2-ol, the stacking gel was poured on top and a 20 well
comb inserted. Once set, the comb was removed and the gel apparatus placed into an
electrophoresis tank. Wells were loaded with 40 pi OMP preparations or 20 pi LPS
preparations, and any empty wells loaded with an equivalent volume of single
strength sample buffer. Samples were electrophoresed through the stacking gel at
90V and through the separating gel at 150V. Once the dye front had run a sufficient
distance, gels were removed and stained appropriately.
Silver stainingfor LPS
LPS was visualised using the method of Tsai and Frasch (1982) as described in
Hancock and Poxton (1988). Solutions used were as follows:
Fixative solution: 7% (v/v) acetic acid, 25% (v/v) propan-2-ol.
Oxidising solution: 1.05 g periodic acid in 150 ml propan-2-ol with 4 ml fixative.
Ammoniacal silver nitrate solution: 1.4 ml ammonia solution and 21 ml 0.36%
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(w/v) sodium hydroxide to which 4 ml of 19.4% (w/v) silver nitrate was slowly
added with mixing. The solution was then made up to 100 ml in pyrogen free H20.
Developing solution: 150 ml formaldehyde solution with 10 mg citric acid,
prewarmed to 22°C.
LPS gels were soaked in fixative solution overnight before oxidisation for 10-15 min
in freshly prepared oxidising solution. Gels were then washed in at least four
changes ofpfH20 over a three hour period. The gel was silver-stained by the
addition of freshly-prepared silver nitrate solution for 15 min before washing in at
least 4 changes ofpfH20 over a 40 min period. The gel was developed by addition
of fresh developing solution at 22°C, which was left on the gel until a sufficient
intensity of staining had been reached. Finally the gel was washed thoroughly in at
least four changes ofpfH20 and kept in water until photographed. All steps, except
developing, were carried out on a shaking platform.
Coomassie blue stainingforprotein
Gels were stained for protein using the method described in Hancock and Poxton
(1988). Solutions were made up in pfH20 as follows:
Solution 1: 25% (v/v) propan-2-ol, 10% (v/v) acetic acid, 0.05% (w/v) Coomassie
brilliant blue R-250 (Bio-Rad, Hemel Hempstead, Herts.).
Solution 2: 10% (v/v) propan-2-ol, 10% (v/v) acetic acid, 0.005% (w/v) Coomassie
blue.
Solution 3: 10% (v/v) acetic acid, 0.025% (w/v) Coomassie blue.
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Solution 4. 40% (v/v) methanol, 10% (v/v) acetic acid.
Solution 5: 10% acetic acid.
All steps were carried out on a shaking platform. Protein gels were soaked overnight
in solution 1. Thereafter gels were placed sequentially in solutions 2 - 5 for one hour
at a time. The stained gel was kept in solution 5 until photography.
2.2.7 Bacterial pre-opsonisation
Overnight bacterial cultures in NYB were pelleted by gentle centrifugation at
1500 x g for 20 min without braking. After at least one wash in either PBS or HBSS,
bacteria were resuspended in PBS or mHBSS and adjusted spectrophotometrically to
a concentration of 1 x 109 cfu/ml. Pre-opsonisation was carried out in 5 ml glass
tubes. Aliquots of bacterial suspensions were mixed with sufficient serum to give a
final concentration of 10% serum and incubated at 37°C for 30 min with gentle
shaking. After further centrifugation at 2500 x g for 15 min, the bacterial pellets
were resuspended in a volume ofmHBSS equivalent to the initial aliquot used.
Bacteria were diluted in PBS or mHBSS to the required concentration before use.
In some chemiluminescence experiments (see section 2.4.4), bacteria were also pre-
opsonised with guinea pig complement (GPC, VH Bio Ltd., Gosforth, Newcastle
upon Tyne). GPC was reconstituted at a concentration of 5 mg/ml in distilled water
from lyophilised preparations stored at -20°C. The resulting stock solution was
aliquoted and stored at -70°C until use. Aliquots were thawed on ice immediately
prior to pre-opsonisation, which was carried out as for serum. Initial LCL
experiments indicated that opsonisation with 4% (v/v) GPC solution gave optimum
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complement activity, and further experiments were carried out using 4% GPC as
standard.
2.3 Extraction And Preparation Of Phagocytic Cells
2.3.1 Preparation of monocytes
For assays of intracellular survival, monocytes were extracted from buffy coat
preparations provided by SEBTS. Buffy coats were diluted 1 in 4 with PBS and
layered onto Histopaque-1077 (Sigma). Gradients were spun at 400 x g for 25-30
min and cells harvested from the interface between the two layers. Cells were
washed in RPMI 1640 (Gibco BRL, Life Technologies Ltd., Paisley, Renfrewshire)
and pelleted by centrifugation at 150 x g for 5 min. After a further wash and
pelleting at 150 x g for 5 min, monocytes were resuspended in a small volume of
RPMI 1640. A 50 pi aliquot was diluted in 450 pi Trypan blue, and the
concentration of monocytes determined by counting in a haemocytometer at a
magnification of x 25. Viability, as determined by the exclusion of the Trypan blue
dye, was greater than 95%. The monocyte suspension was adjusted to give a final
concentration of 5 x 106 viable cells/ml.
For assays of intracellular uptake of bacteria by monocytes, cells were prepared from
fresh blood donated by healthy volunteers. Blood was diluted 1 in 4 in PBS and
monocytes extracted as above. Finally monocytes were resuspended in Eagles
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medium (1% w/v Eagles salts (Gibco), 1% (v/v) HEPES (Sigma) and 1-2% (w/v)
NaHC03) at a concentration of 5 x 106 /ml.
In some experiments, the mouse monocyte cell line J774.2 was used rather than
human monocytes. Briefly J774.2 was cultured in Dulbecco's minimal essential
medium (DMEM; Gibco) with 10% FCS (Sigma) and with 1% stock
penicillin/streptomycin solution (Sigma) in a 5% C02 incubator at 37°C. Cells were
harvested by gentle scraping and washed twice in PBS before resuspension at 1 x 107
cells/ml in DMEM with FCS but without antibiotics.
2.3.2 Neutrophil preparation using the plasma-Percoll method
For killing assays and chemiluminescence experiments neutrophils were extracted
from fresh blood according to the plasma-Percoll method described by Haslett et al
(1985) with minor modifications. Using 3.8% sodium citrate as an anticoagulant
(1 ml citrate per 10 ml blood), fresh whole blood was collected from healthy
volunteers and centrifuged at 300 x g for 20 min. The platelet rich plasma (PRP)
was removed and the cell pellet gently mixed with a solution of 6% (w/v) dextran
(MW: 500,000; BDH) in 0.9% NaCl, prewarmed to 37°C, in a ratio of one part
dextran solution to four parts cell pellet. After making up to double the volume with
NaCl at 37°C, the blood was allowed to sediment at room temperature for 25-40 min.
Platelet poor plasma (PPP) was prepared by centrifugation of PRP at 2500 x g for 10
min. Percoll solutions were made up from a stock Percoll solution of 9 parts Percoll
to 1 part 0.9% NaCl, as described below:
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51%: 1.02 ml Percoll solution 0.98 ml PPP
42% 0.84 ml Percoll solution 1.16 ml PPP
The leucocyte rich upper layer was collected from the dextran sedimentation, spun at
300 x g for 6 min and resuspended in 2 ml PPP. The Percoll density gradient was
overlaid (51% followed by 42% followed by the leukocyte layer) and spun at 275 x g
for 10 min. Neutrophils were collected from the interface between the 51% and 42%
layers, extending into 51% layer. After washing in PPP and then in PBS, RBC were
lysed using 9 parts distilled water for a few seconds, before addition of 1 part xlO
PBS. Neutrophils were washed for a final time in PBS, resuspended in mHBSS and
adjusted to the desired concentration after counting in a haemocytometer. Cell
viability was greater than 95% as confirmed by the trypan blue exclusion test.
Neutrophil purity was confirmed by May-Grunwald/Giemsa staining. Briefly, a
smear of the neutrophil suspension on a glass slide was dried in air before immediate
fixing with methanol for at least 10 min. May-Grunwald stain (Sigma) was added to
the neutrophil smear for 3 min, followed by Giemsa (Sigma) stain for a further 3
min. Smears were viewed under the light microscope at x 25 and were found to
contain >95% polymorphonuclear cells ofwhich >95% were neutrophils.
2.3.3 Neutrophil preparation using the Histopaque method
In superoxide and flow cytometric assays, neutrophils were prepared using the
Histopaque method. Briefly, one part fresh heparinised blood was mixed with 4
parts 6% dextran in 0.9% NaCl and sedimented for 25-40 min at room temperature.
The neutrophil-rich upper layer was collected and layered unto cold Histopaque
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before centrifugation at 150 x g for 30 min. After discarding the upper two layers
the neutrophil cell pellet was washed in HBSS at 150 x g for 5 min. RBC were lysed
by the addition of 9 parts ice cold distilled water for a few seconds, followed by
1 part xlO PBS. After a further wash in HBSS, neutrophils were counted in a
haemocytometer and resuspended in mHBSS to give the desired concentration.
2.3.4 Preparation of washed blood
In the majority of flow cytometry experiments, plasma was removed from whole
blood to prevent any opsonic neutrophil responses to bacteria or LPS. Fresh
heparinised blood from healthy volunteers was transferred to Eppendorf tubes and
spun at 6500 rpm for 30 sec using a Micro Centaur microfuge (MSE, Loughborough,
UK). Following the removal of plasma the cell pellet was washed 4 times in HBSS.
Finally the cell pellet was resuspended in a volume of mHBSS equivalent to the
initial volume ofplasma removed. The resultant 'washed' blood was kept on ice
until use.
2.4 Studies Of Bacteria:Phagocyte Interactions
2.4.1 Washing assay for intracellular survival in monocytes
Intracellular survival of bacteria in monocytes was estimated using an adaptation of
the method utilised by Pruksachartvuthi et al (1990) to demonstrate intracellular
survival of B. pseudomallei in phagocytic cells. Monocytes were prepared according
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to the method outlined in section 2.3.1 above and were resuspended at a
concentration of 5 x 106 cells/ml in RPMI 1640. Overnight cultures of bacteria in
NYB were resuspended in RPMI 1640 at a concentration of 5 x 108 cfu/ml. Reaction
mixtures were prepared in Eppendorf tubes and consisted of 0.5 ml monocyte
suspension, 0.1 ml bacterial suspension, 0.1 ml FCS and 0.3 ml RPMI 1640. After
20 min incubation in a waterbath at 37°C, phagocytosis was stopped by
centrifugation at 6500 rpm in an MSE Microcentaur for 2 min and the resuspension
of the cell pellet in 1 ml ice cold RPMI. Monocytes were washed 5 times in ice cold
RPMI to remove extracellular bacteria before resuspension in 1 ml RPMI +
10% FCS and incubation at 37°C with gentle agitation for 24 hours. Bacterial
viability in RPMI + 10% FCS was assessed concurrently. At intervals samples were
removed and 0.1 ml aliquots mixed with 0.9 ml ice cold distilled water. After
vigorous vortexing to disrupt monocytes, viable bacteria were counted by serial
dilution of the monocyte lysate. Of the remaining sample, 0.5 ml was removed and
fixed with 0.5 ml 2.5% glutaraldehyde (v/v) for electronmicroscopy. After 1 hour,
fixed preparations were washed twice in sodium cacodylate buffer and refrigerated
overnight before electronmicroscopy.
2.4.2 Uptake of bacteria by monocytes using acridine orange/crystal violet staining
J774.2 cells or human monocytes from fresh whole blood were prepared using the
methods outlined in section 2.3.1 above and resuspended in DMEM or Eagles
medium respectively. Overnight cultures of bacteria in NYB were washed once and
resuspended in PBS at a concentration of 5 x 108 cfu/ml, as determined by the OD525.
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Bacterial concentrations were adjusted to give a final concentration approximately
100 times the concentration of illA.2 / monocyte suspensions. In a 1.5 ml
Eppendorf tube, 50 pi pooled human serum, 150 pi cell suspension, 150 pi bacterial
suspension and 50 pi Acridine Orange solution (AO; Pro-Lab Diagnostics,
Bromborough, Merseyside) were mixed and incubated at 37°C for 20 min with gentle
shaking. A 50 pi aliquot was removed from each sample and added to 90 pi cold
0.2% EDTA in PBS to prevent further phagocytosis. After addition of 10 pi
saturated crystal violet solution (CV) for 2 min at room temperature, each sample
was washed once in PBS and, after brief centrifugation at 6500 rpm (MSE
Microcentaur), the supernatant discarded. The resulting cell deposits were
transferred to a glass slide by cytospin and stained for a further 30s with AO at room
temperature before washing in PBS. Finally the stained deposit was covered with a
glass coverslip and sealed with clear nail varnish. Samples were viewed under
incident light fluorescent microscopy and the number of organisms per monocyte
counted for at least 100 cells. Final results were calculated as the average number of
bacteria per monocyte.
To investigate the effect of bacterial viability on the colour of AO staining, studies
were conducted on live and killed bacteria in the absence ofmonocytes. Bacteria
were prepared as above and resuspended spectrophotometrically at a concentration of
5 x 108 cfu/ml. Aliquots were killed either by boiling at 100°C for 5 min or by
exposure to short-wave UV irradiation for 2.5 min at close range. For each
condition, 350 pi bacterial suspension was incubated with 50 pi AO at room
temperature for 2 min before washing in PBS and centrifugation at 6500 rpm (MSE
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Microcentaur) to pellet the bacterial cells. Deposits were cytospun onto glass slides
and covered with glass coverslips before sealing with clear nail varnish and viewing
under incident light fluorescence microscopy.
2.4.3 Killing of bacteria by neutrophils
Killing assays were carried out using neutrophils prepared from fresh whole blood
according to the plasma-Percoll method described in section 2.3.2 above.
Neutrophils were resuspended in PBS at a concentration of 1 x 107 cells/ml.
Bacteria were grown overnight in NYB at 37°C, washed in PBS at 2500 x g for 15
min and finally resuspended in PBS at a concentration of 2.5 x 107 cfu/ml. Assays
were carried out in triplicate in 96 well microtitre plates. To each well, 100 pi
neutrophil suspension, 100 pi bacterial suspension, 5 pi 50 mM CaCl2 solution and
5 pi 50 mM MgS04 solution were added. Control wells were identical except that
the neutrophil suspension was replaced with PBS alone. Plates were incubated at
37°C with shaking. 20 pi aliquots were removed from each well at times 0, 15, 30,
60 and 120 min and added to 1980 pi ice cold distilled water. Samples were kept on
ice for 10 min before vigorous vortexing to ensure adequate disruption of
neutrophils. Bacterial survival was assessed by viable counting.
In initial experiments, killing ofnon-opsonised bacteria was compared with killing of
bacteria opsonised with PHS or with autologous serum from the neutrophil
preparation. Pre-opsonisation was carried out as described in section 2.2.7. Pre-
opsonisation with PHS gave the greatest degree and consistency of bacterial killing
and was used as standard in further killing assays unless otherwise stated.
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2.4.4 Chemiluminescence assay ofneutrophil respiratory burst activity
For chemiluminescence experiments neutrophils were prepared according to the
plasma-Percoll method described in section 2.3.2. Cells were resuspended in
mHBSS prior to use. Unless otherwise stated, bacteria were grown overnight in
NYB at 37°C in an orbital incubator. After centrifugation at 1500 x g for 20 min,
without braking, cultures were resuspended in mHBSS and adjusted
spectrophotometrically to a final concentration of 5 x 108 cfu/ml before use. Where
required, bacteria were pre-opsonised with 10% heat-inactivated serum or 4% GPC
as described in section 2.2.7. Non-opsonised and opsonised zymosan were used as
positive controls for chemiluminescence production. Initial studies indicated that a
concentration of 6 mg/ml zymosan gave adequate results. Zymosan was opsonised
by incubation with pooled human serum for 15 min at 37°C before washing in HBSS
and resuspension in mHBSS at the appropriate concentration.
Studies were carried out in triplicate in 8 or 12 well luminostrips (LabSystems).
Luminol, stored as a 0.1 M solution in DMSO at -20°C, was diluted to a 1 mM
solution in mHBSS prior to use. Luminostrips were loaded in triplicate with 100 pi
neutrophil suspension, 100 pi bacterial suspension and 100 pi luminol solution per
well. Neutrophils were added last, immediately prior to incubation of luminostrips
in the LabSystems luminometer, prewarmed to 37°C. Temperature was maintained
at 37°C and light production measured at 5 min intervals for at least 90 min. Initial
experiments indicated that a neutrophil concentration of 2.5 x 106 cells/ml (i.e.
2.5 x 105 cells/well) gave optimum light production. Bacteria alone produced no
chemiluminescence response.
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Studies using lucigenin rather than luminol chemiluminescence were similar except
that lucigenin was diluted from a 0.1 M stock solution in DMSO to a 30 mM
solution in mHBSS prior to use. In some experiments the inhibitors superoxide
dismutase (SOD) and sodium azide (NaN3) were used. SOD was resuspended in
distilled water at a concentration of 1100 u/ml and stored at -20°C in 100 pi aliquots.
NaN3 was prepared as a 30 mM solution and stored at room temperature. In all
experiments involving inhibitors, 10 pi SOD or 10 pi NaN3 were added to
luminostrips just prior to addition of neutrophil suspensions and incubation in the
luminometer.
2.4.5 Cytochrome c reduction assay for superoxide production
Neutrophils were prepared using the Histopaque method and resupended in PBS
with 0.1% glucose (mPBS) at a concentration of 5 x 106 cells/ml. A solution of
cytochrome c in mPBS at 10 mg/ml was prepared immediately prior to use.
Experiments were carried out in duplicate in Eppendorf tubes, using an initial aliquot
of 0.2 mis neutrophil suspension to which was added 80 pi cytochrome c and the
required volume of stimulant in mPBS. For positive controls, 80 pi zymosan,
previously opsonised with 30% AB+ serum for 15 min at 37°C and resuspended at a
concentration of 10 mg/ml in mPBS, was used as the stimulant. For negative
controls, 80pl SOD (2000 u/ml) was added to the reaction mixture in addition to the
zymosan suspension. The final volume for both samples and controls was made up
to 0.8 mis with mPBS and the resulting reaction mixture incubated at 37°C with
shaking for the desired time period. Reactions were stopped by transfer onto ice,
97
followed immediately by centrifugation at 5°C for 15 min at 400 x g to pellet the
neutrophils. Supernatants were carefully removed and the OD550 read
spectrophotometrically. Extracellular 02~ concentration was calculated using the
following equation:
02" nmol /106 cells /1 min = (Sample OD550 - Negative control OD550) x 68
where t is the time point at which the reaction was stopped.
Stimulants used to assess 02" release included PMA (final concentration: 200 ng/ml)
or bacteria. In the majority of experiments bacteria were resuspended at a
concentration of 5 x 108 cfu/ml and added to the reaction mixture to give a
bacteria:neutrophil ratio of 100:1. However in some experiments varying amounts
ofbacterial suspensions were added to the reaction mixtures to assess the effect of
bacterial concentration on respiratory burst induction. Where required, bacteria were
pre-opsonised with heat-inactivated serum using the method outlined in section
2.2.7.
An attempt was made to develop a microtitre plate assay for cytochrome c reduction
by extracellular 02". Briefly the assay conditions described above were reproduced
in 200 pi volumes in triplicate within microtitre plates. After incubation at 37°C in a
plate warmer for the desired period of time, reactions were stopped by centrifugation
at 5°C for 15 min at 400 x g and 100 pi volumes of supernatant carefully transferred
into ELISA plates for analysis. Optical density was read using a microtitre plate
reader (Tmax Plate Reader, Molecular Devices), and calculated automatically as the
OD550 - OD650, to correct for any defects within the ELISA plate itself. In additional
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experiments, reaction mixtures were prepared as for the standard cytochrome c
method, but after the centrifugation step, supernatants were transferred to ELISA
plates, in triplicate, for reading of the OD550 - OD650.
2.4.6 Flow cytometric analysis of neutrophil surface marker expression
Flow cytometric analysis ofneutrophil CR3 (CD18/CD1 lb) expression was carried
out on purified neutrophils or on neutrophils within whole or washed blood as stated
in the results section. For experiments involving purified cells, neutrophils were
resuspended in mHBSS at a concentration of 5 x 106 cells/ml prior to use. In time
course experiments, neutrophils / blood samples were kept on ice until use. In
experiments involving whole bacteria, overnight cultures in NYB were spun down at
1500 x g without braking, washed once in HBSS and resuspended at a concentration
1 x 109 cfu/ml, using the OD590, before dilution to the desired concentration in
mHBSS.
All experiments were carried out using 100 pi aliquots ofblood or neutrophils in
5 ml polystyrene tubes (Greiner, Stonehouse, Glouc., UK), to which was added an
equal volume of mHBSS or neutrophil stimulant such as whole bacteria, LPS or
haemolysin diluted in mHBSS. The tubes were incubated for the desired time period
at 37°C with gentle shaking. Reactions were stopped by transferring the sample
tubes onto ice After the addition of anti-CD 1 lb:FITC (5 pi) or mouse isotype
control antibody (5 pi) to each sample, the tubes were mixed and incubated for 20
min on ice. Then red blood cells (RBC) were lysed by the addition of 2 ml Lysing
Solution for 30 min. Neutrophils were pelleted by centrifugation at 400 x g, washed
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once in PBS and resuspended in 500 pi CellFIX. Samples were stored at 4°C until
flow cytometric analysis within 24 hours. Neutrophils were gated on forward and
side scatter characteristics using CellQuest 1.2.2 software. CD1 lb expression was
determined as the mean channel fluorescence (MCF) of the neutrophil population
using the green channel (FL1). As considerable inter-donor variation in the
magnitude of neutrophil responses was noted, MCF values were standardised by
expression as a percentage of the MCF of neutrophils treated with buffer alone.
2.4.7 Intracellular H202 production by neutrophils
Neutrophils, bacteria and LPS were prepared as for assessment of CD1 lb expression.
Intracellular H2Oz production was assessed using the fluorescent dye,
dihydrorhodamine (DHR), diluted from the stock solution 1 in 50 times in a 20%
solution of DMSO in mHBSS, before addition to reaction tubes to give a final
concentration of 30 mM DHR (10 pi per 200 pi reaction mixture). Tubes were
incubated at 37°C with gentle shaking for the desired period of time. All
experiments were carried out on an aliquot of 100 pi blood, to which was added an
equal volume of stimulant. Reactions were stopped by transferring the sample tubes
onto ice, RBC were lysed by the addition of 2 ml Lysing Solution for 30 min and the
remaining neutrophils processed as above. As H202 oxidises DHR to fluorescent
rhodamine, intracellular H202 production was determined as the MCF of the
neutrophil population using the red channel (FL2). Results were analysed using
CellQuest and, where required, standardised by expression as a percentage ofMCF
of neutrophils stimulated with buffer alone.
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In experiments investigating the priming of neutrophil respiratory burst responses by
LPS or B. cepacia haemolysin, 100 pi samples ofwashed blood were pre-incubated
with 100 pi priming agent at the required concentration for the desired period of
time. In the majority of experiments, priming was assessed using the neutrophil
stimulant fMet-Leu-Phe (FMLP). A 10"4 M stock solution of FMLP in HBSS was
prepared from a 10"3 M solution in DMSO , and was stored at -20°C. Immediately
before use FMLP was further diluted in mHBSS to give a 10"6 M solution. 200 pi of
FMLP or mHBSS were added to each reaction tube along with 30 mM DHR for a
further 15 min at 37°C. Neutrophil activation was arrested by transfer of the tubes
onto ice and lysis of RBC carried out using 2.4 ml FACS Lysing solution per tube
before proceeding as above.
In experiments measuring priming induced by whole bacteria a similar procedure
was followed except that 100 pi washed blood was incubated with 100 pi bacterial
suspension in the presence of 30 mM DHR before the addition of 10 pi FMLP in
mHBSS at a concentration of 10"5 M to give a final concentration of 5 x 10"7 M. In
experiments measuring the priming of responses to whole bacteria by LPS, bacteria
were resuspended in mHBSS at a concentration of 1 x 108 M and 200 pi added to
each tube, along with 30 mM DHR, after pre-incubation with LPS or mHBSS. After
30 min at 37°C with gentle shaking, reactions were stopped and samples prepared as
above.
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2.5 Studies In The Edinburgh CF Mouse Model
Experiments involving Swiss mice were carried out in collaboration with Dr G
McLachlan, MRC HGU, Western General Hospital, Edinburgh. Otherwise all
studies were carried out in collaboration with Dr DJ Davidson, also from the MRC
HGU.
2.5.1 Bacterial inoculation of mice
Bacteria for inoculation were cultured overnight in NYB, spun down at 2500 x g for
15 min and resuspended in PBS or normal saline before use. Mice were
anaesthetised by intra-peritoneal (i.p.) injection of 0.6 ml 'Avertin', prepared by
dissolving 2.5g tri-bromo-ethanol in 5 ml 2-methyl-2-butanol (tertiary amyl alcohol)
and adding 200 ml distilled water. In the majority of experiments, intubation was
carried out non-surgically using a modified Terumo spinal needle (25g x 3.5").
Mice were inoculated with a 25 pi volume of bacterial suspension or, in initial
experiments, with 25 pi of methylene blue dye which allowed direct visualisation of
administration to the lungs. In studies of the delivery method, mice were killed after
5 min and before recovery from anaesthesia by i.p. injection of 0.5 ml Sagatal
(Rhone-Merieux, Harlow, Essex). In studies ofbacterial clearance mice were
returned to their cages and allowed to recover from anaesthesia before transfer to
isolators within the animal facility.
In some studies, intubation was carried out surgically as follows. A mid-line
incision was placed over the trachea of an anaesthetised mouse and the muscles of
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the throat gently parted to expose the underlying trachea. A specially adapted needle
was passed into the trachea and 25 pi of bacterial suspension inoculated as above. In
all such studies mice were killed by i.p. injection of Sagatal after 5 min and before
recovery from anaesthesia.
2.5.2. Preparation of mice lungs
Mice were killed by i.p. injection of 0.5 ml Sagatal. Death was confirmed by
opening of the peritoneal cavity and dissection of the aorta. A mid line incision was
extended from the peritoneum to the throat, exposing the rib cage and muscles of the
throat. Next the sternum was dissected and the throat muscles parted to reveal the
underlying trachea. A sterile cord was passed under the trachea but above the
oesophagus and tied in a knot around the trachea to prevent contamination with
upper respiratory tract organisms. The trachea was cut above the knot and the lungs
removed by gently pulling the trachea up and forward whilst cutting any connections
of the lung to the underlying rib cage. In the majority of cases this procedure
resulted in the clean removal of the whole lungs.
In some experiments the mouse oesophagus and stomach were also removed after
the removal of the lungs. Briefly the oesophagus was cut at its upper end and gently
peeled from the mediastinal tissue. The stomach was then lifted at its junction with
the oesophagus and removed by applying gentle pressure while cutting any soft
tissue connections.
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Lung lavage was performed prior to lung removal in some experiments. The trachea
was exposed and tied off as above and pierced with a Terumo Surflo i.v. catheter.
1 ml of PBS was infused using a 1 ml sterile syringe, withdrawn and infused again,
and after a few seconds withdrawn again using the same syringe. Recovery of 0.6-
0.8 ml lavage per 1 ml infused was generally obtained. Removal of lungs proceeded
as normal after the lavage process.
Lungs and stomach were placed in sterile plastic bijoux along with 1 ml of PBS, and
specimens kept at 4°C before processing within a 2-3 hour period. Specimens were
homogenised using a hand-held homogeniser (OMNI TH Homogeniser, Camlab,
Cambridge) and bacterial counts determined by serial dilution in saline and plating
onto cepacia medium. Lavage specimens were processed identically except that no
homogenisation step was required. Plates were incubated at 37°C for 48 hours
before counting.
2.6 Statistical Analysis
Statistical analysis was carried out with the aid of Excel v5.0 (Microsoft). The
Students t test was used for the comparison of the means of two samples, where a





Fisher's exact test, the x squared test (with Yates correction), and rank correlation
were carried out as described in Swinscow (1987). For analysis of variance
(ANOVA) raw data were first transformed by conversion to Log10. Mean values (x)
for each experimental conditions were used to calculate the variance of the means
(SD2) and t calculated according to the equation:
t-■





where n is the number of observations per test condition, and Z is the contrast,
derived from the equation:
Z = lxxx +l2x2 + + l„*n
Values for {1, , 12.... ln} were chosen according to the desired comparison to be made
by the test. For example, in flow cytometric analyses of neutrophil priming by
B. cepacia, P. aeruginosa and E. coli LPS, three P. aeruginosa strains were
compared with 5 B. cepacia strains. For each P. aeruginosa strain, 1 = -3, for each
B. cepacia strain, 1 = I and for E. coli 018K- and untreated neutrophils, 1 = 0.
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Chapter 3 Characteristics Of Clinical And
Environmental B. cepacia
3.1 Production Of Extracellular Toxins
A representative panel of clinical and environmental strains of B. cepacia was
assessed for protease, elastase and lipase activity. Clinical isolates consisted of 4 CF
and 2 non-CF strains and included a representative of the ET12 epidemic lineage.
Environmental isolates included 11 strains cultured from various sites within the
Royal Botanic Gardens, Edinburgh (Butler et al, 1995) and representative strains
from the CF Laboratory collection. No B. cepacia strain produced elastase activity at
either 30°C or 37°C. Protease and lipase activity were observed more frequently at
30°C (Table 3.1). Protease activity was detectable in more clinical than
environmental strains but this difference was not statistically significant at either
30°C or 37°C. Lipase activity was more frequent among environmental stains,
particularly at 30°C (p<0.02, Fisher's exact test).
The same panel of strains was tested for haemolytic activity on horse blood agar
(Table 3.2). Haemolytic environmental strains produced either a or p haemolysis
whilst all haemolytic clinical strains produced a haemolysis (Data not shown).
Statistical analysis indicated that significantly more environmental strains displayed
haemolytic activity at 30°C than at 37°C (p<0.05, Fisher's exact test). Furthermore,
fewer clinical strains than environmental produced activity at 30°C (p<0.02, Fisher's
exact test).
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Table 3.1 Protease and lipase activity of environmental and clinical B. cepacia'.
Protease Lipase
30°C 37°C 30°C2 37°C
Environmental 63 56 100 81
Clinical 83 67 50 50
'Results are expressed as the percentage of positive strains out of 15 environmental and 6 clinical
strains
"Difference between clinical and enviromental strains significant, (p<0.02, Fisher's exact probability
test).
Table 3.2 Haemolytic activity of clinical and environmental B. cepacia strains on
horse blood and human blood agar1.
Environmental Clinical
Blood 30°C 37°C 30°C 37°C
Horse2 81 44 17 32
Human 15 0 5 9
'Results are the percentage of positive strains from 15 environmental and 6 clinical strains for horse
blood, and from 13 environmental and 22 clinical strains for human blood
2 Enviromental strains at 30°C significantly different from the same strains at 37°C (p<0.05, Fisher's
exact test) and from clinical strains at 30°C (p<0.02, Fisher's exact test)
Further studies were undertaken using human blood agar (Table 3.2). For both
environmental and clinical strains levels of haemolytic activity against human blood
were less than against horse blood, although the same overall trends could be
observed. In general, clinical strains showed greater activity at 37°C whilst
environmental strains showed greater activity at 30°C. All haemolytic environmental
strains and one non-CF clinical strain showed P haemolysis; however the single
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haemolytic CF strain, the Edinburgh epidemic strain, J2315, only demonstrated a
haemolysis after at least 48 hours of incubation.
Catalase activity was assessed in a panel of 66 environmental and clinical strains
grown at 37°C on cepacia medium. Only one environmental strain displayed no
activity (Table 3.3). For the remaining strains results were classified on the basis of
slow or brisk activity. CF strains demonstrated the greatest degree of catalase
activity, environmental strains demonstrated intermediate levels and non-CF clinical
strains demonstrated the least activity. Differences between environmental strains
and all clinical strains, or CF or non-CF strains alone were not significant. Flowever
comparison ofnon-CF and CF strains found a significant difference between the two
clinical groups (p<0.05, Fisher's exact test).
Table 3.3 Catalase activity of environmental and clinical B. cepacia1
None Slow Brisk
Environmental 3 52 45
Non-CF clinical2 0 73 27
CF2 0 35 65
'Results are the percentage of positive strains from 31 environmental strains, 15 non-CF clinical
strains and 20 CF strains
Significantly different, p<0.05 (Fisher's exact test)
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3. 2 Effect Of Iron On Growth Of B. cepacia
Four B. cepacia strains, comprising the environmental strains J2511 and J2552, and
the CF strains J2315 and CI524, were grown in iron-deficient (Fe-) or iron-rich
(Fe+) minimal media, with or without transferrin (TF). Fig. 1.1 shows representative
growth curves. Strains CI524, J2511 and J2552 displayed vigorous growth reaching
steady state levels by 24 hours for CI524 and 48 hours for the two environmental
strains. However in both Fe+ and Fe- conditions, J2552 and J2511 displayed an
initial drop in viable counts, recovering rapidly between 12 and 24 hours. For
CI524, growth was unaffected by iron concentration whilst for J2552 and J2511
growth in Fe- media was associated with a slight decrease in steady state viable
counts. Growth of J2315 was associated with a long lag phase of approximately 36
hours followed by a slow rise in counts to reach a steady state by 84 hours. Iron-
deficient conditions supported slighty faster growth than Fe+ conditions but final
viable counts were similar in both media.
Addition of 200 pg/ml TF had no effect on the growth of CI 524 in either media. For
both environmental strains, growth in the presence of TF prevented the initial fall in
bacterial numbers observed in TF-ffee media. However, the advantage gained in the
presence of TF did not persist beyond 48 hours for Fe+ media and 24 hours for Fe-
media. Indeed, ultimately the presence of TF was associated with a slight decrease in
steady state bacterial counts. For J2315, the inclusion of TF in either Fe+ or Fe-
media led to a decrease in bacterial growth. Thus for Fe+ media, bacterial levels
after 132 hours were 59% of the levels in TF-free media and for Fe- media, only 3%
of the levels obtained in TF-free media.
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J2315
Fig 1.1a Growth ofB. cepacia J2315 and CI524 in iron rich (Fe+) and iron poor
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Chapter 4 Intracellulars Of B. cepacia
4.1 Uptake By Human Monocytes
Intracellular uptake of environmental and clinical B. cepacia strains by human
monocytes was compared using P. aeruginosa and Listeria monocytogenes as
negative and positive control organisms respectively. Uptake was determined using
acridine orange (AO) to stain intra- and extracellular bacteria before quenching
extracellular fluorescence with crystal violet (CV) solution. AO is believed to
produce green fluorescence in live bacteria but red fluorescence in dead bacteria; thus
it was hoped that the AO/CV technique would allow estimation not only of uptake
but also killing of bacteria by monocytes (West, 1969). In preliminary experiments,
live bacteria were observed to stain a bright green colour. However after heat- or
UV-killing, the majority ofbacteria still maintained a bright green coloration.
Furthermore, those bacteria which showed colour changes in response to heat or UV
killing displayed an orange-green coloration rather than bright red.
Uptake assays were performed using either the monocyte/macrophage murine cell
line J774.2 or purified human monocytes. Bacteria and cells in a ratio of 100 to 1
were co-incubated for 20 min in the presence of AO, before further AO staining and
counter-staining with CV. Stained preparations were viewed under indirect
fluorescence microscopy and bacterial numbers counted for at least 100 monocytes
per slide. Uptake ofboth L. monocytogenes and B. cepacia could be demonstrated
within J774.2 cells and human monocytes. However within any one experiment,
most cells contained few if any organisms whilst a minority of cells were observed to
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take up a large number of bacteria. Overall uptake was greater using human
monocytes; further studies of B. cepacia and P. aeruginosa were therefore carried out
using human monocytes only. Table 4.1 summarises results from three experiments.
In all instances uptake ofL. monocytogenes was greater than uptake of P. aeruginosa
PAOl or B. cepacia J2315 and J2552. In general uptake of P. aeruginosa appeared
to be greater than uptake of both J2315 and J2552 but this difference was not
significant. Virtually all intracellular P. aeruginosa and B. cepacia appeared
orange/green. By contrast, the majority of L. monocytogenes were bright red,
indicating bacterial cell death, although a few green organisms were also observed
suggesting survival of a minority of ingested L. monocytogenes.
Table 4.1 Intracellular uptake of bacteria by human monocytes, including number of
bacteria per monocyte and colour changes on AO staining.
Strain N° bacteria per monocyte Colour
Exp. 1 Exp. 2 Exp. 3
PAOl 6.4 3.01 13.1 orange/green
J2315 1 3.18 5.1 orange/green
J2552 3.9 1.84 4.6 orange/green
L. monocytogenes 18.3 11.87 >50 red, occasional green
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4.2 Survival Of Intracellular Bacteria
Monocytes pre-incubated with bacteria for 20 min at 37°C were repeatedly washed to
remove extracellular bacteria before further incubation at 37°C. Intracellular
bacterial survival was assessed at intervals by lysis ofmonocyte preparations and
counting of surviving bacteria. Additional samples were simultaneously fixed for
electronmicroscopy. Results from three experiments are summarised in Table 4.2.
Table 4.2 Intracellular survival of L. monocytogenes, B. cepacia J2315 and
P. aeruginosa PAOl in monocytes.
Log % of colony forming units at time t=0'
Time (hours) l2 6 19 24
L. monocytogenes 2.14 4.72 ± 0.39 3.44
P. aeruginosa 0.72 ±0.16 1.51 ± 1.02 4.08 ± 0.08 3.32 ±0.13
B. cepacia 1.79 ±0.24 1.97 ±0.45 3.10 ±0.11 3.09 ±0.11
'Results are expressed as mean of three experiments ± SEM
difference between P. aeruginosa and B. cepacia significant; p<0.05 (Students t test)
The intracellular pathogen L. monocytogenes was included as a positive control and
reached maximal levels after 19 hours of incubation when at least a 500-fold increase
in viable counts was observed (Table 4.2). Unlike L. monocytogenes, both
P. aeruginosa and B. cepacia showed an initial decrease in viable counts at time t=l.
Although this decrease was significantly greater for P. aeruginosa than B. cepacia
(p<0.05, Students t test), P. aeruginosa recovered to higher levels than B. cepacia by
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19 hours incubation. By 24 hours incubation viable counts for both P. aeruginosa
and L. monocytogenes began to decrease, whilst levels for B. cepacia continued to
rise slowly. Monocyte viability was assessed at various time points using the trypan
blue exclusion test. For all experiments >95% of monocytes were viable after one
hour of incubation. For both P. aeruginosa and B. cepacia, total monocyte counts
had dropped by 50% after 24 hours. Remaining monocytes were >95% and 72%
viable for P. aeruginosa- and B. cepacia-treated preparations respectively. By
contrast, L. monocytogenes was associated with only 6% monocyte viability after 19
hours and no monocyte survival after 24 hours.
Electronmicroscopy of monocyte preparations pre-incubated with B. cepacia or
P. aeruginosa failed to show any evidence of intracellular bacterial growth as
bacteria could not be identified in these preparations.
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Chapter 5 B. cepacia And Neutrophils: Bacterial
Killing And Effects On The Neutrophil Cell Surface
5.1 Bacterial Killing By Neutrophils
Four B. cepacia strains were investigated in neutrophil killing assays. Bacteria were
pre-incubated in 10% pooled human serum (PHS) prior to addition to neutrophils in a
ratio of approximately 2:1. Control bacteria were pre-incubated in 10% PHS before
addition to buffer alone. Samples were removed at intervals from neutrophil and
control preparations and bacterial survival analysed by neutrophil lysis and viable
counts (Fig 5.1). For strains C1524, J2511 and J2552, a drop in viable counts of
20%, 44% and 15% respectively was observed in controls over a two hour incubation
period. For the environmental strains J2511 and J2552, little or no difference was
observed between neutrophil and control preparations, suggesting that no neutrophil-
mediated killing was taking place. By contrast, the CF strain CI524 showed a
marked increase in viable counts in the presence ofneutrophils, rising to 182% initial
levels after 120 min. Although results for the Edinburgh epidemic strain, J2315,
varied from experiment to experiment, a third distinct pattern could be observed.
Control counts rose initially to an average of 138% starting levels by 15 min,
followed by a drop to 100% by 1 hour and 93% by 2 hours. The initial rapid rise in
levels suggested dissociation of clumped bacteria, rather than bacterial cell growth
per se. J2315 incubated with neutrophils were observed to decrease in number,
reaching an average of 73% of initial counts by 30 min before a gradual increase in
numbers towards an average count of 83% at 120 min.
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Fig 5.1 Survival of 4 strains ofB. cepacia in the presence of neutrophils. Results are
expressed as a percentage of cfu/ml at time t=0 and are the mean of at least three
experiments ± SEM. Controls are bacteria incubated in buffer alone.
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Further experiments focused on J2315, and investigated the impact of opsonisation
with immune serum (IS) from B. cepacia+ CF patients on neutrophil-mediated
bacterial killing. In all studies, opsonisation of J2315 with IS resulted in a greater
decrease in bacterial cfu/ml on incubation with neutrophils than no opsonisation or
opsonisation with non-immune serum. Flowever in neutrophil-free control samples,
IS was associated with a greater drop in cfu/ml than in neutrophil-containing samples
(Data not shown). As this effect was observed using both heat-inactivated and
normal serum samples, it was concluded that the drop in counts represented bacterial
clumping rather than actual killing of bacteria and further studies were discontinued.
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5.2 Flow Cytometric Analyses Of Neutrophil:Bacteria
Interactions
5.2.1 Comparison ofneutrophil preparation techniques on neutrophihbacteria
interactions
Initial studies were carried out to assess the impact of neutrophil preparation
techniques on size, granularity and expression of the cell surface marker complement
receptor 3 (CR3, CD18/CD1 lb). Neutrophils were gated according to forward
scatter (FSC) and side scatter (SSC) characteristics, corresponding to size and
granularity respectively (Fig 5.2). Both neutrophil purification methods used;
namely, Histopaque density gradient separation and plasma-Percoll separation; were
associated with an increase in FSC and a decrease in SSC for the neutrophil
population, although these changes were most marked for the plasma-Percoll
method. By contrast, a whole blood cell preparation from which plasma had been
removed by repeated washing ('washed blood') demonstrated identical FSC and SSC
characteristics as untreated whole blood.
CR3 expression was determined using mouse anti-human CD1 lb monoclonal
antibodies conjugated to FITC (Anti-CDl lb:FITC), with CR3 levels expressed as the
mean channel fluorescence (MCF) of the neutrophil population. Comparison of
MCF values showed that both neutrophil purification techniques were associated
with a drop in CR3 expression compared to untreated blood, a finding which was
surprising given that slight degrees of neutrophil activation during separation
procedures are normally associated with increases in CR3 expression. It is possible,
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Fig 5.2 Comparison ofneutrophils from A. whole blood, B. washed blood, C.
Histopaque density gradient separation and D. plasma-Percoll separation. Charts
show dot plots of SSC vs FSC following flow cytometric analysis.
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whole blood kept at room temperature for 2-3 hours whilst purification ofneutrophils
using both the Histopaque and Percoll techniques was in progress, rather than a loss
of CR3 from purified neutrophils. CR3 levels on neutrophils from the washed blood
preparation were similar to levels on neutrophils from whole blood, indicating that
the washing procedure was not associated with significant neutrophil activation.
Neutrophil responses to the stimulant PMA and to P. aeruginosa J1385 were
compared using neutrophils prepared by each of the above methods (Fig 5.3). With
both stimulants greater levels of CR3 were induced in neutrophils from whole or
washed blood than in purified neutrophils. As expected, PMA induced an increase in
CR3 expression on neutrophils from all of the preparation methods, although this
effect was least marked for the washed blood preparation. P. aeruginosa J1385 was
associated with increases in CR3 at bacterial concentrations of 2.5 x 107 and
2.5 x 108 cfu/ml. For washed blood and for purified neutrophils the increase in CR3
expression was considerably greater at a concentration of 2.5 x 10s cfu/ml, whilst in
untreated blood, a smaller increase was seen at 2.5 x 108 cfu/ml than at 2.5 x 107
cfu/ml. In a larger study of B. cepacia strains and neutrophils in whole blood, a
similar dose-dependent phenomenon was observed, with 4 clinical strains J2315,
J415, C1576 and C1962 and one environmental strain J2540 inducing an increase in
CR3 expression at a concentration of 2.5 x 107 cfu/ml, but provoking a decrease in
expression at 2.5 x 10s cfu/ml. One strain, CI964, induced little change in CR3 at all
concentrations tested whilst another strain, J2552, induced little response at a
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Fig 5.3 Effect of PMA and non-opsonised P. aeruginosa J1385 on expression of
CR3 on neutrophils prepared by 4 different techniques. P. aeruginosa were at a
concentration of either 2.5 x 107 cfu/ml (low) or 2.5 x 108 cfu/ml (high). Results are







Further studies attempted to explain these observations by comparing CR3
expression in neutrophils from whole or washed blood incubated with bacterial
strains at a wider range of concentrations (Fig 5.4). In the absence of plasma, CR3
expression on neutrophils increased proportionally with a logarithmic increase in
bacterial concentration for both P. aeruginosa J1385 and B. cepacia J2315.
However, incubation ofB. cepacia J2315 with neutrophils in untreated blood was
associated with a peak in CR3 expression at a concentration of 5 x 107 cfu/ml, whilst
at higher concentrations a decrease in CR3 expression was seen. By contrast,
incubation of the environmental B. cepacia strain J2552 with neutrophils in whole
blood demonstrated a linear relationship between bacterial concentration and CR3
expression up to a concentration of 1 x 109 cfu/ml. In conclusion, the differences
observed between washed and whole blood preparations implied a role for
opsonisation, either with immunoglobulin or complement, in bacteria/neutrophil
interactions within whole blood. Thus strains which are effectively opsonised
induced increased CR3 expression at lower concentrations but were associated with a
decrease in CR3 at higher concentrations, either through receptor down-regulation or
simply through masking of anti-CD 1 lb binding sites by bacteria. It may be relevant
to note that both strains showing little opsonisation effect, CI964 and J2552, belong
to B. cepacia genomovar I. However another genomovar I strain, J2540, appeared to
be effectively opsonised within whole blood and, in this respect, seemed more akin
to the genomovar III strains J2315 and J415, and the genomovar II strains C1576 and
CI 962. Overall, in view of the strain-specific effects observed above, further studies
were carried out using washed blood as standard.
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Fig 5.4 Expression of CR3 by neutrophils stimulated with increasing concentrations
of non-opsonised bacteria for 60 min. Results are the MCF ofneutrophils stained
with anti-CDl lb:FITC. A. whole blood. B. washed blood.
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5.2.2 Induction of CR3 by non-opsonised bacteria on neutrophils in washed blood
A panel of CF isolates ofB. cepacia and P. aeruginosa were compared for induction
of CR3 on neutrophils in washed blood. Samples were incubated with bacteria at a
concentration of 5 x 108 cfu/ml for 60 min at 37°C before staining with anti-
CD 1 lb:FITC. CR3 expression was determined as the MCF of the neutrophil
population. All B. cepacia strains induced CR3 levels at least twice those of
neutrophils exposed to buffer alone; by comparison, only 3 out of 5 P. aeruginosa
strains induced similar levels. Mean CR3 expression induced by B. cepacia strains
was 260% of levels on control neutrophils, compared to a mean of 212% control
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Fig 5.5 Expression of CR3 by neutrophils exposed to buffer alone, or B. cepacia or
P. aeruginosa at a concentration of 5 x 108 cfu/ml for 60 min at 37°C. CR3 is
determined as the MCF of neutrophils treated with anti-CDl lb:FITC.
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Chapter 6 Neutrophil Respiratory Burst Responses To
B. CEPACIA
6.1 Chemiluminescence Responses To Non-Opsonised B. cepacia
And P. aeruginosa
6.1.1 Luminol chemiluminescence responses to non-opsonised bacteria
Bacteria were incubated with plasma-Percoll purified neutrophils in the presence of
luminol over a 90 min period at 37°C and respiratory burst activity assessed by the
production of light from activated luminol. Zymosan opsonised with normal serum
(OZ) was used as a positive control and induced an early sharp peak in neutrophil
responses, occasionally followed by a second smaller peak (Fig. 6.1). Bacteria alone
produced no LCL responses, but did stimulate a variety of strain-dependent
responses when co-incubated with neutrophils. Responses varied in terms of initial
rates, peak LCL production and the sustained nature of the response. In general,
bacterially-induced responses were slower than responses to zymosan and of a lesser
magnitude. Wide inter-donor variations in the magnitude and speed of responses
were observed, but patterns for individual bacterial species were consistent. Thus,
for example, the CF P. aeruginosa strain J1385 was associated with an early and
sustained rise in LCL, whilst the B. cepacia strain, C2040, showed a later response,
decreasing more rapidly than that for J1385. The Edinburgh epidemic strain, J2315,
was associated with either no response, or a late moderate rise in LCL after 1 hour of
incubation. In the majority of experiments, results were analysed using both peak
LCL up to 90 min to assess magnitude and LCL at 10 min (LCL10) to assess initial
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rate of responses. Preliminary studies using bacteria at a range of concentrations
indicated that responses increased up to a ratio of 125 bacteria per neutrophil before
declining. Further experiments were carried out using 100 bacteria per neutrophil as
standard.
time (min)
Fig 6.1 Examples of LCL induction in neutrophils exposed to zymosan,
P. aeruginosa J1385 and B. cepacia J2315 and C2040.
127
6.1.2 Comparison of clinical and environmental B. cepacia
In a series of experiments, non-opsonised B. cepacia from clinical and environmental
sources were compared. Results from 2-6 experiments per strain were standardised
as the percentage ofboth peak LCL and LCL10 in response to OZ (Fig 6.2).
Statistical analysis was carried out using analysis of variance. CF strains
demonstrated a variety of responses, from virtually no activity to the moderate
activity shown by J2315, with a mean peak LCL equal to 27.3% OZ levels and mean
LCL10 equal to 4.1% OZ levels. Environmental strains showed overall similar levels
of activity (mean peak LCL = 32% OZ, mean LCL10 = 8.2% OZ), although one
strain, J2511, induced a much larger and faster response than all other environmental
and CF strains tested. For non-CF clinical strains, results for both peak LCL (mean =
92.9% OZ) and LCL10 (mean = 16.8% OZ) were significantly greater than levels
induced by environmental and CF strains. (ANOVA, p<0.001).
An attempt was made to confirm these results using a larger panel of strains with at
least 9 isolates in each group. However, comparison of results from an individual
experiment using the Wilcoxon rank sum test demonstrated no significant difference
between any of the groups tested.
6.1.3 Comparison ofB. cepacia and P. aeruginosa isolated from CF patients
It was noted in several experiments that the P. aeruginosa strain PAOl induced
neutrophil LCL responses greater than any of the B. cepacia strains tested. In one























































































































Fig 6.2 LCL activity in neutrophils stimulated with clinical and environmental
B. cepacia. Results are expressed as the percentage of A. peak LCL and B. LCL10
induced by opsonised zymosan in each experiment and are the mean of 2-6
experiments per strain ± SEM
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from CF patients were compared (Fig 6.3). Mean peak LCL and LCL10 for
B. cepacia strains were 8.0 and 1.8 respectively and for P. aeruginosa strains were
15.1 and 9.1 respectively. However considerable inter-strain variation in responses
was noted, particularly for P. aeruginosa strains, where a subpopulation of 4 strains
(A603, A607, J1385 and A15) induced early large peaks in LCL responses whilst a
fifth strain, A605, was associated with a later marked peak in LCL. By contrast all
B. cepacia were slow inducers of LCL responses and only one strain, C2040, induced
a late peak equivalent to peak values for the highly active P. aeruginosa
subpopulation. Although most strains of both species induced at least a slight LCL
response, four strains; B. cepacia CI987 and A599, and P. aeruginosa H230 and
A609; demonstrated no activity, i.e. both peak LCL and LCL10 values were lower
than values for neutrophils alone.
In view of the skewed distribution of responses to P. aeruginosa strains, statistical
analysis was carried out by applying the Wilcoxon rank sum test. Differences
between B. cepacia and P. aeruginosa strains failed to reach significance for peak
LCL and were just short of significance at a 5% level for LCL10. However, if the
four strains inducing no response were excluded from analysis, results for LCL10
reached significance at p<0.01. Thus active B. cepacia strains were found to induce
a slower response than active P. aeruginosa strains
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Fig 6.3 A. Peak LCL and B. LCLI0 induced in neutrophils by non-mucoid CF
isolates ofB. cepacia and P. aeruginosa.
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6.1.4 Effect of growth conditions on LCL induction
A panel ofB. cepacia were grown at 37°C in either shaken or static culture, in order
to test the hypothesis that growth in conditions favouring hydrophobicity, ie static
culture, would increase bacteria: neutrophi 1 interactions and hence LCL induction.
Changes in LCL induction following static growth varied in a strain-dependent but
reproducible manner. Lig. 6.4 shows results from a representative experiment. For
the P. aeruginosa strain PAOl and two B. cepacia non-CF clinical strains, J2660 and
J2684, static growth was associated with a decrease in peak LCL although initial
rates of LCL induction remained largely unchanged. By contrast, results for two CF
B. cepacia; C1987 and J2315; displayed an increase in both initial rates of LCL
induction and peak LCL following static growth, although overall levels were still
much lower than those for PAOl, J2660 or J2684. Of two environmental strains,
J2511 and J2552, static growth conditions were associated with a slight increase in
responses.
6.1.5 Comparison of luminol and lucigenin chemiluminescence responses
Whilst LCL detects ROS production secondary to myeloperoxidase (MPO) activity,
lucigenin-dependent chemiluminescence (LuCL) detects the production of
intracellular superoxide anions (02~) and thus gives a direct measure ofNADPH
oxidase activity and hence respiratory burst initiation. LCL and LuCL responses





































Fig 6.4 Effects of growth in an orbital incubator (shaken culture) or in static culture
on LCL induction by P. aeruginosa PAOl and representative strains of B. cepacia.
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Fig 6.5 Comparison of LCL and LuCL induced in neutrophils incubated with buffer
alone and three representative bacterial strains.
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instances, including neutrophils incubated with buffer alone, a rise in LuCL was seen
prior to or concurrent with any rise in LCL. However peak LuCL levels showed no
consistent correlation with peak LCL levels induced by non-opsonised bacteria.
Furthermore patterns of LuCL induction for individual bacterial strains did not
correlate with patterns of LCL induction.
The observation of little or no correlation between LuCL and LCL activity was
surprising, as it was supposed that both lucigenin and luminol detected different
points within the same respiratory burst pathway. Thus experiments were conducted
using superoxide dismutase (SOD) to selectively inhibit LuCL responses and sodium
azide (NaN3) to inhibit LCL responses. In neutrophils stimulated with non-opsonised
zymosan or with non-opsonised J2315 (Fig 6.6), the use ofNaN3 was associated with
the complete abolition of LCL responses but a marked increase in LuCL activity,
consistent with the build up of 02" within the neutrophil. By contrast, SOD was
associated with the complete abolition of LuCL responses and a marked reduction in
LCL responses, suggesting that LCL activity is at least partly dependent on 02"
production within the neutrophil.
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—No inhibiton -s- SOD -a— Azide
Fig 6.6 Effect of SOD and sodium azide on the induction of LCL and LuCL by non-
opsonised B. cepacia J2315 and zymosan. Charts show LuCL for A. J2315 and C.
zymosan, and LCL for B. J2315 and D. zymosan. Note the differences in scale for
both LCL and LuCL between J2315 and zymosan.
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6.2 Effect Of Opsonisation On Chemiluminescence Responses
6.2.1 Effect of complement and serum on LCL and LuCL responses to the
Edinburgh epidemic strain of B. cepacia
Neutrophil LCL and LuCL activities were analysed in response to B. cepacia J2315
pre-incubated with 10% heat-inactivated serum from B. cepacia+ patients with or
without 4% guinea pig complement (GPC). Pre-opsonisation was associated with
reproducible changes in chemiluminescence induction. Results from a representative
experiment are shown in Fig 6.7. Non-opsonised J2315 induced little or no LCL or
LuCL activity above control neutrophils incubated with buffer alone. Bacterial pre-
opsonisation with complement alone was associated with an initial slight reduction in
LCL activity, before a gradual increase in levels after one hour of incubation. By
contrast, any LuCL activity was completely abolished. Pre-opsonisation by serum
alone led to an early peak in both LCL and LuCL induction. Similar LuCL levels
were induced by bacteria opsonised with serum alone or with complement plus
serum. However addition of complement to opsonising serum was associated with
an augmentation of LCL activity with, in some instances, an increase in peak LCL
or, as in the example shown, a more sustained LCL response.
Although direct correlation of LuCL and LCL levels could not be demonstrated,
investigation of responses using the inhibitors NaN3 and SOD confirmed the
relationship between them (Fig 6.8). Thus, for bacteria pre-opsonised with immune
serum, SOD led to an almost complete abolition in LuCL activity and a significant
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Fig 6.7 Effect ofpre-opsonisation on A. LCL and B. LuCL induced by B. cepacia
J2315. Bacteria were either non-opsonised or pre-opsonised with 10% heat-
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Fig 6.8 Effect of the inhibitors, SOD and sodium azide, on A. LCL and B. LuCL
induction by B. cepacia J2315 pre-opsonised with 10% immune serum.
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almost complete reduction in LCL levels but marked augmentation of LuCL activity
consistent with 02" build up within the neutrophil. Similar changes in both LCL and
LuCL induction were observed for bacteria opsonised with GPC alone or with
immune serum and GPC (Data not shown).
6.2.2 Chemiluminescence induction following pre-opsonisation of a range of
B. cepacia strains
Given the diversity ofbacterial isolates presently identified as B. cepacia, the effects
ofpre-opsonisation of a panel of strains with immune serum were investigated. In all
instances, pre-opsonisation was carried out using heat-inactivated serum from
patients colonised with the Edinburgh epidemic strain of B. cepacia. Representative
results are shown are shown in Fig 6.9. Effects ofopsonisation on LCL induction
were strain dependent with the CF strains J2315, J415, C1632, C1576, C1444 and
CI524, and one environmental strain, J2540, showing a rapid early rise in LCL levels
followed by a sustained response. By contrast, the CF strains CI964 and CI962, and
the environmental strain J2552, showed less augmentation of responses. Pre-
opsonisation of the CF strain C2040 was associated with an earlier but diminished
peak in LCL response in comparison to non-opsonised bacteria.
In a number of these studies, LuCL levels were measured simultaneously with LCL
activity. Opsonisation with serum was associated with a marked increase in LuCL
activity, generally occurring prior to or concurrently with any rise in LCL activity.
However, as for non-opsonised bacteria, no direct correlation could be found
































Fig 6.9 LCL in neutrophils stimulated with representative strains of B. cepacia pre-
opsonised with immune serum from a B. cepacia+ CF patient.
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6.2.3 Comparison of sera from B. cepacia+ and B. cepacia- CF patients
Preliminary studies using pooled human serum from healthy volunteers and pooled
immune serum from CF patients colonised with the Edinburgh epidemic strain of
B. cepacia indicated that the magnitude ofpeak responses to J2315 were much
greater if bacteria were pre-opsonised with immune serum. Further studies were
carried out to investigate the opsonising activity of sera from B. cepacia+ and
B. cepacia- CF patients. Results from two experiments using serum samples from 6
B. cepacia+ and at least 5 B. cepacia- patients, are summarised in Table 6.1. Fig
6.10 also shows patterns of LCL induction in experiment 1.
Table 6.1 Peak LCL and LCL10 induced by J2315 pre-opsonised with sera from
B. cepacia+ and B. cepacia- CF patients1.
Exp. 1 Exp. 2
Peak LCL2 LCL103 Peak LCL2 LCLI03
No opsonisation 3.7 2.1 5.1 0.5
B. cepacia + 24.4 ± 1.1 14.1 ± 1.0 12.7 ± 1.4 7.1 ± 1.4
B. cepacia - 18.8± 1.3 5.2 ±2.0 8.5 ±0.6 1.6 ±0.7
1 Results are mean ± SEM
2 Difference between B. cepacia+ and B. cepacia- sera significant: p<0.05 (Students t test)
3 Difference between B. cepacia+ and B. cepacia- sera significant: p<0.01 (Students t test)
Non-opsonised J2315 induced little or no LCL response. In general pre-opsonisation
with B. cepacia+ serum was associated with a greater rate and magnitude of LCL
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Fig 6.10 Comparison of serum samples from R. cepacia+ and R. cepacia- CF
patients. Results show LCL in neutrophils stimulated with non-opsonised B. cepacia
J2315 or with B. cepacia J2315 pre-opsonised with serum from 6 B. cepacia+
patients (red lines) and 6 B. cepacia- patients (blue lines).
were considerably greater following pre-opsonisation with B. cepacia+ sera than with
B. cepacia- sera and these differences were statistically significant at a 5% level for
peak LCL and a 1% level for LCL10.
For two patients, G and S, stored serum samples were used to analyse changes in
opsonising activity both before and after colonisation with B. cepacia (Fig 6.11). For
both patients LCL10 values displayed greater reproducibility than peak LCL values.
The variability in peak LCL values made interpretation difficult; however a rising
trend was detected for patient G before and after colonisation, whilst for patient S,
peak values were observed to decline in the two year period prior to colonisation
before a slight rise in the few months after colonisation. For patient G, LCL10 also
increased before and after colonisation whilst for patient S, LCL10 values were
comparatively constant until a few months before the first detection ofB. cepacia,
after which a slight rise in values was detected.
To confirm that the above results indicated a specific effect of serum from
B. cepacia+ patients, further studies were carried out using immune sera absorbed
against a panel ofB. cepacia strains and a representative CF strain of P. aeruginosa,
J1385 (Fig 6.12). Neutrophils were stimulated with B. cepacia J2315 pre-opsonised
with absorbed sera and LCL recorded over a 90 min period. Sera absorbed against
P. aeruginosa J1385 or B. cepacia C1444, CI524 or J2511 opsonised J2315 as
effectively as non-absorbed serum. By contrast, pre-opsonisation with serum
absorbed against J2315 was associated with a marked drop in LCL responses with
peak LCL declining to 11.8 from 24.2 for non-absorbed serum. To confirm the
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Fig 6.11 Peak LCL and LCL]0 induced by J2315 pre-opsonised with heat-inactivated
serum collected over a 7-8 year period from A. patient G and B. patient S, both
eventually colonised by the Edinburgh epidemic strain of B. cepacia. Results are
shown from two separate experiments per patient. Arrows indicate date of first
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Fig 6.12 Effect ofpre-opsonisation with absorbed sera on LCL induction by A.
B. cepacia J2315 and B. P. aeruginosa J1385.
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P. aeruginosa J1385. In this instance, serum absorbed against J2315 opsonised
J1385 as effectively as non-absorbed serum whilst serum absorbed against J1385 was
associated with a drop in peak LCL from 50.9 for non-absorbed serum to 42.2.
In the above experiment, LuCL was measured concurrently with LCL levels. As
expected, pre-opsonisation of J2315 or J1385 with non-absorbed sera was associated
with an increase in both the magnitude and initial rate of LuCL responses. Unlike
LCL, however, pre-absorption of opsonising sera with J2315 or J1385 did not
diminish the effects of opsonisation on LuCL induction by J2315 or J1385
respectively (Fig 6.13). Furthermore, comparison of peak LuCL and peak LCL for
each test condition showed no correlation between values. Indeed, although
opsonised J1385 induced LCL to levels twice those induced by opsonised J2315,
induced LuCL levels were much lower for J1385 than for J2315 (Fig 6.13). A
similar relationship between LCL and LuCL values was observed using non-
opsonised J2315 and J1385 although overall levels were much lower.
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Fig 6.13 Comparison ofpeak LCL and LuCL values in neutrophils stimulated with
P. aeruginosa J1385 or B. cepacia J2315. Bacteria were either non-opsonised or pre-
opsonised with serum from a P. aeruginosa+, B. cepacia+ CF patient. Serum was
non-absorbed or absorbed against B. cepacia J2315 (abs. J2315) or P. aeruginosa
J1385 (abs. J1385).
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6.3 Production Of Superoxide Anions By Neutrophils
LCL results suggested that strains ofP. aeruginosa isolated from CF patients were
greater inducers of a respiratory burst than CF strains of B. cepacia. However, as
LCL is a non-specific assay, and as interpretation of results is difficult due to the
variety of responses obtained, an attempt was made to confirm LCL data using the
reduction of cytochrome c following the extracellular release of 02 to detect
respiratory burst initiation. These studies were performed by the candidate in the
laboratory of Professor G. Doring, University of Tubingen, Germany. Neutrophils
were prepared using Dextran sedimentation and Histopaque density gradient
separation. Unstimulated neutrophils produced little 02~ but could be induced to
produce significant amounts by the chemical stimulus, PMA, or by opsonised
zymosan.
All non-opsonised bacteria tested, including P. aeruginosa J1385, a non-mucoid CF
isolate, and the B. cepacia strains J2315, C2040, C1524, C1555 and C1960, gave low
levels of superoxide production after one hour of incubation with neutrophils. For
strains J1385, J2315 and C1524, a further small increase in 02" production was
detected after 90 min (Table 6.2). P. aeruginosa strain, J1385, consistently gave
higher results than the B. cepacia strains used. However, for all isolates, absolute
levels of 02" production were too low to signify a meaningful respiratory burst.
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Table 6.2 Production of extracellular 02~ anions by neutrophils stimulated with
zymosan or non-opsonised bacteria.
Stimulant Superoxide production (nmol/106 cells)





CI 524 1.97 2.86
CI 444 0.82 0.82
CI 960 2.11 2.04
The effect of bacterial numbers on 02 production was investigated in a further
experiment using varying concentrations of non-opsonised P. aeruginosa J1385 and
B. cepacia J2315 to stimulate neutrophils over a 60 min period (Fig 6.14). At all
bacterial concentrations, extracellular release of 02" was markedly lower than that
induced by opsonised zymosan (15.3 nmol /106 neutrophils after 15 min), and
correlated in a linear fashion with the bacteria to neutrophil ratio (J1385: r = 0.989,
J2315: r2 = 0.945). At all concentrations above 10 bacteria per neutrophil, J1385
induced greater 02~ production than J2315. However, as bacterial cultures cannot be
standardised with sufficient accuracy using optical density techniques, it is possible
that the observed strain differences resulted from relatively small variations in the
150
400
number ofbacteria per neutrophil
Fig 6.14 Production of extracellular 02" by neutrophils stimulated with non-
opsonised P. aeruginosa J1385 and B. cepacia J2315 for 60 min at 37°C.
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concentration of bacterial preparations. Overall, these results suggest that the
interaction between neutrophils and non-opsonised bacteria is non-specific,
depending only on the contact time between bacteria and neutrophils: hence
increased responses occur over longer incubation periods and with higher
concentrations of bacteria.
Pre-opsonisation of both B. cepacia J2315 and P. aeruginosa J1385 with immune
serum was associated with a marked increase in 02" induction in neutrophils to levels
greater than that induced by opsonised zymosan (Fig 6.15). For B. cepacia J2315,
pre-absorption of sera with J2315 was associated with a 52% drop in 02 induction
from 27.1 nmol/106 cells to 13.1 nmol/106 cells. By contrast, pre-absorption of sera
with J1385 was associated with only a 13% drop to 23.7 nmol/105 cells. Further
investigation using serum samples from 4 CF patients colonised with B. cepacia
and/or P. aeruginosa or with neither, indicated that only sera from patients colonised
with the appropriate species were opsonic in this assay, since sera from two
B. cepacia- patients did not opsonise B. cepacia J2315; nor did serum from one
P. aeruginosa- patient opsonise P. aeruginosa J1385 (Fig 6.16). In the above assay,
02" production was measured at both 15 and 30 min; levels were raised after 15 min
and no further increases were observed at 30 min (data not shown). Thus, the
opsonic effects of serum appeared to be mediated by highly specific and non-















































Fig 6.15 Effect of opsonisation on bacterial induction of extracellular 02" release by












□ 1652 Bc+, Pa+
^ 1654 Bc+, Pa+
13 1666 Be-, Pa-
m 1671 Be-, Pa+
J2315
Fig 6.16 Extracellular release of 02~ by neutrophils stimulated with B. cepacia J2315
or P. aeruginosa J1385 pre-opsonised with serum from 4 CF patients. Results are
shown after 15 min of incubation. Legend key shows serum samples with
colonisation status of each patient; Be: B. cepacia; Pa: P. aeruginosa.
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In a subsequent experiment, the effects of growth condition on bacterial opsonisation
were investigated using B. cepacia J2315 and P. aeruginosa J1385 grown in air with
shaking or in 5% C02 without shaking. Results are shown in Table 6.3. In all cases,
the response provoked by the sera followed the same pattern as previous
experiments. However for P. aeruginosa, growth in C02 was associated with an
increase in opsonisation and superoxide induction whilst for B. cepacia, growth in
C02 resulted in a diminution in superoxide induction.
Table 6.3 Effect of growth conditions on opsonisation of bacteria by immune sera.
Bacteria + serum3 02" production (nmol / 106 neutrophils /15 min)
Air C02
J2315 + 1652 21.76 12.512
J2315 +1654 18.224 9.792
J2315 +1666 0 0.68
J2315 +1671 0.204 0.68
J1385 + 1652 32.64 33.73
J1385 +1654 17.54 25.77
J1385 + 1666 0.47 1.22
J1385 +1671 13.26 20.06
aSerum samples from 4 CF patients: 1652, B. cepacia+, P. aeruginosas-, 1654, B. cepacia+,
P. aeruginosas-, 1666, B. cepacia-, P. aeruginosa--, 1671, B. cepacia-, P. aeruginosas.
As these results may reflect changes in the bacterial outer surface, outer membrane
protein (OMP) extracts were prepared for both J2315 and J1385 grown in air or in
5% C02. Polyacrylamide gel electrophoresis and Coomassie blue staining (Fig 6.17)
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indicated a number of differences in the OMP profile ofboth J2315 and J1385 grown
in different atmospheric conditions; notably the modification of a band at 36 kDa, the
loss of bands at 63, 28 and 18 kDa and the appearance of bands at 46 and 26.5 kDa
for J2315 grown in C02, and the loss of bands at 22 and 23.5 kDa for J1385 grown in
C02. Surprisingly the potentially virulence-associated band at 30 kDa previously
described for B. cepacia (Burnie et al, 1995; Shaw, 1995) was not observed in the
profile of J2315, a representative of the ET12 intercontinental epidemic lineage; the
nearest band being measured at 28 kDa. Repeat OMP extraction and PAGE
confirmed the absence of the 30 kDa band for this strain of B. cepacia.
These studies of 02~ production by neutrophils depended upon the
spectrophotometric measurement of changes in the OD550 of cytochrome C using a
standard spectrophotometer. An attempt was made to adapt this method for use in a
microtitre plate assay using an Rmax plate reader. Initial studies using neutrophil
stimulants such as PMA or zymosan were encouraging as reproducible and marked
changes in OD550 could be detected. However, in subsequent experiments using
opsonised bacteria the dramatic changes in OD550 observed in our original studies
could not be reproduced, and, although bacterial opsonisation was associated with
slight increases in OD550 , absolute levels were too low to allow meaningful
interpretation of the results. The basis for this discrepancy remains unclear but may
reflect the different modes of determining optical density used by standard
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Fig 6.17 Coomassie blue-stained polyacrylamide gel showing outer membrane
protein profdes of B. cepacia J2315 and P. aeruginosa J1385. Tracks are 1, 6,11:
Protein standards; 2, 3: J2315 grown in air; 4, 5: J2315 grown in air with 5% C02; 7,
8: J1385 grown in air; 9, 10: J1385 grown in air with 5% C02.
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6.4 Production Of Intracellular H202 By Neutrophils
Stimulated With B. cepacia And P. aeruginosa
Dihydrorhodamine (DHR) is rapidly converted to fluorescent rhodamine in the
presence of H202 and thus provides a rapid and simple means of detecting neutrophil
respiratory burst production in a flow cytometric assay. As the use of flow cytometry
permits the investigation of individual cell types within mixed populations, studies
were carried out using whole blood cell preparations with plasma removed.
In initial studies, dose response curves to two strains ofB. cepacia, J2315 and
C2040, and two strains of P. aeruginosa, J1385 and H228 were generated (Fig
6.18A). Bacteria were incubated with neutrophils within washed blood at
concentrations ranging from 2.5 x 106 cfu/ml to 5 x 108 cfu/ml. For all strains,
neutrophil responses increased with increasing concentrations ofbacteria, with little
response being generated at the lowest concentration ofbacteria. Considerable H202
production was detected following incubation of neutrophil with strains J1385, H228
and C2040. By contrast, responses to the ET12 strain, J2315 were limited, even at a
concentration of 5 x 108 cfu/ml. To determine whether DHR responses were due to
whole bacteria or released products, neutrophils were also incubated with filtrate
from bacterial preparations at the highest concentration used. For strains J1385,
J2315 and C2040, responses to bacterial filtrate was less than 10% responses to
whole bacteria. For strain H228 however, responses to bacterial filtrate accounted
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Fig 6.18 H202 production in neutrophils exposed to B. cepacia J2315 and C2040 and
P. aeruginosa J1385 and H228. A. Dose response following 60 min incubation.
B. Time course following incubation with 5 x 108 cfu/ml bacteria. H202 production
is determined as the MCF of neutrophil populations in the presence of DHR.
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In time course experiments measuring the DHR response to bacteria incubated with
washed blood at a concentration of 5 x 108 cfu/ml, P. aeruginosa J1385 was found to
provoke the fastest neutrophil response with a considerable increase in intracellular
H202 after 30 min incubation, whilst B. cepacia J2315 only induced slight H202
prodution after 90 min of incubation. Responses to C2040 rose after one hour of
incubation, before decreasing to near baseline levels at two hours. Thus neutrophil
H202 production in response to each strain followed a similar pattern to LCL
induction in response to the same strains (Fig 6.1).
The above differences in B. cepacia J2315 and P. aeruginosa J1385 were confirmed
in studies of LPS priming (see section 7.3, Fig 7.12), where J1385 were found to
induce significantly more H202 production than B. cepacia J2315 following 30 min
incubation with unprimed neutrophils in washed blood. In view of this finding and
previous results from studies of LCL responses, a panel of CF isolates of B. cepacia
and P. aeruginosa were compared for the stimulation of H202 production by
neutrophils. Bacteria were incubated with washed blood for 60 min at a
concentration of 5 x 108 cfu/ml. Results are shown in Fig 6.19. As for LCL results,
considerable intraspecies variability in respiratory burst induction were detected. For
most strains, results correlated well with LCL data, however two P. aeruginosa
strains, H228 and CI249, which induced little LCL response were observed to induce
a sizeable DHR response. Overall, P. aeruginosa strains appeared to induce a greater
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Fig 6.19 H202 production by neutrophils exposed to B. cepacia and P. aeruginosa
strains at a concentration of 5 x 108 cfu/ml for a period of 60 min at 37°C. H202
production is determined as the MCF of the neutrophil population in the presence of
DHR.
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In the above experiment, individual bacterial strains were also compared for ability to
prime neutrophil respiratory burst responses. Priming was assessed by addition of
5 x 10"7 M FMLP, 15 min before the end of the bacteria:neutrophil incubation period,
and expressed as the difference between MCF in neutrophils treated with bacteria
alone and MCF in neutrophils treated with bacteria followed by FMLP. Within both
P. aeruginosa and B. cepacia populations considerable variation in neutrophil
priming was observed, although all strains were observed to have at least a slight
priming effect (Table 6.4). Overall results suggested that B. cepacia strains primed
to a greater degree than P. aeruginosa strains (mean priming effect: B. cepacia,
717.27; P. aeruginosa 406.03) but this difference failed to reach statistical
significance. Indeed, it is possible that the lesser priming effect seen for
P. aeruginosa is merely a reflection of the greater respiratory burst activity induced
by some P. aeruginosa strains, particularly if the respiratory burst induced by an
individual strain approaches the maximum capacity of a neutrophil to generate H202.
However the spread of results was such that this effect did not appear to play a major
role in determining the degree ofpriming for any individual strain.
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Table 6.4 Priming ofneutrophils by whole bacteria
Strain MCF Priming effect0
Bacteria alone3 Bacteria + FMLPb
P. aeruginosa
CI 249 2910.78 3035.57 124.79
H230 204.64 333.74 129.1
J1385 2430.09 2633.29 203.2
H228 1817.49 2132.88 315.39
A609 157.9 688.72 530.82
A603 1645.34 2778.23 1132.89
B. cepacia
J2315 377.7 656.96 279.26
CI 964 206.02 598.38 392.36
CI 524 896.65 1301.55 404.9
CI 444 1081.65 1847.96 766.31
C2040 1928.97 2986.91 1057.94
C1576 218.35 1621.2 1402.85
a Washed blood incubated with bacteria at a concentration of 5 x 108 cfu/ml bacteria for 60 min in the
presence of DHR.
b Washed blood incubated with bacteria (5 x 108 cfu/ml) in the presence of DHR for 45 min, followed
by the additon of 5 x 10"7 M FMLP for 15 min.
c Determined as the difference between the MCF of neutrophils exposed to bacteria alone and the
MCF of neutrophils exposed to bacteria followed by FMLP
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Chapter 7 Effect Of B. cepacia Products On
Neutrophils
7.1 Effect Of Lipopolysaccharide On Neutrophil CR3 Expression
7.1.1 Lipopolysaccharide extracts
Lipopolysaccharide (LPS) was extracted from B. cepacia J2315 and J2552 and
P. aeruginosa J1385 using the aqueous phenol method. Fig 7.1 shows
polyacrylamide gel elctrophoresis and silver staining of the above extracts and
extracts of other B. cepacia and P. aeruginosa provided by Dr D Shaw and of a
representative E. coli strain provided by Dr D Delahooke, MPRL, Medical
Microbiology. LPS preparations from B. cepacia strains J2315 and CI504 and
P. aeruginosa strains J1385 and C1250 showed profiles consistent with rough LPS.
By contrast, clear ladder patterns could be distinguished for E. coli 018K- and
B. cepacia J2540 and J2552. Less distinct ladder patterns were also visible for
P. aeruginosa PAOl and B. cepacia J2505.
7.1.2 Induction of CR3 on neutrophils stimulated with LPS from representative
strains.
The effect of bacterial LPS on neutrophil CR3 expression was initially compared in
washed and whole blood samples. Neutrophil cell surface CR3 was detected using
anti-CD 1 lb: FITC and results were expressed as the MCF of the neutrophil
population gated on FSC and SSC characteristics. Although increased CR3
expression could be demonstrated in whole blood using lower LPS concentrations
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Fig 7.1 Polyacrylamide gel electrophoresis and silver staining of LPS from
B. cepacia and P. aeruginosa strains. Lanes are aqueous phenol extracts of 1: E.
coli 018K-, 2-4: P. aeruginosa PAOl, J1385 and C1250, 5-9: B. cepacia J2540,
J2552, J2505, J2315, and C1504.
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than in washed blood, levels induced by LPS concentrations of 100 ng/ml and above
were much greater in washed rather than whole blood. Further studies were therefore
conducted in washed blood standard. CR3 expression amongst the washed blood
neutrophil population was unimodal in distribution with MCF generally lying in the
100 - 200 region for unstimulated neutrophils (Fig 7.2). Up-regulation of CR3
following exposure to LPS was also unimodal in distribution, indicating that changes
in CR3 expression were largely homogenous within the neutrophil population.
Neutrophils were exposed to LPS at a range of concentrations from 1 ng/ml to 1
mg/ml for a 30 min period. It was noted that both B. cepacia J2552 and J2315 LPS
extracts induced a slight increase in CR3 expression at a concentration of 10 pg/ml
and marked increases to at least 300% baseline levels at concentrations of 100 pg/ml
and above. By contrast, LPS from P. aeruginosa J1385 only induced an increase in
CR3 expression at a concentration of 1 mg/ml when MCF rose to 175% baseline.
However as these LPS concentrations were too high to be considered physiological,
further studies were carried out using lower concentrations over longer time periods.
Fig 7.3 shows the effect of increasing concentrations of LPS from B. cepacia J2315,
P. aeruginosa J1385 and E. coli 018K- on CR3 expression after two hours of
incubation at 37°C. Both E. coli and B. cepacia LPS increased CR3 expression on
neutrophils, although responses to E. coli LPS could be demonstrated at a lower
concentration (1 ng/ml) than B. cepacia LPS (10 ng/ml). The greatest effect was
seen using 100 ng/ml E. coli LPS where CR3 expression reached 2.2 times levels on
neutrophils incubated with buffer alone.
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Fig 7.2 Histogram showing distribution of CR3 expression on neutrophils within a
washed blood preparation. Curves are 1: unstimulated neutrophils treated with
control antibody, 2: unstimulated neutrophils treated with anti-CD 1 lb monoclonal
antibody, and 3: neutrophils pre-incubated with 100 ng/ml E. coli LPS before addition
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Fig 7.3 Induction of CR3 on neutrophils following stimulation with varying
concentrations ofLPS from E. coli 018K-, B. cepacia J2315 and P. aeruginosa
J1385. Results are expressed as a percentage of the MCF of neutrophils treated with
buffer alone for 2 hours (mean of 4 experiments ± SEM).
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At all LPS concentrations, CR3 levels induced by E. coli were greater than those
induced by B. cepacia. However for both organisms, raised CR3 levels were
significantly above baseline only at concentrations of 100 ng/ml and above (p<0.02,
Student's t test). LPS from the CF strain ofP. aeruginosa, J1385, had no effect on
neutrophil CR3 expression at all concentrations tested.
Preliminary time course experiments indicated that at low concentrations (1 ng/ml)
B. cepacia LPS was associated with a late rise (after 3 hours) in neutrophil CR3
expression (Fig 7.4). By contrast, higher LPS concentrations induced a rise in CR3
expression to equivalent levels in under 2 hours. Subsequent experiments comparing
LPS from B. cepacia, P. aeruginosa and E. coli were carried out using a
concentration of 100 ng/ml LPS (Fig 7.5). Incubation with buffer alone was
associated with a slight elevation in CR3 expression between 60 and 120 min,
returning to baseline levels by 150 min. E. coli LPS was found to induce statistically
significant levels of CR3 by 60 min (p<0.01), peaking at 90 min (p<0.001) with
levels 2.3 times greater than those on neutrophils treated with buffer alone.
Responses to B. cepacia LPS were slower to develop, rising to 1.8 times the levels on
neutrophils treated with buffer alone by 90 min and reaching statistical significance
after 120 min (p<0.01). Incubation with P. aeruginosa LPS had little effect on CR3
expression over the entire incubation period.
169
time (hours)
° - buffer only A LPS 1 ng/ml
♦-LPS 100 ng/ml ■ LPS 10,000 ng/ml
Fig 7.4 Representative time course of CR3 induction on neutrophils exposed to
buffer alone, or LPS from B. cepacia J2315 at a range of concentrations. Results are































J2315 —♦— J1385 ■■— 018K-buffer alone
Fig 7.5 Time course of induction of CR3 on neutrophils following stimulation with
buffer alone or 100 ng/ml LPS from E. coli 018K-, B. cepacia J2315 and
P. aeruginosa J1385 at 37°C. Results are expressed as a percentage of the MCF of
neutrophil treated with buffer alone at time t=0 (mean of 4 experiments ± SEM).
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7.1.3 Neutrophil CR3 induction by LPS from a range of bacterial strains
LPS samples from a wider range of B. cepacia and P. aeruginosa strains were
investigated for their ability to induce CR3. Neutrophils were incubated with
100 ng/ml LPS for 90 min at 37°C before staining for CD1 lb. LPS from E. coli
018K- was included as a positive control and induced maximal CR3 expression at
270% baseline (Fig 7.6). LPS from all B. cepacia strains, except the environmental
strain J2540, induced levels of CR3 expression comparable with those induced by
E. coli LPS. Furthermore LPS from all B. cepacia strains, including J2540, induced
CR3 levels which were higher than those induced by all P. aeruginosa LPS
preparations. Of the P. aeruginosa strains tested, only LPS from strain PAOl, the
classic laboratory strain, increased CR3 expression above that of unprimed
neutrophils, whilst LPS from both a non-mucoid (J1385) and a mucoid CF strain
(CI250) had no effect. Direct comparison of individual P. aeruginosa with
B. cepacia strains using the Students' t test found a significant difference (p<0.05)
for all combinations except PAOl and J2540. Finally, analysis of variance between
mean results for P. aeruginosa and B. cepacia strains indicated a significant
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Fig 7.6 Induction of CR3 on neutrophils following 90 min incubation at 37°C with
buffer alone, or 100 ng/ml LPS from strains of P. aeruginosa, B. cepacia, and E. coli
(mean of 6 experiments ± SEM).
173
7.2 Priming Of Fmlp-Induced Respiratory Burst Activity By
Bacterial Products
7.2.1 Priming by LPS from B. cepacia J2315 and E. coli 018K-
Dihydrorhodamine was used in a flow cytometric assay to detect the presence of
intracellular H202 as a measure ofneutrophil respiratory burst activity. Neutrophils
were primed with buffer alone or with LPS before the addition of the neutrophil
stimulant FMLP. Initial studies indicated that FMLP induced little or no respiratory
burst activity in unprimed neutrophils but that priming with E. coli LPS was
associated with a marked increase in intracellular H,02 production on exposure of
neutrophils to FMLP, thus providing an effective assay of LPS priming activity.
Comparison of unprimed and primed neutrophils in their responses to FMLP
revealed the presence of a highly responsive sub-population within the primed
neutrophil population (Fig 7.7). Unstimulated neutrophils and unprimed neutrophils
stimulated with FMLP were gated within the R1 region (Fig 1.1A) However,
stimulation of LPS-primed neutrophils with FMLP led to the appearance of a second
population ofneutrophils with greater FSC but lower SSC values than the original
population (Fig 7.7B, C; R2). Neither LPS-priming alone nor stimulation of
unprimed neutrophils with FMLP were associated with a shift in neutrophils from the
R1 to the R2 population (Fig 7.7A). In all instances, MCF for R2 populations was
greater than MCF for R1 populations (Fig 7.7D-F), indicating greater H202
production within R2 cells. However, the patterns of change in MCF within each
individual experiment were virtually identical for both R1 and R2 neutrophils and in
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Fig 7.7 Size, granularity and intracellular H2O2 production of neutrophils stimulated
with FMLP following pre-incubation with E. coli LPS. A-C: Dot plots of SSC versus
FSC. Neutrophils are gated as two populations, R1 and R2. D-F: Histograms
showing fluorescence of neutrophils in populations R1 and R2 in the presence of
DHR. Neutrophils were pre-incubated with A, D: buffer alone; B, E: 1 ng/ml LPS; C,
F: 100 ng/ml LPS.
175
subsequent experiments, respiratory burst activity was generally expressed as the
MCF of the total neutrophil population (R1 + R2).
Both E. coli 018K- and B. cepacia J2315 LPS primed for responses to FMLP in a
dose dependent manner. By contrast, P. aeruginosa J1385 LPS had no priming
effect on neutrophils at all concentrations tested. Priming effects using E. coli LPS
could be detected at lower concentrations (1 ng/ml) than B. cepacia LPS (100 ng/ml)
and were greater in magnitude at all concentrations tested (Data not shown).
Subsequent time course experiments were carried out using 100 ng/ml LPS as
standard. Neutrophils from individual donors varied considerably in both the
magnitude and timing ofpriming responses (Fig 7.8), but several general trends
could be observed. None of the LPS preparations induced a respiratory burst in the
absence of stimulation with FMLP (Data not shown). Pre-incubation with buffer
alone was associated with little or no priming of responses to FMLP. However, both
E. coli LPS and B. cepacia LPS were potent priming agents of a respiratory burst
response, with priming occurring after as little as 30 min incubation. Responses to
FMLP following stimulation with E. coli LPS generally peaked earlier and were of a
greater overall magnitude than responses to B. cepacia LPS.
7.2.2 Priming of neutrophil respiratory burst responses by a panel of representative
strains
In a series of experiments, priming of neutrophil responses to FMLP by LPS from
representative B. cepacia and P. aeruginosa were assessed. Similar trends were
observed for priming effects as for induction of CR3 expression (Fig 7.9). LPS from
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Fig 7.8 Priming ofFMLP-induced neutrophil respiratory burst responses by pre¬
incubation with buffer alone or 100 ng/ml LPS from E. coli 018K- or B. cepacia
J2315. Charts show results from studies on 4 individual donors. Results are the
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Fig 7.9 Priming of FMLP-induced intracellular H202 production in neutrophils
following 90 min incubation at 37°C with buffer alone or 100 ng/ml LPS from strains
of P. aeruginosa, B. cepacia, and E. coli (mean of 5 experiments ± SEM).
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B. cepacia J2552 and E. coli 018K- primed FMLP responses to the greatest degree
(1100% and 1041% baseline respectively). LPS from all B. cepacia strains primed
responses to levels greater than all P. aeruginosa strains tested and these
observations were significant for all combinations of strains except PAOl and J2540
(Students' t test, p<0.05). Although slight neutrophil priming effects were observed
for LPS preparations from both P. aeruginosa PAOl and P. aeruginosa CI250 these
results were not statistically significant. LPS from P. aeruginosa J1385 had almost
no effect on FMLP-induced respiratory burst activity compared to buffer controls.
Again, analysis of variance confirmed a significant difference between LPS from the
P. aeruginosa and B. cepacia populations tested (p<0.001).
7.2.3 Analysis of neutrophil subpopulations
In selected experiments, R1 and R2 populations were analysed individually with
respect both to MCF and the number ofneutrophils in each population. In all
instances, MCF activity was greatest within the R2 population, although considerable
overlap in results for individual neutrophils occurred (Fig 7.7D-F). Priming with
both E. coli 018K- and B. cepacia J2315 LPS increased FMLP-induced respiratory
burst responses in both R1 and R2 populations in a dose dependent manner.
Furthermore, LPS was associated with a shift of neutrophils from the R1 to the R2
population on stimulation with FMLP (Fig 7.1 OA). Movement from the R1 to R2
population was dose-dependent for both E. coli and B. cepacia LPS but at each
concentration was greater for E. coli than B. cepacia. Furthermore, for priming with
both E. coli and B. cepacia LPS, the increase in MCF within R2 correlated in a linear
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fashion with an increase in the percentage of total neutrophils within the R2
population (r2 = 0.94, p<0.01) whilst the increase of MCF within R1 correlated with a
decrease in the percentage of neutrophils within the R1 population (r2 = 0.94, p<0.01)
(Fig 7.1 OB). Thus, LPS priming appeared to have a dual effect by firstly increasing
the magnitude of responses in both R1 and R2 neutrophils and secondly by shifting
more neutrophils into the highly responsive R2 population.
The nature of the phenotypic change underlying the shift from R1 to R2 populations
by neutrophils was unclear from the above experiments. The observation of an
increase in MCF in both R1 and R2 populations, and the overlap in MCF values for
neutrophils within both populations suggested that the R2 phenotype was not merely
a result of respiratory burst induction per se. Comparison of mean CR3 expression
and mean intracellular H202 induction in total neutrophil populations stimulated with
LPS from a range of strains (Fig 7.6, 7.9) revealed a close correlation between both
parameters (R2 = 0.96, p<0.01). However, the skewed distribution of fluorescence
values in experiments using DHR was in sharp contrast to the unimodal distribution
of increased CR3 expression on neutrophils incubated with LPS (Fig 7.2, 7.7),
suggesting that a simple increase in generalised receptor expression was not
responsible for the R2 phenotype. An attempt was made to develop the DHR
technique for two-colour fluorescence experiments to allow comparison of CR3
expression and H202 production in individual neutrophils. Unfortunately, however,
the overlap in the emission spectra between DHR and FITC was too great to allow
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Fig 7.10 Effect of LPS priming on the production of H202 by neutrophils following
exposure to FMLP. A. Percentage ofneutrophils falling within the R1 and R2
populations following 15 min incubation with FMLP. B. Relationship between
percentage of neutrophils within the R1 and R2 populations and H202 production,
expressed as the MCF in the presence of DHR.
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7.2.4 Effect ofB. cepacia J2315 haemolysin on neutrophil respiratory burst activity
Neutrophils were pre-incubated with B. cepacia J2315 haemolysin at concentrations
of 50-500 ng/ml for 90 min before addition of either buffer alone or 5 x 10~7 M
FMLP in the presence of DHR for 15 min. Haemolysin alone induced no respiratory
burst activity but did, however, prime responses to FMLP in a dose-dependent
manner (Fig 7.11). At all concentrations from 50 ng/ml to 500 ng/ml, haemolysin
primed neutrophil activity to levels greater than pre-incubation with 100 ng/ml
B. cepacia J2315 LPS.
— buffer alone —■— FMLP
haemolysin (ng/ml)
Fig 7.11 Neutrophil respiratory burst activity following pre-incubation with
B. cepacia J2315 haemolysin. Neutrophils were pre-incubated with haemolysin for
90 min at 37°C before addition of either buffer alone or 5 x 10"7 M FMLP. Control
neutrophils were pre-incubated with 100 ng/ml B. cepacia J2315 LPS before addition
of FMLP. Intracellular H202 production was detected as increased MCF in the
presence of DHR.
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7.3 Priming Of Neutrophil Respiratory Burst Responses To
Whole Bacteria
In a series of experiments, the effect of LPS on neutrophil respiratory burst responses
to whole bacteria were compared. Neutrophils within washed blood were pre-
incubated with buffer or with 100 ng/ml LPS for 90 min at 37°C before addition of
DHR and either buffer alone, bacteria to a final concentration of 2.5 x 107/ml,
supernatant from filtered bacterial suspensions or FMLP. Results expressed as MCF
ofneutrophil populations were transformed by conversion to Log10. Only
P. aeruginosa J1385 induced a statistically significant respiratory burst in non-
primed neutrophils (p<0.01, Students t test) with an average MCF of 425.1 against an
average baseline MCF of 143.9 (Fig 7.12). Neither B. cepacia J2315, nor
supernatants from B. cepacia and P. aeruginosa suspensions, nor FMLP induced a
respiratory burst in unprimed neutrophils. However, as previously, significant
respiratory burst activity was seen in response to FMLP in neutrophils primed with
E. coli 018K- and B. cepacia J2315 LPS but not P. aeruginosa J1385 LPS.
Responses to P. aeruginosa were significantly greater in neutrophils primed with
LPS from both B. cepacia and E. coli than in unprimed neutrophils, with average
MCF values of 1039.9 (P<0.05) and 1374.5 (p<0.05) respectively. By contrast, LPS
priming induced only slight increases in responses to B. cepacia J2315.
Furthermore, the observation of a similar small increase in responses to B. cepacia
filtrate indicated that any respiratory burst activity induced by B. cepacia was due to
extracellular factors rather than the bacteria themselves. Pre-incubation of
neutrophils with LPS from P. aeruginosa J1385 had no effect on either FMLP- or
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Fig 7.12 Effect of LPS-priming on neutrophil respiratory burst responses to whole
B. cepacia J2315 and P. aeruginosa J1385. Neutrophils were pre-incubated with
LPS or buffer alone for 90 min prior to addition ofbuffer alone, whole bacteria,
supernatant from bacterial suspensions or FMLP. Data was transformed by
conversion to Log10. Results are the mean of three experiments ± SEM. Legend key
shows stimuli for primed neutrophils: Be, B. cepacia; Pa, P. aeruginosa; Sn,
bacterial supernatant.
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Chapter 8 Studies Of B. cepacia In A Mouse Model
8.1 Background Flora And Delivery Of Bacteria
8.1.1 Background flora
Studies carried out by previous investigators indicated considerable variability in the
background respiratory flora ofmice housed in standard conditions. Thus, in an
early study, respiratory flora of three strains of mice were compared with mice of the
CFhgu lineage by plating out of lung homogenates (Table 6.1). For each strain of
mouse considerable background flora was apparent. Although the variety and
number ofbacteria varied considerably from mouse to mouse, strain-specific patterns
of colonisation could be detected. Both inbred murine strains, CI29 and C57/B1,
generally had heavy contamination of the respiratory tract, particularly with Gram-
negative organisms, including coliforms. Mice of strain CI29 differed from C57/B1
mice with heavy colonisation by non-coliform Gram-negative organisms.
Furthermore those organisms identified as coliforms for both CI29 and C57 mice
were distinct for each strain. Unlike inbred strains, an outbred mouse strain, MF1,
was predominantly colonised by streptococcal organisms with only one mouse
showing slight growth of coliform organisms. CFHG(J mice showed a mixed pattern
of growth with high numbers ofboth streptococcal and coliform organisms in three
mice whilst a fourth mouse showed only an occasional staphylococcal organism. For
all strains little staphylococcal colonisation was apparent.
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Table 8.1 Background flora of4 strains ofmice
Staphylococci Streptococci Coli forms3 Otherb
CI29 1 ++++GNB (Mac )
GNC
2 +c ++ + ++ GNC




3 ++ +++ ++++
4 ++ ++++
MF1 1 + ++++
2 + I I II
3 + +++ ++
4 +




a Defined as Gram-negative bacilli which grow on MacConkey's agar.
b ONB: Gram-negative bacilli; GNC: Gram-negative cocci; Mac": No growth on MacConkey's agar.
c + < 100 cfu / lung, ++ 101-1000 cfu / lung, +++ 1001-10,000 cfu / lung,
++++ > 10,000 cfu / lung.
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In view of the variety and degree of colonisation of the respiratory tract in mice
within standard housing conditions, a further experiment was carried out to compare
mice from standard housing and from the SPF housing within the transgenic animal
unit (TGU). Results are shown in Table 8.2. For both standard and TGU mice,
overall levels ofbackground flora were much lower than those observed in the
previous study, with little evidence of coliform (GNB) colonisation and only small
numbers of staphylococcal and streptococcal organisms. This difference may reflect
changes in practices within the animal house or in the source of the mice used;
significantly all of the mice used were bred in-house rather than imported from other
animal units.
Although overall colonisation levels were low, two unusual organisms; filamentous
bacteria and yeast-like organisms; where detected in three mice from the TGU and
one mouse from standard housing. Growth ofboth organisms was much heavier in
the mouse from standard housing conditions. Furthermore in a comparison of nasal
lavage, tracheal homogenates and lung homogenates for TGU mouse 1, yeast-like
organisms were only cultivated from nasal lavage and tracheal samples but not lung
homogenates, suggesting that the low numbers of organisms in other TGU mice may
arise from contamination of lung homogenates with intra-tracheal bacteria rather than
lower respiratory tract colonisation per se. However for mouse 5 from standard
housing, high counts of yeast-like and filamentous organisms were present in
tracheal and lung homogenates, indicating genuine lower respiratory tract
colonisation.
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Table 8.2 Comparison ofmice in standard animal house and transgenic unit (TGU).
Housing Mice3 Staphylococci Streptococci GNBb Other
TGU 1 N + ++ + ? yeast
1 T + + ? yeast
1 L
2 + + ? yeast
+ filamentous
3 + + ? yeast
4 +
Standard 5 N + ++ +
5 T ++ + + +++ ? yeast
+++ filamentous
5 L + + +++ ? yeast
+++ filamentous
6 N +




a Mice strains were heterozygote CFHGU and CFunc. For mice 1, 5 and 6, samples include N: nasal
lavage, T: tracheal homogenate and L: lung homogenate. For other mice, samples are homogenates
of lungs plus trachea.
b Gram-negative bacilli
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8.1.2 Intratracheal inoculation of bacteria: delivery and bacterial recovery
Surgical and non-surgical techniques were compared in order to identify the most
effective and reproducible method of intratracheal inoculation ofbacteria with
minimum harm to the mouse. Mice were inoculated with B. cepacia J2315 and
delivery assessed by removal ofboth lungs and stomach 5-10 minutes after
inoculation. In initial studies surgical inoculation was more reliable than non¬
surgical inoculation, with no delivery failures (defined as recovery from lungs < 1%
total bacteria) for surgical techniques but 3 out of 8 for non-surgical techniques. On
exclusion of delivery failures, surgical inoculation was associated with higher
delivery to the lungs but lower delivery to the stomach (Lungs: mean 21.8%, range
9.1% - 37.1%; Stomach: mean 0.2%, range <0.1% - 1.2%) than non-surgical
inoculation (Lungs: mean 14.5%, range 5.6% - 35.4 %, Stomach: mean 3.1%, range
<0.1 - 6.7%). However it was noted that non-surgical delivery improved both in
terms of greater bacterial recovery from the lung and fewer delivery failures with the
experience of the inoculator and that there was considerable overlap between the
ranges of percentage recovery for surgical and non-surgical techniques. Reliability
was further improved by the development of a frame to hold anaesthetised mice in an
upright position whilst illuminating the trachea via a cold light source. Given that
non-surgical intubation involved much less trauma to the mouse, further experiments
were conducted using non-surgical intratracheal inoculation as standard.
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8.2 Clearance Of B. cepacia J2315 In CF And Non-CF Mice
Clearance of B. cepacia J2315 after intratracheal inoculation in non-CF mice was
determined in Swiss mice. Mice were inoculated with a high dose ofB. cepacia
(1.25 x 107 bacteria) and kept in isolated conditions until culling. B. cepacia were
recovered from lung homogenates in 1 ml PBS onto cepacia medium. Results are
shown in Fig 8.1. Rates of bacterial recovery immediately post-inoculation were low
but rose by over 100-fold by 1 day post inoculation. Subsequently levels dropped
until 5 days post-inoculation when no mice remained colonised.
A time point of 48 hours was chosen for further clearance experiments comparing CF
and non-CF mice from the standard animal house. Mice were a combination of
CFhgu and CFunc wild-type, heterozygote, compound heterozygote, and homozygote
mice. Following intratracheal inoculation with 2.5 x 107 bacteria, mice were
transferred to isolators for 48 hours before culling and plating out of lung
homogenates. Results from three experiments are summarised in Fig 6.2 and in
Table 8.3.
Recovery of B. cepacia J2315 varied considerably both between and within
individual experiments. In experiments 1 and 3, average bacterial recovery was
lower from non-CF than CF mice. By contrast, in experiment 2, two CF mice
compared to only one non-CF mouse had completely cleared B. cepacia by 48 hours
post-inoculation, resulting in a higher average recovery for non-CF than CF mice.
Attempts at statistical analysis were confounded by the high degree of variability
from experiment to experiment, particularly as numbers ofmice within individual
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Days post inoculation
Fig 8.1 Recovery ofB. cepacia J2315 from lung homogenates of Swiss mice
inoculated with 1.25 x 107 bacteria at time t=0.
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experiments were low. However the overall trend of results was towards a higher
bacterial recovery and hence poorer clearance in CF than non-CF mice. It may be
relevant to note that in each experiment, mice demonstrating the poorest clearance
were always CF rather than non-CF mice.
Table 8.3. Recovery ofB. cepacia J2315 from the lungs ofmice inoculated
intratracheally with 2.5 x 107 bacteria, 48 hours previously.
CF Non-CF
Experiment N° of Mean cfu/lung N° of Mean cfu/lung
mice (range) mice (range)
1 4 8.7 xlO3 4 1.3 xlO3
(5.4 xlO3 - 1.2 x 104) (0 - 5.1 x 103)
2 3 3.7 xlO3 3 6.7 xlO3
(O-l.lxlO4) (0-1.0xl04)
3 3 6.7 x 106 4 9.6 x 105
(3 x 103 - 1 x 107) (5.1 x 103 - 3.5 x 106)
The variability between individual mice in the above experiments may reflect
differences in the background flora of animals reared within the standard animal
house. Thus a further clearance experiment was undertaken using CF mice and non-
CF littermates from the TGU. Results are shown in Fig 8.3. As for previous
experiments a wide range of values was obtained within both populations, with the
highest bacterial recovery occurring in two CF mice. Although the trend was again
towards poorer clearance by CF mice, results failed to reach statistical significance
(CF: mean 2.6 x 104, range 5.6 x 103 - 6.3 x 104; non-CF: mean 1.1 x 104, range
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Fig 8.2 Clearance of B. cepacia J2315 by CF and non-CF mice from the standard
animal house. Results are from three experiments and show bacterial recovery from
mice lungs, 48 hours after intratracheal delivery of 2.5 x 107 bacteria. Note the
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Fig 8.3 Clearance of B. cepacia J2315 by CF and non-CF mice from the TGU.
Results show recovery of bacteria from mice lungs 48 hour after intratracheal
delivery of 2.5 x 107 bacteria. Genotypes: + - wildtype, h - CFHGU, u - CF^.
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8.3 Clearance Of Environmental And Clinical B. cepacia
Clearance ofB. cepacia J2315 and the environmental B. cepacia J2552 were
compared in wild-type and non-CF heterozygote mice from the TGU CF breeding
programme. Mice were inoculated intratracheally with 2.5 x 107 bacteria per mouse.
Clearance was assessed after 48 hours by plating out of lung homogenates. Results
of two experiments involving a total of 24 mice are summarised in Fig 8.4. Mean
recovery of B. cepacia J2552 was 2.4 x 106 cfu/lung (range 8.4 x 104 - 5.9 x 106)
whilst mean recovery of B. cepacia J2315 was 2.9 x 104 cfu/lung (range 3.2 x 103 -
9.2 x 105). Thus, recovery of B. cepacia J2552 was on average 80 times that of
B. cepacia J2315 and this difference was significant at a 1% level (Students t test,
p<0.01).
In a further experiment, clearance of J2552 and J2315 were compared in CF TGU
mice. Mean recovery of J2552 from three mice was 6.2 x 104 (range 5.2 x 104 -
8.1 x 104) whilst mean recovery of J2315 from 4 mice was 6.2 x 103 (range 1.9 x 103
- 1.5 x 104). Despite the small numbers of mice involved, the 10 fold difference in
recovery of J2552 from recovery of J2315 was statistically significant (Students t
test, p<0.01). Surprisingly, whilst clearance of J2315 was similar in experiments
involving non-CF or CF mice, clearance of J2552 appeared to be greater in CF than
non-CF mice. However direct comparison of J2552 clearance in CF and non-CF













Fig 8.4 Recovery ofB. cepacia J2552 and B. cepacia J2315 from non-CF mice
48 hours post intratracheal inoculation of 2.5 x 107 bacteria. Bars show mean
cfu/lung for each bacterial species
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Chapter 9 Discussion
9.1 The pathogenicity of B. cepacia
The impact ofB. cepacia on the CF community cannot be overemphasised. First,
colonisation is associated with deteriorating lung function and decreased life
expectancy. Second, current antibiotic regimes are ineffective against this
multiresistant pathogen. Third, fears of epidemic spread of B. cepacia within and
between CF centres have led to the introduction of draconian and indiscriminate
segregation policies for colonised patients. Although our understanding of factors
responsible for patient-to-patient spread of epidemic B. cepacia lineages is
increasing, knowledge of the pathogenic mechanisms underlying disease in colonised
patients remains elusive. Several key questions need to be addressed if effective and
novel strategies are to be developed to face the challenge of B. cepacia. For
example, how do B. cepacia establish colonisation in the hostile environment of the
CF lung, particularly in the presence ofmucoid P. aeruginosa and other CF
pathogens? Furthermore, what are the mechanisms underlying lung damage in the
B. cepacia-colonised lung and what role do host factors play in these processes,
particularly in the development of cepacia syndrome in a subset of colonised patients.
The aims of this project were therefore to identify and investigate potential
pathogenic mechanisms employed by B. cepacia in CF lung disease.
Several hypotheses of B. cepacia pathogenesis have been proposed. Initial
comparisons of B. cepacia with P. aeruginosa found no evidence of classic
P. aeruginosa virulence factors, including exotoxin A, elastase, pyocyanin and
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alginate, amongst CF isolates of B. cepacia (Nelson et al, 1994). Comparative
studies of clinical and environmental isolates ofB. cepacia for other putative
virulence factors including proteases, lipases, haemolysins and siderophores, have
also failed to conclusively identify virulence-related determinants. The close
relationship of B. cepacia with B. pseudomallei, the lack of obvious virulence factors
and the persistence ofB. cepacia in the presence of a pronounced humoral response
in CF patients led to suggestions that B. cepacia may survive intracellularly within
either epithelial or phagocytic cells. Finally, increasing evidence has suggested that
B. cepacia may exert a marked pro-inflammatory effect within the CF lung, thus
triggering further damage to the lung parenchyma and consequent respiratory
deterioration (Shaw et al, 1995a; Palffeyman et al, 1997). In the following sections,
these various hypotheses will be discussed in relation to investigations described in
this thesis.
9.2 B. CEPACIA Exoproducts
Historically there has been little evidence to associate B. cepacia exoproducts with
virulence. Nevertheless, in view of the availability of a well-defined panel of
B. cepacia isolates, clinical and environmental strains were compared for production
of a range of potential exotoxins, including protease, elastase, lipase (lecithinase /
phospholipase C), haemolysin and catalase. Results were largely in agreement with
those of other investigators; for example virtually all strains produced catalase whilst
only a few produced haemolytic activity and none produced elastase (Gessner and
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Mortensen, 1990). Protease activity was found in the majority of isolates, although
more frequently in clinical than environmental strains. By contrast, lecithinase
activity was found more frequently in environmental strains, particularly when tested
at 30°C. Overall, the observation of non-proteolytic, non-lipolytic strains amongst
clinical isolates suggests that production of these enzymes may not be important for
colonisation and pathogenesis in CF patients.
Bacterial haemolytic activity is generally mediated by small pore-forming molecules,
which insert into lipid bilayers, giving rise to abnormal ionic movement across cell
membranes and subsequent erythrocyte lysis (Hutchison et al, 1997, 1998).
However, the pathogenic significance of bacterial haemolysins is usually due to their
effects on cell types other than erythrocytes. For example, the ability of
L. monocytogenes to survive intracellularly within macrophages is dependent on the
haemolysin-mediated escape of ingested organisms from the phagosome into the
cytoplasm prior to formation of a phagolysosome (Falkow et al, 1992; Brunt et al,
1990). Haemolysins may also interfere with phagocytic cell activity by inducing
apoptosis, resulting in cell death and loss of an important constituent of antimicrobial
defences, or by triggering degranulation, with release of harmful substances into the
extracellular environment (Jonas et al, 1994). The observation of haemolytic activity
amongst environmental B. cepacia strains is not surprising, given the role these
agents may also play in survival within the soil ecosystem and in phytopathogenicity,
particularly in facilitating invasive infections of plant material.
Previous investigators have identified haemolytic activity in some CF strains of
B. cepacia, but in all studies, the majority of CF isolates appear to be non-haemolytic
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(Gessner and Mortensen, 1990; McKevitt and Woods, 1984). Indeed, in the present
study, activity against human erythrocytes was virtually absent amongst clinical
B. cepacia isolates with only two non-CF isolates producing P haemolysis at 30°C,
and one CF isolate, a representative of the ET12 lineage, producing a small degree of
a haemolysis after prolonged incubation at 37°C. This relatively simple screening
study implies that haemolytic activity is not important in the pathogenesis of
B. cepacia respiratory disease, particularly in CF. However, a recent in depth
analysis (Hutchison et al, 1998) has demonstrated the production of a powerful and
multifunctional haemolysin by a representative strain of the ET12 lineage.
Significantly, activity was only produced when bacterial cells were grown under
highly-oxygenated conditions and not under conditions of colonial growth on agar at
37°C. Similar environmental regulation of haemolysin production in vivo may be
important in the early stages of B. cepacia colonisation, when interference with
neutrophil functions, including the induction of apoptosis by low concentrations of
haemolysin, may enable B. cepacia to establish a foothold in the CF lung.
Catalase is produced by many bacterial species and functions primarily to degrade
endogenously-produced H202, although the protective effect of catalase against host
H202 may also be important in infectious diseases. Our investigation of a large panel
of strains confirmed the general description of B. cepacia as a catalase-positive
species, with only one strain showing no catalase activity. However, in a semi¬
quantitative assay, CF strains demonstrated significantly greater catalase activity than
non-CF strains. B. cepacia are sensitive to oxidative killing mechanisms employed
by neutrophils (Speert et al, 1994) and must therefore have evolved strategies to
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evade ROS generation within the context of the CF lung. One such strategy may be
the degradation of H202 by catalase to minimise the burden ofROS, thus enabling
bacterial survival. It seems probable that B. cepacia strains with high catalase
activity would be better adapted to survival within the oxidant-rich environment of
the CF lung. By contrast, many non-CF B. cepacia infections occur in situations
where oxidative defences are reduced; for example in individuals with CGD, in
neutropenic patients within intensive therapy units, or, in patients with adequate
numbers of functional neutrophils, at sites where phagocytic cell numbers are
generally low.
An ability to sequester iron in competition with natural iron chelators is a pre¬
requisite for bacterial growth in both clinical and environmental situations. Bacteria
have evolved a number of strategies to compete for reduced iron supplies; most
notably, the production of small iron-binding compounds, termed siderophores,
which compete for iron with host iron-storage proteins and bind to specific receptors
expressed at the bacterial outer membrane. In addition, some bacterial species, such
as pathogenic Neisseriae produce receptors for the human iron storage compounds
transferrin and lactoferrin, thus allowing these organisms to directly utilise host iron
for bacterial growth. In many instances, the potential pathogenicity of an individual
bacterial strain has been linked to an ability to compete effectively for iron in iron-
limited conditions. However, to date, a direct link between B. cepacia siderophore
production and human pathogenicity has not been demonstrated.
To investigate the role of iron limitation in the colonisation of the CF lung by
B. cepacia, four B. cepacia strains were screened for ability to grow in iron-rich and
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iron-deficient conditions, with or without the human iron-binding protein, transferrin.
Surprisingly, the representative ET12 strain, J2315, demonstrated slower growth than
all other strains tested, even when using a 100-fold greater inoculum size. In
addition, inclusion of transferrin in the growth medium was associated with a
decrease in the growth rate for J2315 and, particularly in iron-deficient conditions, a
lower steady state viable count. By contrast, growth of the CF strain CI 524 was
unaffected by iron-deficiency or the presence of transferrin, whilst inclusion of
transferrin appeared to enhance the initial survival and growth ofboth environmental
strains, but had little effect upon steady state levels. These results support previous
studies which failed to categorise clinical and environmental strains on the basis of
siderophore production (Nelson et al, 1994) and suggest that, at least for the ET12
lineage, adaptation to conditions of iron-limitation are not a major feature of
pathogenicity in the CF lung. Studies of the effects of iron-limitation on B. cepacia
were therefore not pursued.
In conclusion, attempts to separate clinical and environmental B. cepacia on the basis
of exotoxin production were largely unsuccessful, and, with the possible exception of
catalase activity amongst CF B. cepacia strains, no extracellular virulence factors
were identified in comparative studies of B. cepacia populations. Further studies
therefore focused on two areas; firstly the proposed intracellular model of B. cepacia
infection, and secondly the interaction of B. cepacia with neutrophils, the
predominant immune cell in the CF lung.
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9.3 B. cepacia And Intracellularity
B. cepacia infection in CF shares several features with known infections caused by
intracellular pathogens; for example, persistent lung colonisation in the presence of a
pronounced, specific and damaging immune response bears some similarity to
infection with B. pseudomallei and Mycobacterium tuberculosis, both ofwhich
survive intracellularly within phagocytic cells (Falkow et al, 1992). Many invasive
gastrointestinal pathogens, such as enteroinvasive E. coli, Shigella or Salmonella spp,
penetrate and survive within epithelial cells (Falkow et al, 1992; Korth et al, 1994),
suggesting that invasive respiratory pathogens may utilise a similar mechanism to
spread beyond the respiratory tract. Published studies of B. cepacia intracellularity
are few and have dealt solely with B. cepacia invasion of epithelial cells; for
example, a recent publication demonstrated enhanced invasion of a respiratory cell
line by a representative strain of the ET12 lineage, in comparison to a non-epidemic
B. cepacia strain (Burns et al, 1996). However, the significance of in vitro invasion
of epithelial cell lines within tissue culture systems remains unclear, particularly in
relation to pathogenesis in respiratory tract infections (Miller, 1995; Pier et al, 1996).
Indeed, a recent publication has even suggested that enhanced uptake of CF
pathogens by epithelial cells expressing normal CFTR, followed by epithelial
desquamation, may be an important host defence mechanism rather than a bacterial
virulence determinant (Pier et al, 1996).
B. cepacia is closely related to the intracellular pathogen B. pseudomallei, which
survives within phagocytic cells; thus the current project focused on the uptake and
survival of B. cepacia in monocytes, using L. monocytogenes and P. aeruginosa as
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positive and negative control organisms respectively. Conventional techniques for
investigating intracellular bacteria have depended on the use ofnon-penetrating
antibiotics to kill extracellular organisms. However, the intrinsic antibiotic resistance
of B. cepacia severely restricts the use of this approach. Similar problems have
plagued the investigation of B. pseudomallei as an intracellular pathogen and it was
not until 1990 that definitive evidence ofB. pseudomallei intracellularity was
presented by Pruksachartvuthi et al who used a washing technique coupled with EM
to demonstrate that B. pseudomallei can survive and multiply within human
leukocytes. However, our attempts to repeat this experiment using B. cepacia were
largely unsuccessful; neither B. cepacia nor P. aeruginosa were demonstrated
intracellularly by EM implying that the increasing bacterial counts for both of these
organisms reflected growth of extracellular but adherent bacteria, rather than
intracellular organisms. Both B. cepacia and P. aeruginosa showed a decrease in
viable counts after one hour of incubation, suggesting killing of ingested organisms.
Interestingly, however, this decrease was significantly greater for P. aeruginosa than
B. cepacia, implying that B. cepacia may display greater resistance to monocyte
killing mechanisms than P. aeruginosa.
An alternative approach to the study of intracellularity is the utilisation of a
differential staining technique, in this case, the acridine orange (AO) / crystal violet
(CV) method. AO is a fluorescent dye which binds to DNA in a bimodal fashion,
whereby binding to intact DNA is characterised by green fluorescence whilst binding
to denatured DNA is associated with cross-linking of the AO molecules and the
emission of red fluorescence (West, 1969). Theoretically, AO can therefore
204
distinguish viable and non-viable bacteria on the basis ofDNA denaturation.
Furthermore, AO penetrates mammalian cells whilst CV, which quenches the
fluorescence of AO, remains in the extracellular environment. Hence addition of CV
to AO-stained monocytes will mask the fluorescence of any extracellular bacteria
adherent to the monocyte cell surface.
AO/CV staining was used to assess uptake and initial survival ofB. cepacia within
monocytes, with L. monocytogenes and P. aeruginosa as positive and negative
controls respectively. Results indicated no increased uptake of the representative
ET12 strain, B. cepacia J2315, in relation to an environmental B. cepacia strain,
J2540, or a representative P. aeruginosa strain, PAOl. By contrast, uptake of
L. monocytogenes was at least three times greater than that of the other strains tested.
Interpretation of colour changes with respect to bacterial viability proved difficult,
particularly as earlier studies ofheat-killed or UV-irradiated bacteria suggested that
neither B. cepacia nor P. aeruginosa displayed the characteristic green to red colour
change associated with bacterial cell death. Nevertheless, the majority of ingested
organisms for both P. aeruginosa and B. cepacia were orange/green in colour
implying some degree of DNA damage, and suggesting that some bacterial killing
was taking place. By contrast, the majority of ingested L. monocytogenes appeared
bright red in colour, indicating rapid killing of ingested bacteria. This latter
observation seems paradoxical, given the proven intracelhilarity of
L. monocytogenes. However, previous investigators have also demonstrated that the
majority of ingested L. monocytogenes are killed by phagocytic cells with only a
minority escaping the phagolysosome to grow within the cytoplasm (de Chastellier
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and Berche, 1994). Furthermore, in the assays ofbacterial intracellular survival over
a 24 hour period, the observation ofkilling of all monocytic cells after 24 hours
incubation with L. monocytogenes supports a model ofL. monocytogenes
intracellular survival where a small number of ingested organisms multiply within
the cytoplasm until monocyte death and release of the intracellular organisms occurs.
In conclusion, no evidence was found to support the hypothesis that B. cepacia
persistently colonises the CF lung by intracellular growth within monocytic cells. As
a caveat, however, comparison of results for B. cepacia and P. aeruginosa in assays
of intracellular bacterial survival, suggested that the evasion ofphagocytic cell
killing mechanisms may be important in the persistence ofB. cepacia in the CF lung.
9.4 Interaction Of B. cepacia With Neutrophils
Since neutrophils are the predominant immune cell in the CF lung, survival of
B. cepacia depends upon either evasion of or resistance to neutrophil-mediated
killing mechanisms. Further studies therefore focused on the interaction of
B. cepacia with neutrophils, particularly in relation to bacterial killing and neutrophil
respiratory burst induction.
Killing ofB. cepacia by neutrophils
Initial assays of neutrophil-mediated bacterial killing compared killing of non-
opsonised B. cepacia, with killing ofbacteria opsonised in 10% pooled human serum
(PHS) and indicated that serum factors were required for bacterial killing. However,
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in further studies of a panel of B. cepacia strains pre-opsonised with PHS, no
evidence of significant killing of clinical or environmental strains could be
demonstrated. For example, levels of the environmental strains, J2511 and J2552,
were similar following incubation with neutrophils or buffer alone, whilst one CF
isolate, CI524, actually increased in number to almost double initial counts when
incubated with neutrophils for a two hour period. Results for the ET12 strain, J2315,
were even more intriguing; bacteria incubated with buffer alone displayed a marked
increase in numbers, rising to 138% initial levels after 15 min incubation followed by
a steady decline towards initial levels, whilst bacteria incubated with neutrophils
displayed a slight decrease in numbers. The rapid and early rise in counts observed
in control bacteria is consistent with dissociation ofbacterial aggregates rather than
bacterial growth per se\ it is possible, therefore, that the extent ofbacterial killing in
the presence of neutrophils has been masked by the dissociation of existing bacterial
clumps. Conversely the tendency ofB. cepacia J2315 to form aggregates could lead
to an underestimation of bacterial viability in the presence ofneutrophils. Thus any
data generated from assays of neutrophil-mediated killing of B. cepacia, particularly
of the ET12 lineage, must be interpreted with caution.
The confounding effect ofbacterial aggregation was further demonstrated in
comparative studies of neutrophil-mediated killing following opsonisation with
immune and non-immune sera. Initial studies suggested that heat-inactivated
immune serum was associated with greater bacterial killing than similarly treated
non-immune serum. However, the observation of a similar or even greater decline
amongst pre-opsonised bacteria in the absence of neutrophils, indicated that the
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apparent killing of B. cepacia by neutrophils was in fact due either to serum
sensitivity or bacterial aggregation. Serum sensitivity depends upon the presence of
active complement; thus the observation of a similar pattern of viable counts
following pre-opsonisation with either heat-inactivated or untreated serum suggests
that antibody-mediated bacterial aggregation is the basis of any decline in bacterial
counts. Given this phenomenon, further killing assays using pre-opsonised bacteria
were discontinued.
Respiratory burst activity
In view of the difficulties encountered with neutrophil-mediated killing assays, an
alternative approach to the assessment of neutrophil defences against B. cepacia was
required. Speert et al (1994) have demonstrated that B. cepacia are resistant to
neutrophil non-oxidative killing mechanisms; the generation of an effective
respiratory burst is therefore necessary for the clearance of these organisms. Thus,
the induction of neutrophil respiratory burst activity in response to B. cepacia was
investigated.
Respiratory burst activity can be assessed using a variety of methodologies, all of
which measure different products in the sequence of events leading to ROS
generation. Techniques used in this thesis included luminol- and lucigenin-enhanced
chemiluminescence (LCL and LuCL respectively), flow cytometric analysis using
the fluorescent dye dihydrorhodamine (DHR) and spectrophotometry measurement
of extracellular cytochrome c reduction. Both LuCL and the cytochrome c assay
detect 02", the first product of the NADPH oxidase pathway; notably, however, LuCL
detects intracellular 02" whilst the cytochrome C assay only detects 02" released
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extracellularly. DHR is used to detect intracellular production of H202 whilst LCL
detects the generation of MPO-dependent ROS, although the exact nature of the
oxidant species involved is not clear.
Initial studies focused on the induction of LCL by non-opsonised B. cepacia and
P. aeruginosa. Interpretation of the results generated by this technique was difficult.
For example, considerable inter-donor variation was observed, with wide variations
in the magnitude and timing of responses from donor to donor. However, this was
partly corrected by using the LCL response to opsonised zymosan (OZ) as a
standard, and calculating activity of all other agents as a percentage of OZ activity.
Perhaps a more difficult problem was how best to analyse the wide variety of
patterns of activity obtained, with individual bacterial isolates inducing peaks of
activity at differing time points, or a sustained response over the duration of the assay
period. Data could be interpreted in a number of ways, including the magnitude and
timing ofpeak responses, the initial rate of responses or the area under the LCL
curve. Comparison of various parameters indicated that analysis ofpeak LCL and
LCL at 10 min (LCL10), gave the most consistent results and further data were
interpreted on the basis of these two parameters. Since previous investigators have
demonstrated that the timing of LCL responses correlates with neutrophil
phagocytosis and bacterial killing to a greater degree than the magnitude of peak
responses (Speert et al; 1986), LCL10 data may be particularly important in terms of
bacterial sensitivity to neutrophil-mediated killing.
Comparison of a panel of environmental, non-CF clinical and CF B. cepacia strains
indicated that LCL induction varied considerably from strain to strain. Nevertheless,
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CF strains, including representative epidemic strains, did appear to induce less
respiratory burst activity than non-CF strains, whilst environmental strains displayed
a variety of responses (Fig 6.2). This observation supports a hypothesis of
B. cepacia infection in CF where bacterial survival depends upon avoidance of a
meaningful neutrophil respiratory burst; thus those strains ofB. cepacia less likely to
induce activity have an advantage in terms of respiratory colonisation and survival.
However, given the diversity ofbacterial strains currently identified as B. cepacia, a
greater number of isolates would need investigation to confirm these findings.
Perhaps more significantly, CF strains ofB. cepacia were observed to display less
respiratory burst activity than CF strains ofnon-mucoid P. aeruginosa. In particular,
the range of activities induced by P. aeruginosa was much greater than that induced
by B. cepacia strains, suggesting that the evasion of a neutrophil respiratory burst is
less relevant to survival ofP. aeruginosa than B. cepacia (Fig 6.3). Indeed, as
P. aeruginosa is sensitive to non-oxidative neutrophil defence mechanisms (Speert et
al, 1994), killing of P. aeruginosa will occur whether or not an effective respiratory
burst is mounted. Survival of P. aeruginosa within the CF lung depends upon the
conversion ofnon-mucoid P. aeruginosa (NMPA) to a mucoid phenotype (MPA),
which enables the organism to evade host defence mechanisms by sheltering within a
protective layer of alginate. A model ofP. aeruginosa infection can be hypothesised
where MPA within the alginate biofilm, periodically revert to non-mucoid forms,
resulting in the presence of both MPA and NMPA in sputum. Thus, the persistence
ofNMPA within the CF lung depends upon the continued presence of a pool of
mucoid strains which sporadically give rise to non-mucoid forms, rather than the
direct avoidance ofneutrophil-killing mechanisms.
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The interaction ofnon-opsonised bacteria with neutrophils is generally believed to be
mediated or enhanced by hydrophobic interactions between the bacterial and
neutrophil cell surfaces. The characteristics ofbacterial cell surfaces are in part
determined by cultural conditions; for example, bacterial growth in static conditions
favours bacterial aggregation and enhanced hydrophobicity, whilst bacteria grown in
shaken culture will tend to be less hydrophobic. Therefore the effects of growth in
either static or shaken culture on LCL induction were compared for a panel of CF,
non-CF clinical and environmental B. cepacia strains (Fig 6.4). Both CF strains,
J2315 and CI987, and the environmental strain, J2552, induced little LCL activity
when grown in shaking condition; static growth, however, was associated with an
increase in reactivity, implying that, for these strains, bacteria/neutrophil interactions
were dependent on non-specific hydrophobic bacterial binding. By contrast, when
grown under shaken conditions, two non-CF clinical strains, J2660 and J2684,
induced a sizeable respiratory burst, which was not enhanced by growth under static
conditions, suggesting that receptor-mediated rather than non-specific hydrophobic
reactions were responsible for LCL induction by these bacteria. Again, these results
support the hypothesis that evasion of respiratory burst induction by CF strains of
B. cepacia is important for the survival ofB. cepacia within the CF lung; strains
which are more likely to trigger a respiratory burst are less likely to be implicated in
CF respiratory disease.
As LCL is a relatively non-specific technique for the detection of respiratory burst
activity, attempts were made to confirm the above results using lucigenin to detect
the generation of 02". Theoretically, LCL detects oxidant species produced in a
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MPO-dependent manner, suggesting that activity requires the presence of H202,
generated from superoxide anions. Measurement of LuCL and LCL levels in
simultaneous experiments allowed direct comparison ofNADPH oxidase activation
and 02" production with LCL generation. Neutrophils treated with buffer alone
demonstrated a small peak in LuCL activity at 30 min, which declined to baseline
levels after one hour of incubation, whilst LCL activity remained unchanged.
Incubation ofneutrophils with bacteria had varying effects on LuCL activity, either
inducing a greater peak than untreated neutrophils (eg B. cepacia C2040), or a more
sustained LuCL response (eg B. cepacia J2315, P. aeruginosa J1385). Surprisingly,
little consistent correlation was seen between LCL and LuCL with respect to both
peak activity and the initial rate of responses (Fig 6.5). However, the presence of a
sustained LuCL response did appear to correlate with either a sustained LCL
response (eg P. aeruginosa J1385) or a late LCL response (eg B. cepacia J2315).
Furthermore, studies using two inhibitors of respiratory burst activity provided strong
evidence to support the proposed relationship between LuCL and LCL activity (Fig
6.6). Treatment with NaN3 virtually abolished LCL activity whilst augmenting
LuCL activity, suggesting that at least a component of LCL activity is a downstream
event of 02 production. Simultaneous experiments using SOD confirmed this
relationship by demonstrating a complete abolition of LuCL activity associated with
a reduction in LCL activity.
Further studies of neutrophil respiratory burst induction were carried out using
alternative methodological approaches, including the detection of extracellular 02" by
reduction of ferricytochrome c, and the detection of intracellular H202 by oxidation
212
of dihydrorhodamine (DHR). Virtually no extracellular 02" could be detected
following exposure ofneutrophils to a range ofB. cepacia strains, whilst only a
slight response was induced by a representative P. aeruginosa strain, under similar
assay conditions to those utilised in LCL and LuCL experiments (Table 6.2). By
contrast, flow cytometric analysis of neutrophils treated with DHR demonstrated the
generation of intracellular H202 in response to a range of bacterial strains (Fig 6.19).
However, as for LCL assays, a greater range of activities was detected in response to
representative CF isolates of P. aeruginosa than B. cepacia. Furthermore, for the
majority ofbacterial isolates, considerable correspondence in the timing and level of
DHR and LCL responses was observed. In particular, the pattern of DHR activity
over time seen in response to the strains P. aeruginosa J1385, B. cepacia C2040 and
B. cepacia J2315 correlated well with the respective early, medium and late rises
seen in LCL responses to these bacteria (Fig 6.1, Fig 6.18). In conclusion, results
from studies of respiratory burst activity using a variety of methodologies supported
our hypothesis that non-opsonised CF isolates ofB. cepacia induce little respiratory
burst activity in human neutrophils.
9.5 Bacterial Opsonisation And Respiratory Burst Induction
Colonisation with B. cepacia in CF is associated with a marked and specific humoral
immune response. Unlike P. aeruginosa, elevated titres of anti-R. cepacia antibodies
do not correlate with a decline in lung function but nor do they appear to confer a
protective effect upon the patient (Nelson et al, 1993) leading some observers to
213
speculate that the IgG response seen in colonised patients may be largely non-
opsonic, and thus have little impact on killing ofB. cepacia by phagocytic cells
(Butler et al, 1994b). ELISA techniques to detect immunoglobulin give little
information regarding the opsonic activity of serum antibody; by contrast,
measurement ofneutrophil respiratory burst induction by bacteria following pre-
opsonisation with non-immune and immune serum provides a functional assay for
the effectiveness of an immunoglobulin response. We thus investigated the effects of
pre-opsonisation in response to a representative of the ET12 lineage, J2315, using
serum from the adult CF clinic based at the Western General Hospital, Edinburgh,
where several patients are colonised by this strain.
Pre-opsonisation of J2315 with heat-inactivated immune serum was associated with
an increase in LCL induction; this response was enhanced still further ifpre-
opsonisation was carried out with serum plus active complement, primarily through
the induction of a more sustained LCL response (Fig 6.7). Pre-opsonisation with
complement alone, however, was associated with the induction of little or no LCL
activity. LuCL activity induced by J2315 was also increased if bacteria were pre-
opsonised with immune serum; however, opsonisation with complement and serum
was not associated with any further increase in activity and opsonisation with
complement alone was associated with the complete abolition of LuCL responses.
Although this latter result agrees with the observation that complement receptors
alone do not provoke a respiratory burst, the abolition of even the slight LuCL
response observed in neutrophils treated with buffer alone suggests that under these
circumstances, complement may actually down-regulate respiratory burst activity.
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Furthermore, the enhancement of LCL but not LuCL induction by pre-opsonisation
ofbacteria with both complement and serum suggests that complement receptor
activation may have downstream effects during neutrophil respiratory burst
activation processes. For example, complement-mediated enhancement of azurophil
degranulation would increase the availability of MPO in phagolysosomes, thus
promoting the generation of the MPO-dependent ROS detected by the LCL assay.
The role ofopsonic activity in disease progression
Since the inclusion of complement with serum had comparatively little effect on peak
LCL or LCL10, further studies of immune and non-immune serum from colonised
patients were conducted using serum alone, rather than serum plus complement.
Heat-inactivated serum from a panel of CF patients, ofwhom all the B. cepacia-
colonised patients harboured the ET12 lineage ofB. cepacia, were compared for
opsonic activity against B. cepacia J2315. Although bacterial pre-opsonisation with
serum from both colonised and non-colonised patients increased LCL responses
dramatically, significantly greater activity in terms of both peak LCL and LCL10 were
induced by serum samples from colonised patients (Table 6.1; Fig 6.10). Absorption
studies using a CF strain ofP. aeruginosa, and a range of other B. cepacia strains
indicated that this effect was specific to B. cepacia J2315 and was not due to cross-
reacting antibodies against P. aeruginosa (Fig 6.12). In further studies, the
cytochrome c assay was used to assess the effects of opsonisation on induction of
extracellular 02" release. Results confirmed those of the LCL assay, by indicating the
species-specific effect of pre-opsonisation ofboth B. cepacia and P. aeruginosa with
patient serum (Table 6.3, Fig 6.16). For example, serum from a patient colonised
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with P. aeruginosa alone had no opsonic activity against B. cepacia, whilst patients
colonised with both organisms possessed opsonic activity against both B. cepacia
and P. aeruginosa. Again, the use of absorbed serum confirmed the lack of cross-
reactivity between the B. cepacia and P. aeruginosa responses (Fig 6.15).
Of the B. cepacia-positive patients investigated, no correlation could be observed
between serum opsonic activity and clinical status; thus a specific role for anti-
B. cepacia opsonic antibody in the pathogenesis ofB. cepacia lung disease could not
be demonstrated. Nelson et al (1993) had previously demonstrated high anti-
B. cepacia LPS immunoglobulin titres in both patients with stable clinically mild
disease and patients who subsequently succumbed to severe lung disease. Notably,
the development of septicaemia in patients with cepacia syndrome was not prevented
by the presence of high immunoglobulin titres, suggesting that an inappropriate non-
opsonic IgG subclass response may be made to B. cepacia, preventing effective
complement- and phagocytic cell-mediated killing of this organism (Butler et al,
1994b). However in the present study, we have demonstrated the presence of
specific and opsonic anti-2?. cepacia immunoglobulin, suggesting that an appropriate
IgG response is mounted. The persistence of B. cepacia in the face of a pronounced
humoral response may therefore reflect the disruption of opsonic processes within the
CF lung by proteolytic cleavage of complement receptors and immunoglobulin,
rather than a defect in the immunoglobulin response. Nevertheless, such a
hypothesis does not explain the ability of serum-sensitive B. cepacia to cause
septicaemia in a subset of colonised patients.
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Effect ofatmospheric conditions
An interesting observation from the above studies was the demonstration of differing
opsonic activity of serum against B. cepacia and P. aeruginosa grown in different
atmospheric conditions. As expected, growth in conditions of air enriched with 5%
C02, which resemble the in vivo situation, was associated with increased
opsonisation of a CF strain of P. aeruginosa. By contrast, however, opsonisation of
the ET12 lineage ofB. cepacia was decreased when the bacteria were grown under
C02-enriched conditions (Table 6.3). Analysis of OMP expression for both
organisms suggested that changes in OMP profile may be responsible for the
differing opsonisation patterns seen. Burnie et al (1995) have hypothesised that an
improved prognosis in B. cepacia-colonised patients can be correlated with the
production of antibodies against a 30 kDa protein, presumptively identified as the 28
kDa OMP D porin (Aronoff and Stem, 1988), which is believed to associate with the
37 kDa OMP C porin to form an 81 kDa band (Gotoh et al, 1994). In the present
study, analysis of the OMP profile of B. cepacia ET12 grown in air revealed no
obvious band at 81 kDa, but major bands were apparent at 36 kDa and 28 kDa
(Fig 6.17). Interestingly, growth in C02-enriched conditions was associated with the
loss of the 28 kDa band and the appearance of a new band at 26.5 kDa. Furthermore,
a slight shift was observed in the 36 kDa band, suggesting some modification of this
OMP. Thus, phenotypic modification of B. cepacia within the CF lung may alter the
organisms antigenic profile, enabling bacterial persistence in the presence of a
specific immunoglobulin response. In addition, growth in a C02-enriched
environment has been implicated in increased resistance of B. cepacia to
antimicrobial agents, possibly through altered OMP expression (Corkill et al, 1994a);
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the changes observed in the present study may contribute to the phenomenon
whereby B. cepacia which display antibiotic sensitivity in vitro, are found to be
resistant to antibiotic therapy in vivo.
Opsonic immunoglobulin and B. cepacia colonisation
An attempt was made to assess the relationship of opsonic immunoglobulin
production to B. cepacia colonisation by conducting longitudinal studies in two
patients, using serum samples taken before and after the first positive sputum for
B. cepacia (Fig 6.11). Both patients became persistently colonised with the ET12
lineage of B. cepacia. For patient G, a steady increase in opsonic activity, as
determined by both peak LCL and LCL10, was observed after colonisation with
B. cepacia, although rising activity was also detected prior to colonisation. Results
for patient S were more intriguing, with the demonstration of considerable pre-
colonisation opsonic activity for several years before a fall in activity in the two year
period prior to the isolation ofB. cepacia. Previous investigators have demonstrated
the presence ofhigh titres of anti-R cepacia LPS antibodies in a small number of
apparently B. cepacia-negative patients (Nelson et al, 1993), leading to speculation
that, in some patients, exposure to B. cepacia may be followed by a protective
immune response, preventing the establishment of colonisation. Such a hypothesis
would be consistent with our observations regarding patient S; colonisation with
B. cepacia only occurred after a demonstrable drop in anti-B. cepacia opsonic
activity. Alternatively, the presence of an apparently pre-colonisation antibody
response to B. cepacia may represent the presence of low numbers of B. cepacia
within the CF lung, which are not detected by standard cultural techniques. Indeed
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the possibility of culture-negative B. cepacia colonisation in CF patients has been
suggested by a number of investigators. For example, Nelson et al (1993) described
a rise in patient anti-5. cepacia titres in the months immediately before the first
positive sputum for B. cepacia, implying that B. cepacia was not detected by sputum
culture until a certain level of colonisation was reached. LiPuma et al (1994) have
also speculated that B. cepacia sputum-negative patients may actually harbour the
organism, following the apparent transmission of a B. cepacia strain between two
patients prior to the first positive sputum culture for either patient. Most recently,
PCR of sputum from apparently non-colonised patients using B. cepacia-specific
primers, has demonstrated positive results in a proportion of patients, again
suggesting that colonisation may be undetected in some CF individuals (S Elborn,
personal communication). Thus the rise in titres seen in patients S and G in the
months immediately prior to positive sputum culture may reflect early undetected
B. cepacia colonisation. However, epidemiological data for patient S has identified
only one definite episode of exposure to B. cepacia, occurring a few weeks before
positive sputum culture; thus a prolonged period of inapparent B. cepacia
colonisation seems unlikely for this patient.
Relationship to other B. cepacia strains
Immune sera from CF patients colonised with the ET12 lineage of B. cepacia were
used to assess the relationship between B. cepacia ET12 and other B. cepacia strains.
Considerable variation was seen in the opsonic activity of individual serum samples
in response to a panel of clinical and environmental strains. However, in all
instances, genomovar III strains, ofwhich the ET12 lineage is a member, were most
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likely to be opsonised by serum from ET12-colonised patients, as determined by the
earlier induction of an LCL response (Fig 6.9). Results for representative strains of
other genomovars were less clear cut. For example, the genomovar I strains, CI964
(CF) and J2552 (environmental), were not opsonised by serum from an ET12-
colonised patient, whilst another environmental genomovar I strain, J2540, induced a
dramatically enhanced LCL response following pre-opsonisation. It may be relevant
to note that the OMP profile of B. cepacia J2540 appears to be closely related to that
of the ET12 lineage (Dr Kathy Taylor, personal communication); by contrast, studies
of TNF-a induction by B. cepacia LPS have indicated that LPS from J2540 is less
active than that a representative ET12 strain (CI359), or other clinical B. cepacia
strains (Shaw et al, 1995a). Thus the exact nature of the relationship between
B. cepacia J2540 and the ET12 lineage remains unclear. Genomovar II strains were
also opsonised to differing degrees by anti-ET12 serum, with no opsonic activity
demonstrated against a non-CF clinical strain (CI962) whilst considerable activity
was demonstrated against a CF isolate, CI576. This latter isolate is a representative
of the Glasgow epidemic strain; thus a common transmissibility factor may be
present in both the Glasgow and ET12 epidemic lineages. Indeed, both of these
lineages are known to contain the B. cepacia epidemic strain marker described by
Mahenthiralingam et al (1997), although the role of this marker in antigen expression
by B. cepacia is as yet unknown.
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9.6 B. cepacia And The Respiratory Burst Pathway
Interpretation of data regarding the induction of a neutrophil respiratory burst by
non-opsonised and opsonised bacteria was complicated by the apparently
contradictory results obtained using a range of techniques to determine respiratory
burst activity. Thus, for example, the bacterial strains P. aeruginosa J1385 and
B. cepacia C2040, which both induced marked LCL and DHR responses, induced
little detectable extracellular 02", as determined by the cytochrome c assay (Fig 6.1;
6.3; Table 6.2). Similarly, little correlation was observed between LCL and LuCL
activity, despite the demonstration of a relationship between these two parameters
when respiratory burst induction was analysed in the presence of specific inhibitors.
Opsonisation ofbacteria with immunoglobulin enhanced both 02" production and the
generation of MPO-dependent ROS, but complement appeared to enhance only the
latter stages of the respiratory burst pathway and not the initial production of 02~.
One explanation for these anomalies may be the generation of MPO-dependent ROS
from bacterially-derived rather than neutrophil-derived H202. Alternatively,
neutrophil stimulation may upregulate later processes in the respiratory burst
pathway as well as 02 generation. Indeed, recent studies have indicated that MPO
activity can be increased independently ofNADPH oxidase activation. For example,
Witko-Sarsat et al (1996) demonstrated a constitutive increase in MPO activity in
neutrophils from CF patients and heterozygote carriers. Other investigators have
demonstrated an increase in MPO activity, independent of an increase in NADPH
oxidase activity, in neutrophils from healthy individuals following in vivo cytokine
treatment (Allen et al, 1997; Zipfel et al, 1997). It is possible that an MPO-
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dependent increase in H202 utilisation and hence 02 dismutation may have removed
02" before detection in the various assays used in the present study, thus masking the
tme extent of 02" generation. One criticism of this hypothesis arises from the
observation of dramatically increased levels of 02" detected by cytochrome c,
following neutrophil stimulation with pre-opsonised rather than non-opsonised
bacteria. However, since the cytochrome c method detects only extracellular 02", this
phenomenon may represent increased granule exocytosis in addition to the induction
of respiratory burst activity. Evidently, where possible, respiratory burst activity
should be analysed by more than one technique, if a complete picture of neutrophil-
bacterial interactions is to be obtained.
In any investigation of neutrophil-bacterial interactions, consideration must be given
to bacterial products which may modulate respiratory burst responses. A possible
role for catalase production in the down-regulation of ROS responses by B. cepacia
has already been discussed, but other bacterial substances may provide the organism
with protection against neutrophil oxidative killing mechanisms. In the present
study, comparison of LuCL and LCL induction by a pre-opsonised non-mucoid
P. aeruginosa strain and a pre-opsonised B. cepacia of the ET12 lineage revealed
marked differences in the patterns of activity induced. In particular, LCL responses
were greater for the P. aeruginosa strain, whilst the B. cepacia strain induced greater
LuCL activity (Fig 6.13). This intriguing observation suggests that B. cepacia ET12
may actually inhibit the generation of MPO-dependent ROS, even in the presence of
NAPDH activation and 02" production. Production of carotenoid pigments which
quench singlet oxygen, one of the main ROS detected by the LCL assay, has been
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proposed as a bacterial defence mechanism employed to evade oxidative killing
(Krinsky, 1974). It would be tempting to speculate that the ET12 lineage of
B. cepacia, which, unlike most other B. cepacia, is characterised by the production of
a brown diffusible pigment, may utilise a similar mechanism to evade oxidative
killing mechanisms. However, other investigators have failed to detect carotenoid
pigments in this strain of B. cepacia (Dr Kathy Taylor, personal communication) and
preliminary experiments towards the present study failed to demonstrate any
inhibition of LCL activity by supernatant from B. cepacia cultures. Nevertheless, the
findings presented above are consistent with the hypothesis that inhibition of ROS
generation by B. cepacia ET12 may play a role in the persistent colonisation of the
CF lung.
9.7 The Pro-Inflammatory Effect Of B. cepacia
Accumulated evidence indicates that B. cepacia colonisation in CF is associated with
an upregulation in respiratory inflammation, promoting further lung damage in
patients who acquire this pathogen. Given that neutrophil products, including ROS
and proteolytic enzymes, are widely believed to be the pathogenic mediators of this
inflammatory damage; it seems reasonable to investigate the ability of B. cepacia to
promote neutrophil activation and degranulation. Although we have already
demonstrated that CF strains of B. cepacia tend to be poor inducers of a respiratory
burst, these strains may augment neutrophil activation in other ways, either through
enhancing neutrophil recruitment to the lung or by increasing the magnitude of
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activation events. Respiratory burst induction and degranulation of azurophil
granules are end-stage events in neutrophil activation. By contrast, degranulation of
other granule subtypes and priming of respiratory burst activity, whereby responses
to any subsequent stimulus are increased, occur earlier in neutrophil activation
processes. Neutrophil degranulation can be assayed through the measurement of
released enzyme activity in neutrophil supernatants or increased expression of cell
surface receptors originally stored within the granule membrane. In the present
study, flow cytometry was used to assess CR3 expression as a measurement of non-
azurophil degranulation in response to B. cepacia and P. aeruginosa. Since many
agents induce neutrophil priming at the same time as non-azurophil degranulation,
priming ofneutrophil responses to the stimulant FMLP was also measured, using
DHR to detect intracellular H202 production.
CR3 is a pivotal receptor in such diverse neutrophil functions as adhesion,
transmigration, phagocytosis and degranulation; therefore an increase in CR3
expression is a key event in neutrophil activation processes. Analysis of a panel of
B. cepacia strains indicated that these bacteria induced increased CR3 expression
both in the presence and absence of serum. However, for some strains, including the
ET12 lineage and other representatives of genomovar III, CR3 responses to high
concentrations of bacteria were down-regulated in the presence of serum. By
contrast, responses in the absence of serum correlated logarithmically with the
concentration ofbacteria present (Fig 5.4). The nature of this strain-specific effect
remains unclear, but, given the low anti-/i. cepacia titres generally found in healthy
individuals, is unlikely to involve opsonisation with immunoglobulin. As fresh
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blood samples were used, the effect of serum may be linked to the binding and
activation of complement by some B. cepacia strains. Decreased detection of CR3
expression at high bacterial concentrations would thus represent either masking of
antibody binding sites on the CR3 molecule by bound bacteria or the internalisation
of bound bacteria with consequent down-regulation of CR3 expression. Binding of
activated complement is severely disrupted within the CF lung by the proteolytic
cleavage of complement receptors; thus the majority of further studies were
conducted on neutrophils in the absence of serum.
Pro-inflammatory effects ofwhole bacteria
Neutrophil responses to a panel of B. cepacia and P. aeruginosa strains isolated from
CF patients were compared for both induction ofnon-azurophil degranulation and
priming of respiratory burst activity. All B. cepacia strains were found to induce a
marked increase in CR3 expression, whilst several strains primed respiratory burst
responses to FMLP. (Fig 5.5; Fig 6.19; Table 6.4). Little CR3-inducing activity or
priming activity was present in filtered supernatants from bacterial suspensions; thus
activity appeared to depend on the presence of whole bacteria, rather than on
bacterial products. However, as incubation times of up to one hour were used, it is
possible that bacterial products, released during the course of the experiment, were
responsible for these effects. Comparison ofB. cepacia and P. aeruginosa strains,
supported our hypothesis that B. cepacia are less likely to induce a respiratory burst
response but do trigger other pro-inflammatory neutrophil responses. Thus,
P. aeruginosa triggered a greater average respiratory burst response, while B. cepacia
induced greater average CR3 expression. Priming activity also tended to be greater
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for B. cepacia than P. aeruginosa strains. However, overall differences between
P. aeruginosa and B. cepacia failed to reach statistical significance, and further
studies using a greater number of strains for each bacterial species are required to
confirm these observations.
The nature of the B. cepacia-neutrophil interaction inducing increased CR3
expression and priming remains to be determined. B. cepacia may bind to specific
receptors or may bind non-specifically to the neutrophil surface by hydrophobic
interactions. Results from LCL studies of bacterial growth conditions, and the
observation by previous investigators of high surface hydrophobicity in CF strains of
B. cepacia, including the ET12 lineage (Shaw, 1995), suggest that the latter
mechanism is probably the basis of B. cepacia-neutrophil interactions. However,
receptor-mediated binding may also be enhanced by hydrophobic interactions, and
seems more likely to trigger the neutrophil degranulation and priming seen in
response to B. cepacia strains. One intriguing possibility is that B. cepacia may
actually bind to the CR3 molecule itself, thus triggering neutrophil degranulation and
phagocytosis without inducing a respiratory burst. Ideally, studies ofbinding of
B. cepacia to neutrophils utilising specific monoclonal antibodies raised against
B. cepacia, would be required to establish the exact nature of B. cepacza-neutrophil
interactions. It is hoped that the current development of anti-R. cepacia monoclonal
antibodies will allow rapid progress in this field of research.
B. cepacia products in neutrophil activation processes
Bacterial products may also interact with neutrophils to induce priming and
degranulation. For example, LPS from a number of bacterial species are potent
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neutrophil priming agents. B. cepacia, including the ET12 lineage, is known to
produce LPS which is active in bioassays measuring induction of the pro¬
inflammatory cytokine, TNFa from monocytes (Shaw et al, 1995a). Thus the
interaction of LPS molecules extracted from strains of B. cepacia and P. aeruginosa
with neutrophils was investigated, using E. coli LPS as a positive control.
In initial studies, induction of CR3 by LPS from B. cepacia J2315 was compared in
washed and whole blood. High levels of CR3 were induced on neutrophils within
washed blood by concentrations of LPS of 100 ng/ml or greater. LPS activity was
demonstrated at lower concentrations when incubated with neutrophils in whole
blood, but no CR3 induction was seen at higher concentrations. Furthermore, the
overall level of activity was much lower for LPS in whole blood than washed blood.
One explanation for this observation may be the presence of monocytes within the
blood samples used; monocytes express much greater levels of CD 14 than resting
neutrophils and may therefore bind LPS-LBP complexes before any interaction with
neutrophils can occur. Thus in the absence of serum and hence LBP, more LPS
would be available for binding to neutrophils in a non-CD 14 dependent manner.
While these results suggest that circulating B. cepacia LPS may have little impact on
neutrophils within the bloodstream, the observation of enhanced CR3 expression in
neutrophils treated with LPS in the absence of serum factors is particularly relevant
to inflammation in the CF lung, where concentrations of serum factors are likely to
be low. As both P. aeruginosa and B. cepacia are typically found in CF sputum at
high concentrations of approximately 108-109 cfu/ml, it is likely that concentrations
of shed LPS from both viable and non-viable bacteria will also be elevated. Thus,
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further studies were conducted in serum-free conditions using a concentration of
100 ng/ml LPS as standard. Extracts of LPS from a panel ofB. cepacia and
P. aeruginosa isolates were compared for both induction of increased CR3
expression and priming ofneutrophil responses to FMLP. LPS from both clinical
and environmental strains ofB. cepacia induced a marked increase in neutrophil CR3
expression (Fig 7.6). By contrast, LPS from three representative P. aeruginosa
strains had little effect on CR3 expression. These results are consistent with those of
Shaw et al (1995a) who first reported the surprising finding that B. cepacia LPS
induced a TNFa response from circulating blood monocytes, which was 9-fold
greater than that induced by P. aeruginosa LPS. In these studies, TNFa was
detectable between 2.5 - 4.5 hours after the addition ofB. cepacia LPS, and levels
peaked at approximately 3.5 hours. As the assays in the present study were carried
out on a whole blood cell population, it is possible that the increase in CR3
expression was due to secondary stimulation ofneutrophils following the release of
cytokines from the monocyte population. Indeed at low LPS concentrations an
increase in neutrophil CR3 expression occurred after 3 hours, possibly through
stimulation by monocyte-derived TNFa (Fig 7.4). However the earlier timing of
responses to higher concentrations ofLPS (< 2 hours) suggests a direct effect of LPS
on neutrophils.
E. coli LPS has been demonstrated to prime FMLP-induced respiratory burst
responses in neutrophils (Karlsson et al, 1995). Comparison of B. cepacia and
P. aeruginosa LPS with E. coli LPS in the current study indicated that whilst
B. cepacia LPS molecules were potent neutrophil priming agents, little priming was
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induced by P. aeruginosa LPS (Fig 7.9). Of the B. cepacia strains tested only J2540,
an environmental strain, failed to induce priming significantly above levels of all
P. aeruginosa strains tested. In time course experiments using LPS from B. cepacia
J2315 and E. coli 018K-, priming was observed after as little as 30 min and 45 min
respectively, suggesting that neutrophil priming responses were not secondary to
LPS-induced cytokine release from circulating monocytes. LPS from two
P. aeruginosa strains: PAOl, a well-characterised laboratory strain and CI250, a
mucoid strain isolated from a CF patient, primed neutrophils to a low degree.
However LPS from the non-mucoid CF strain, J1385, had no priming effect.
Interestingly in a study of LPS extracted from 5 CF strains of P. aeruginosa,
Kharazmi et al (1991) observed similar variation in neutrophil priming, with LPS
from two mucoid strains showing the greatest overall activity.
Our observation of a high degree of correlation between mean CR3 surface
expression and mean FMLP-induced respiratory burst activity agrees with published
studies (Yee and Christou, 1993). Unlike increased CR3 expression, however,
priming responses were not uniform throughout the neutrophil population and a
subpopulation ofhighly responsive neutrophils were identified by changes in size
(forward scatter) and granularity (side scatter) on stimulation with FMLP (Fig 7.7).
These results agree with those of Yee and Christou (1993) who observed that the
FMLP-induced elevation of intracellular Ca2+ levels in neutrophils primed with LPS
was due to raised levels in a subpopulation of responsive cells. Similarly, Daniels et
al (1994) demonstrated the recruitment ofpreviously non-responsive neutrophils
into a responsive population following treatment with physiological priming agents.
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In the present study, highly responsive cells were virtually absent in unprimed
populations but appeared in samples primed with LPS from both B. cepacia and
E. coli. The observed changes in forward and side scatter for R2 neutrophils
(Fig 7.7) may simply reflect the activation of these cells following FMLP simulation.
However, since respiratory burst responses also increased amongst R1 neutrophils,
and since a considerable overlap in individual responses for neutrophils in R1 and R2
populations was observed, it seems more probable that LPS is associated with a
significant phenotypic change in R2 neutrophils prior to stimulation with FMLP.
The nature of such a phenotypic change remains unclear but could involve changes in
receptor expression. However comparison ofhistogram distributions of CR3
expression and FMLP-induced intracellular H202 production indicated that the highly
responsive subpopulation of neutrophils could not be identified on the basis of
increased CR3 expression. FMLP receptors were not measured in the present study;
however, previous investigators have found that both CR3 and FMLP receptors are
upregulated on LPS-treated neutrophils in a unimodal fashion, with no evidence of
neutrophil subpopulations (Yee and Christou, 1993), suggesting that increased
receptor expression is not the mechanism underlying the highly responsive
phenotype.
Additional studies assessed the impact of neutrophil exposure to LPS on respiratory
burst induction by whole bacteria and provided an insight into the potential role of
LPS in the colonisation of the CF lung by B. cepacia. The majority of B. cepacia-
colonised CF individuals harbour large numbers of P. aeruginosa within their
sputum prior to acquisition ofB. cepacia. In our studies of representative B. cepacia
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and P. aeruginosa strains, priming with LPS from B. cepacia J2315 was associated
with a significant increase in respiratory burst induction by whole P. aeruginosa
J1385. By contrast, whole B. cepacia J2315 induced little or no respiratory burst in
both primed and unprimed neutrophils. Thus, B. cepacia LPS appeared to selectively
upregulate responses to non-mucoid P. aeruginosa, whilst having little effect upon
neutrophil interactions with B. cepacia itself. It seems reasonable to speculate that
the induction of an increased anti-pseudomonal neutrophil response may enable
B. cepacia to establish itself within the bacteriologically-crowded CF lung.
The interaction of B. cepacia haemolysin with neutrophils has recently been
described by Hutchison et al (1998). This lipopeptide induces neutrophil azurophil
degranulation, as determined by increased expression of surface neutrophil elastase,
when incubated with neutrophils at concentrations of 100 ng/ml and above. In the
present study, concentrations of haemolysin from 50 ng/ml to 500 ng/ml induced no
respiratory burst response, but primed FMLP-induced responses to a level at least
twice that induced by E. coli LPS. These results indicate a further mechanism by
which B. cepacia strains of the ET12 lineage may potentiate neutrophil activation
within the CF lung, thus increasing the inflammatory damage seen in colonised
patients.
9.8 Studies In The CF Mouse
CF lung disease is characterised by complex physiological and pathological defects,
associated with respiratory colonisation by a diverse spectrum of microbial
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pathogens. Consequently, many aspects ofpathogenesis in CF can only be
definitively investigated within a suitable animal model. CF has not been identified
within any naturally-occurring animal population; however, CF mice have recently
been developed by genetic manipulation of the gene coding for the murine homolog
of CFTR. Many of these mutant mice display physiological and pathological defects
similar to those seen in human CF, particularly in relation to gastrointestinal disease
and the development of intestinal obstruction. However, less information is available
on the development of respiratory disease and susceptibility to CF microbial
pathogens in these animals. Indeed, microbiological data is only available for one
murine model, the Edinburgh HGU/HGU CF mouse, which is more susceptible to
the development of lung pathology in response to the CF pathogens, S. aureus and
B. cepacia, than non-CF siblings (Davidson et al, 1995). As part of this thesis,
further studies of the interaction of B. cepacia with the Edinburgh CF mouse were
conducted.
Results from the present investigations have highlighted several potential problems
in the analysis of data from bacteriological studies in CF mouse models. For
example, considerable variability was observed in results within both CF and non-CF
groupings in experiments assaying the clearance of B. cepacia J2315. Such
variability was also noted in previous studies (Davidson et al, 1995) and may be due
to several factors, including the effects of the variable genetic background of the
outbred murine strain on the severity of the CF phenotype, the variable expression of
residual CFTR due to the 'leaky' mutation in this strain, or differential exposure of
mice within standard animal housing to environmental factors such as potential
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respiratory pathogens. The extent of variability in the present study was such that a
significant difference in terms of clearance ofB. cepacia could not be demonstrated
between CF mice and their non-CF siblings. Nevertheless, trends were clearly
towards poorer clearance in CF than non-CF mice, suggesting that CF mice may be
more susceptible to colonisation with B. cepacia than non-CF mice. In particular, the
observation that individual CF mice demonstrated the poorest clearance in all
experiments implies that the CF phenotype may only be fully expressed in a subset of
these mice, reflecting the genetic diversity of the outbred murine strains used.
Development of inbred strains may aid investigators in attempts to establish more
fully the CF mouse model for bacteriological studies; however, as inbred strains
displaying a less CF-like phenotype are more likely to breed successfully,
development of such strains will require careful monitoring to ensure that the CF
phenotype is not 'bred out' despite the presence of a genetic CF defect. In the
meantime, studies in the Edinburgh CF mouse are continuing in an effort to establish
more fully this model of microbiological disease in CF.
9.9 Genomovar Status And Bacterial Origin; Are
Environmental Strains Of B. cepacia Pathogenic?
Concern regarding the development of B. cepacia as a biopesticide has reached a new
level with a recent application to the US Environmental Protection Agency for
permission to conduct large scale field trials involving the administration of several
tons of B. cepacia annually across the USA. Thus, an urgent need has arisen to
define the features of B. cepacia which are linked to pathogenicity and hence prevent
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the commercial development of strains which may present a human hazard. Whilst
the increased incidence of B. cepacia infection in CF can be attributed to a small
number of epidemic strains which may be only distantly related to environmental
strains, the continuing acquisition of apparently non-epidemic strains of B. cepacia
by CF patients, particularly within segregated clinics, suggests that environmental
strains may pose a threat to patients. In addition, B. cepacia in chronic
granulomatous disease and, indeed, in the rare cases of infection in apparently
immunocompetent individuals, is presumably acquired from an environmental rather
than clinical source. Furthermore, in view of the genetic complexity and inherent
variability ofB. cepacia (Wise et al, 1995), it is feasible that the emergence of
epidemic strains represents the in vivo adaptation of environmental organisms to the
CF lung, possibly through genetic recombination with other Burkholderia spp
(Simpson et al, 1995). Such a possibility must be taken into consideration in any
programmes developing environmental B. cepacia for large-scale release.
An understanding of the bacterial factors underlying B. cepacia colonisation and
pathogenesis in CF would greatly assist in attempts to select 'safe' strains for
commercial exploitation. Shaw et al (1995a) produced evidence suggesting that LPS
from environmental strains is less inflammatory than LPS from CF and other clinical
isolates; however, the inflammatory potential of environmental B. cepacia LPS was
still significantly greater than that of representative strains of P. aeruginosa. In the
present study we have demonstrated the induction ofboth neutrophil priming and
non-azurophil degranulation by LPS from CF, non-CF clinical and environmental
strains, with one environmental strain, J2552, showing the greatest activity. By
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comparison, P. aeruginosa LPS has little or no activity. Thus it would seem that all
B. cepacia strains possess LPS capable ofproducing a marked and damaging
inflammatory response in colonised individuals. Furthermore, comparison of an
ET12 strain, J2315, with the environmental strain, J2552, in studies of clearance
from mouse lungs following intratracheal bacterial instillation suggested that the
environmental strain had the greater colonising ability. As this finding was apparent
in both CF and non-CF mice, a respiratory predilection for J2552-like B. cepacia in
healthy as well as CF individuals cannot be ruled out, despite the apparently
innocuous origin of this strain.
The identification of individual B. cepacia genomovars within panels of clinical and
environmental strains may provide a means by which pathogenic and non-pathogenic
strains can be separated. To date, the majority of environmental isolates tested have
belonged to genomovars I or IV, whilst genomovars II and III have predominated
amongst CF patients, and are associated both with transmissibility and, particularly
for genomovar III, with rapid pulmonary deterioration (Govan et al, 1996; Revets et
al, 1996; Dr P Vandamme, personal communication). However, such data has been
gathered on a relatively small number of strains, and further work is required to
confirm these findings. In the meantime, efforts to develop B. cepacia for biocontrol
have focused on environmental isolates, particularly the genomovar V AMMD strain
which has recently been proposed for large scale release in North American crop
spraying trials. Little data is available, however, on the potential pathogenicity of
this strain, particularly in relation to CF and other respiratory diseases.
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As work towards this thesis has reached its final stages, information regarding the
genomovar status of some of the strains investigated has become available. Initially
it was hoped that separation of strains into individual genomovars would help explain
some of the variability found between isolates, particularly in chemiluminescence
experiments. However, little correlation was observed between genomovar status
and neutrophil respiratory burst induction. In studies of opsonisation, all genomovar
III strains were well opsonised by immune serum from patients colonised with the
ET12 lineage. Results from isolates belonging to genomovars I and II were less
clear-cut, with opsonic activity against some strains but not others, suggesting the
existence of some cross-reactive epitopes on the surface of genomovar I, II and III
isolates. In further studies of LPS activity in neutrophil degranulation and priming
assays, both the genomovar I strains, J2540 and J2552, and the ET12 genomovar III
strain, J2315, showed similar levels of pro-inflammatory activity to E. coli LPS,
suggesting that both genomovars have the potential to initiate inflammatory damage
within the CF lung. A further strain, J2505, which shares characteristics of
genomovars I, III and IV was also highly pro-inflammatory in these assays. Finally,
the results of clearance studies in non-CF and CF mice, suggested that genomovar I
strains such as J2552 may actually demonstrate an equivalent or greater colonising
ability than genomovar III strains such as J2315. As current proposals to release the
environmental B. cepacia strain, AMMD, recently identified as a genomovar V strain
(i.e. B. vietnamiensis), consist of the repeated administration of several ounces of
organisms per acre to fields in several States of the USA, individuals may be exposed
to abnormally high inoculae of this organism. The risks of such exposure for both
healthy individuals and individuals with CF seem impossible to predict, particularly
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in the absence of data regarding the inflammatory potential of the AMMD strain.
Thus, further studies should be urgently conducted on this strain before permission
for environmental release is granted.
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Chapter 10 Conclusions
Increasing evidence suggests that the pathogenesis of lung disease in CF patients
colonised with B. cepacia is mediated by a marked inflammatory response to this
unusual but potentially devastating respiratory pathogen. Research carried out in
pursuit of this thesis has provided further evidence to support this hypothesis, by
indicating the potent pro-inflammatory potential ofB. cepacia and B. cepacia
products, particularly LPS. Thus, induction ofnon-azurophil degranulation,
associated with the priming of respiratory burst responses, may promote both
neutrophil recruitment to the respiratory tract, followed by an enhanced response on
exposure to a suitable stimulus within the lung. It is tempting to speculate that
cepacia syndrome develops whenever the burden of activated neutrophils within the
lung becomes too great for over-stretched regulatory mechanisms, increasing the rate
of inflammatory damage and permitting the bacteraemic spread of B. cepacia beyond
the lung parenchyma. B. cepacia itself seems to induce little respiratory burst
activity and may thus evade neutrophil killing mechanisms, particularly if neutrophil-
bacteria interactions occur in the absence of effective opsonisation. Indeed, the
development of rapid lung deterioration and cepacia syndrome may be a consequence
of activation of B. cepacia LPS-primed neutrophils by a secondary stimulus such as
other co-colonising bacteria, including P. aeruginosa, or exposure to a respiratory
viral infection. Such a model of B. cepacia pathogenesis may go some way to
explaining the great variety of clinical outcomes seen in colonised patients, with the
prognosis for individual patients linked not only to the response to B. cepacia but
also to other co-colonising organisms.
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The development of an inflammatory model ofB. cepacia pathogenesis provides
several potential avenues for investigation. In particular, the effects of co-
colonisation with B. cepacia and P. aeruginosa requires further study. Ideally,
confirmation of this hypothesis will come with the refinement of current animal
models of CF, enabling in vivo studies of bacterial co-colonisation on pathogenesis.
Considerable work will be required, however, if mouse models are to reach this stage
of development, particularly in the establishment of chronic P. aeruginosa infection
within the mouse lung. An alternative approach could include the in vitro
comparison of the inflammatory potential of combinations ofpaired B. cepacia and
P. aeruginosa strains from individual patients with clinical data regarding patient
well-being and lung function.
Further investigations of the nature of B. cepacia LPS-neutrophil interactions are
anticipated in an attempt to identify the main neutrophil receptors utilised by
B. cepacia LPS, particularly in the absence of serum, and to analyse the nature of
signal transduction events leading to the induction of non-azurophil degranulation
and priming. At present, there is an urgent need for a novel therapeutic approach to
the treatment ofB. cepacia infection, particularly as there is little prospect of the
development of an effective anti-5. cepacia antimicrobial agent at present. It is
therefore hoped that an understanding of the molecular processes by which
B. cepacia LPS upregulates neutrophil activation will provide new target molecules
for the development of anti-inflammatory therapies.
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Environments Present a Potential Hazard?
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An environmental survey of 55 sites yielded only 12 Burkholderia cepacia isolates, none of which displayed the
phenotypic properties of a multiresistant epidemic strain associated with pulmonary colonization in patients
with cystic fibrosis. Although the environment probably poses a low risk for patients with cystic fibrosis as a
source of B. cepacia, the pathogenic potential of individual environmental strains remains unclear. We advise
caution in the development of B. cepacia as a biocontrol agent.
First described in 1950 by Burkholder (5) as the cause of soft
rot of onions, Burkholderia cepacia (basonym Pseudomonas
cepacia) is now of wider and increasing interest in agriculture,
biotechnology, and medicine. Reasons for this interest include
the organism's abilities to promote plant growth by antagoniz¬
ing soilborne plant pathogens (15, 16, 25), to degrade hydro¬
carbons and thus assist in the bioremediation of contaminated
soil and water (11), and to cause opportunistic human infec¬
tions, particularly in patients with chronic granulomatous dis¬
ease (22, 30) and cystic fibrosis (CF) (1, 14, 19, 36). In patients
with CF, B. cepacia is now a major pathogen because of the
following: first, its association with cepacia syndrome, a rapidly
fatal necrotizing pneumonia, sometimes accompanied by sep¬
ticemia (19); second, its innate multiresistance to antibiotics
(23, 34); third, person-to-person transmission through social
contact (14, 24, 38); and fourth, the risk of nosocomial acqui¬
sition (40). In the last decade, there have been increased at¬
tempts to reduce the risk of B. cepacia transmission by segre¬
gation of B. cepacia-colonized patients and publication of
guidelines concerned with hygiene and social behavior (1, 29,
42). The social effects of segregation on patients with CF and
organizations for people with CF are psychologically devastat¬
ing, and the policy has not been universally welcomed, partic¬
ularly in centers for patients with CF in which B. cepacia
colonization or transmission has remained low (1, 33, 39). The
introduction of hygiene guidelines and segregation has un¬
doubtedly reduced acquisition of B. cepacia in patients with CF
(14, 38, 42), but acquisition has not been eliminated. The
source of B. cepacia responsible for new acquisitions is unclear,
and there is increasing concern about the risk that the envi¬
ronment may present as a source of this opportunistic sapro¬
phyte (10, 20). At present, rational judgments on this issue are
frustrated by the following uncertainties: first, the distribution
of B. cepacia in natural environments; second, the pathogenic
potential of environmental isolates; and third, the potential
hazards associated with the development and use of B. cepacia
as a biological control agent.
B. cepacia has been cultured from a range of environmental
sources, including soil, water, and vegetation (2, 15, 26), and
from clinical material (17). There are few reports, however, of
prospective studies of the organism's natural habitats, and
there is little documented evidence to support the use of the
* Corresponding author. Mailing address: Department of Medical
Microbiology, University of Edinburgh Medical School, Teviot Place,
Edinburgh EH8 9AG, Scotland. Phone: 031 650 3164. Fax: 031 650
6531.
term ubiquitous to describe the organism's environmental dis¬
tribution. LiPuma et al. (24) cited previous failures to recover
B. cepacia from environmental surfaces to support person-to-
person transmission as the primary mode of B. cepacia acqui¬
sition in patients with CF. In a subsequent study, B. cepacia was
cultured from only 1% of samples obtained from homes and
4.5% of samples obtained from salad bars and food stores (10).
The use of the term environmental isolates also can be mis¬
leading since in epidemiological studies of nosocomial B. ce¬
pacia infections, it is not always possible to identity whether
isolates cultured from environmental surfaces have contami¬
nated patients or vice versa. The aims of our study were to
investigate prospectively the distribution of B. cepacia in other
natural environments and to obtain authentic environmental
isolates for future comparative studies with clinical isolates to
investigate B. cepacia virulence factors and to determine the
pathogenic potential of environmental strains.
A large botanical complex was chosen for this survey to
provide an extensive range of soils, aquatic sites, and vegeta¬
tion located in a natural temperate climate and tropical, sub¬
tropical, and arid microclimates within greenhouses. Fifty-five
samples of soil, soil rhizosphere, water, and vegetation were
collected and cultured for B. cepacia by using selective media
and screening procedures adapted from two previous surveil¬
lance studies (10, 28). Prior to sampling, swabs were first moist¬
ened in a selective broth that consisted of Malka minimal broth
(35) supplemented with polymyxin (300 U/ml) and plated di¬
rectly onto selective agar that consisted of 300 U of polymyxin
per ml and 100 p,g of ticarcillin per ml (Mast cepacia agar;
Mast Diagnostics, Ltd., Bootle, United Kingdom). Water sam¬
ples (100 ml) were filtered (pore size, 0.2 p.m; Millipore). The
same swabs, filter membranes, soils, and vegetation were trans¬
ferred to Malka minimal broth supplemented with polymyxin,
incubated at 30°C for 5 days, and subcultured to the selective
agar described. After 48 h at 30°C, bacterial colonies were
subcultured to MacConkey agar and fluorescent pigment-en¬
hancing King's B medium (21). After a further 48 h at 30°C,
nonfluorescent, non-lactose fermenters were screened on argi-
nine-glucose medium, B. cepacia isolates were presumptively
identified by biochemical reactions (13), and identification was
confirmed by the API 20 NE system (bioMerieux, Basingstoke,
United Kingdom). Individual B. cepacia isolates were then
investigated for catalase production (32), lipopolysaccharide
(LPS) content by polyacrylamide gel electrophoresis following
proteinase K extraction as previously described (6), and anti¬
microbial susceptibility by an agar dilution method on Mueller-
Hinton agar (23), with sensitivity defined in terms of the British
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TABLE 1. Antibiotic resistance of 48 clinical and 25 environmental
isolates of B. cepacia with sensitivity defined in terms of breakpoints
Breakpoint No. of resistant isolates (%)
(mg/liter) Clinical Environmental^
Piperacillin 64 20(42) 1(4)
Ceftazidime 2 39 (81) 4(16)
Meropenem 4 25 (52) 2(8)
Chloramphenicol 8 44 (92) 18 (72)
Ciprofloxacin 4 18(38) 2(8)
PD 127391 4 10(21) 0(0)
PD 131628 4 14 (29) 0(0)
" Defined by the British Society for Antimicrobial Chemotherapy Working
Party (4), apart from PD 127391 and PD 131628, which have been defined by
Lewin et al. (23).
h Includes 10 isolates in this study and 15 isolates previously held in our
collection.
Society for Antimicrobial Chemotherapy Working Party
breakpoints (4) (Table 1). Pulsed-field gel electrophoresis
(PFGE) was performed by the technique of Vasil et al. with
some modifications (43). Bacteria were grown in nutrient broth
no. 2 (Oxoid, Basingstoke, United Kingdom) that contained
0.5% yeast extract (Difco, Surrey, United Kingdom). Cells
were washed with 75 mM NaCl-25 mM EDTA, standardized
to an optical density at 590 nm of 1.0, and mixed with an equal
volume of molten 1% low-melting-point preparative-grade
agarose (Bio-Rad, Hemel Hempstead, United Kingdom).
DNA restricted with Xbal (TCTAGA) and Spel (ACTAGT)
(Gibco BRL, Paisley, United Kingdom) was separated by
PFGE by using the CHEF DRII system (Bio-Rad) with pulses
of 2.9 to 35.4 s at 200 V for 22 h at 14°C. Gels were stained with
ethidium bromide at a concentration of 1 |xg/ml for 15 min and
then destained in distilled water for 30 min.
B. cepacia was cultured from 12 (21.8%) of 55 samples and
sites (Table 2). This recovery rate exceeds that reported by
Fisher and colleagues (10) for homes (1%) and food stores
(4.5%); however, both studies indicate that it is an exaggera¬
tion to describe B. cepacia as ubiquitous or widely distributed
in nature. The data also emphasize the biological puzzle posed
by Palleroni (31), namely, if B. cepacia is so nutritionally ver¬
satile, why is this species not more readily cultured from nat¬
ural habitats? In our study, B. cepacia isolates were not recov-
TABLE 2. Environmental sites in botanical gardens from which
B. cepacia strains were cultured
Isolate Site Area
J2534 Rotting bark Orchid and cycad house
J2535 Rotting bark Orchid and cycad house
J2536 Soil Gardens
J2537 Soil Rhododendron house
J2538 Soil Rhododendron house
J2539" Rhizosphere of Hohenbergia Temperate aquatic house
stalata
J2540 Rhizosphere of banana plant Tropical aquatic house
J2541 Rhizosphere of Epidendnim Orchid and cycad house
o 'brieniamum
J2542 Rhizosphere of Nautilocalyx Orchid and cycad house
lynchii
J2543" Pond water Tropical aquatic house
J2552 Rhizosphere of Carludoucas Tropical aquatic house
palmata
J2553 Sansevieria leaf Tropical palm house
" Identical PFGE profiles.
ered from healthy or diseased cacti or from soil within the
cactus greenhouse; the majority of recovery sites were in moist
soil or soil rhizosphere, which suggests that these environments
are natural habitats for this microbial saprophyte.
Previous studies (6,14) have shown that B. cepacia J2315, an
epidemic strain associated with morbidity and mortality in pa¬
tients with CF and epidemic outbreaks in regional clinics for
those with CF in the United Kingdom, has unusual phenotypic
characteristics, including a dry rough colonial morphotype,
dark melanin-like pigmentation, a sodium dodecyl sulfate-
polyacrylamide gel electrophoresis profile indicative of rough
LPS, and multiresistance to co-trimoxazole and all of the an¬
tibiotics listed in Table 1. These characteristics were not ob¬
served for any of the 12 environmental isolates of B. cepacia.
The results of antibiotic sensitivity testing are shown in Table
1; in general, environmental isolates, including 15 previously
held in our collection, showed greater sensitivity than did CF
isolates of B. cepacia. Interestingly, however, epidemic strain
J2315 and 10 of 12 environmental isolates were catalase posi¬
tive, a characteristic of opportunistic pathogens responsible for
recurrent life-threatening infections in patients with chronic
granulomatous disease (22).
Genomic analysis of DNA from environmental isolates of B.
cepacia by PFGE following endonuclease digestion with Spel
and Xbal illustrated the genomic diversity of this species. With
one exception, each of these 12 isolates produced a distinct
endonuclease restriction profile which also differed from the
PFGE profiles of epidemic strain J2315 and 10 other clinical
isolates of B. cepacia cultured from patients with CF.
Accumulated evidence from this study and previous reports
(10, 18) suggests that compared with the heavily colonized
respiratory secretions of B. cepacia-colomzeA patients with CF,
the environment is a relatively low-risk source of B. cepacia for
patients with CF. Honicky et al. recovered B. cepacia from only
4 (3 from lake water and 1 from ice water from a picnic jug) of
58 environmental samples in a study of B. cepacia acquisition
in patients with CF who attended summer camps (18). Fur¬
thermore, genomic fingerprinting of B. cepacia cultures from
the 16 (6.6%) of 244 campers whose acquisition of B. cepacia
was associated with camp attendance showed that the majority
of new colonizations involved strains shared by other camp
attenders and that no patient with CF had acquired a strain
which shared a genotype found in environmental isolates.
An important caveat to the conclusion that the environment
is not a major source of B. cepacia infection in humans con¬
cerns the development and release of B. cepacia as a biological
agent to control plant disease and soil decontamination. In a
recent report, Bevivino et al. (3) concluded that environmental
isolates probably pose little threat in human disease since they
lack the abilities to produce gelatinase and a hydroxamate
siderophore and to adhere to human uroepithelial cells. This
conclusion needs to be treated with considerable caution. Only
two environmental isolates and two clinical isolates were in¬
vestigated; furthermore, there is no evidence that the putative
virulence determinants investigated in this study play a role in
human infections, including colonization and pathogenesis in
patients with CF (27).
Equally relevant to the issue of the use of B. cepacia in
biological control are the questions of whether clinical and
environmental B. cepacia organisms represent two distinct
groups and, in particular, whether environmental strains cause
human infections, either de novo or through adaptation. In
respect to the latter, in longitudinal studies of B. cepacia-
colonized patients with CF, there is no phenotypic evidence of
adaptation in vivo, which is so characteristic of mucoid al-
ginate-producing Pseudomonas aeruginosa (27). Previous re-
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FIG. 1. Soft rot of onion segments inoculated with B. cepacia clinical isolate
J2315 (left) and an uninoculated, undamaged control (right), both incubated at
30°C for 72 h.
ports (12, 44) concluded that the two groups of B. cepacia are
distinct and that clinical isolates do not have the ability to act
as phytopathogens; however, this distinction is unfounded
since most clinical isolates, including epidemic strain J2315,
readily cause soft rot of onions (Fig. 1). In turn, evidence that
environmental isolates have the ability to cause human infec¬
tion is provided by the macerated, hyperkeratotic foot lesions
encountered by troops during swamp training, known as
swamp rot (41). The distinctive phenotypic properties of mul-
tiresistant epidemic B. cepacia isolates, including J2315 (14,
37), suggest that a subpopulation of B. cepacia may have a
predilection for the lungs of patients with CF. Recent evidence
(37) that such strains possess characteristics of B. cepacia and
the closely related phytopathogen Burkholderia gladioli and
that the genomic constitution of B. cepacia may facilitate ge¬
netic rearrangements (7) supports speculation that the transi¬
tion of environmental B. cepacia isolates from phytopathogen
to pulmonary colonization in patients with CF is enhanced by
intraspecies adaptation or the emergence of bacterial hybrids
of the two species.
At present, unequivocal statements on the potential of en¬
vironmental B. cepacia isolates to cause infections in patients
with CF and in other immunocompromised hosts are frus¬
trated by our scanty knowledge of the virulence factors and
mechanisms of pathogenesis involved (27). The recent devel¬
opment of mutant mice with CF (9) and the demonstration
that B. cepacia J2315 causes pneumonia in mice with CF but
not in control animals (8) provide a useful model to investigate
the pathogenic potential of environmental B. cepacia isolates
for patients with CF.
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The increasing challenge posed by multiresistant saprophytes in medical microbiology is
strikingly demonstrated by the emergence of Burkholderia (formerly Pseudomonas)
cepacia as an opportunist pathogen in immunocompromised patients, particularly
individuals with chronic granulomatous disease and cystic fibrosis (CF). Best known
previously as a phytopathogen and the cause of soft rot of onions, B. cepacia presents
three major problems for the CF community: innate multiresistance to antimicrobial
agents; person-to-person transmission of epidemic strains through nosocomial or social
contacts; and 'cepacia syndrome', a fulminating fatal pneumonia, sometimes associated
with septicaemia, that occurs in approximately 20% of colonised patients, including
those with previously mild disease. Accumulated evidence to dispel earlier suggestions
that the organism is avirulent and merely a marker of existing lung disease includes:
case-controlled studies in CF patients; reports of serious infections in non-CF patients;
in-vitro and in-vivo evidence that B. cepacia induces production of pro-inflammatory
markers, including the major cytokine TNFa; and histopathological evidence that
exposure of transgenic CF mice to B. cepacia results in pneumonia. By the early 1990s,
the use of selective culture media and DNA-based bacterial fingerprinting confirmed
suspicions of epidemic person-to-person spread of B. cepacia. This evidence provided
scientific justification for draconian and controversial measures for infection control, in
particular, segregation of B. ee/7«c7«-colonised patients during treatment at CF centres
and their exclusion from social gatherings and national conferences. Recently, molecular
analyses of type strains and clinical isolates have revealed that isolates identified
previously as B. cepacia belong to at least three distinct species and have increased
concern regarding the reliability of current laboratory detection and identification
systems. Clarification of the taxonomy of B. cepacia-like organisms and the pathogenic
potential of environmental isolates remains a high priority, particularly when the
organism's antifungal and degradative properties have created interest in its potential
use as a biological control agent to improve crop yields and its use for the
bioremediation of contaminated soils.
Introduction
'The development of multiresistance in major
microbial pathogens is well-recognised; in con¬
trast, little attention has been paid to the
pathogenic potential of naturally resistant envir¬
onmental saprophytes
Known originally as a phytopathogen, Burkholderia
cepacia (previously Pseudomonas cepacia, P. multi-
Received 10 June 1996; accepted 19 June 1996.
Corresponding author: Dr J. W. R. Govan.
vorans, P. kingii, 'Eugonic oxidiser 1') exhibits
impressive nutritional versatility. Some microbes have
an inherent or acquired ability to degrade antibiotics,
but few have the ability to use penicillin as a sole
carbon source [1] or to reduce onions to a macerated
pulp! The earlier name, P. multivorans, reflected the
organism's omnivorous appetite, but it was not until
1950 that its pathogenic potential was recognised
when Burkholder identified the organism as the cause
of soft rot of onions—particularly 'compromised'
onions damaged during harvesting—and provided an
appropriate species epithet (Latin: cepia = onion) [2],
In the early 1990s, following taxonomic re-appraisal,
the RNA group II pseudomonads were recognised as
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the new genus Burkholderia, with B. cepacia as the
type species [3], At present, the genus Burkholderia
comprises B. cepacia, B. gladioli, B. mallei, B.
pseudomallei, B. caryophylli, and recently added to
the group, B. plantarii, B. glumae, B. vandii [4], B.
cocovenenans [5] and B. vietnamiensis [6].
The general characteristics of B. cepacia include the
following: gram-negative, non-spore-forming, aerobic
bacillus; motile with a respiratory metabolism and
typically catalase- and oxidase-positive; various non-
fluorescent pigments may be produced and poly-/3-
hydroxyalkanoates can be accumulated as reserve
materials; the optimal temperature for growth is 30-
35°C [7]. Recently, elegant molecular analyses have
provided scientific evidence that may account for the
organism's impressive versatility, including multilocus
linkage disequilibrium analysis of environmental
populations [8]—which suggested an extraordinarily
high rate of recombination in B. cepacia relative to
binary fission—and demonstration of multiple repli-
cons and insertion sequences in type strains [9, 10],
The natural habitats of B. cepacia have been described
as soil, water and vegetation [11]. However, it is a
common but erroneous belief that B. cepacia is a
ubiquitous saprophyte sharing similar environmental
habitats with Pseudomonas aeruginosa and other
pseudomonads. Extensive surveillance studies have
shown that culture of B. cepacia from natural sources,
including soil, water and plants, or from hospitals,
foodstores, restaurant salad bars and patients' homes is
surprisingly difficult, with detection rates of only 1 -
16% [12-16],
In agricultural microbiology, ecological awareness and
an increasing incidence of pesticide-resistant patho¬
gens have led to interest in B. cepacia as a potential
agent for biological control and soil decontamination.
B. cepacia produces several antimicrobial agents,
including pyrrolnitrins, altericidins, cepalycins and
bacteriocin-like agents [17-20], that inhibit bacterial
and fungal phytopathogens and suppress tobacco wilt
and other plant diseases [21], B. cepacia is also
capable of degrading industrial waste and herbicides,
including 2,4,5-trichlorophenoxyacetic acid (2,4,5-T),
the principal ingredient of the highly potent 'agent
orange' [22], Indeed, B. cepacia has been shown to
degrade 2,4,5-T in heavily contaminated soils at a rate
up to 20 000-fold greater than other known degrada-
tive bacteria [23].
In contrast to its potential agricultural benefits, B.
cepacia has also emerged as a multiresistant oppor¬
tunist human pathogen, leading to concern about the
relationship between environmental and clinical iso¬
lates [14, 24-26] and the potential hazards of releas¬
ing B. cepacia as a biological control agent [14,24],
This review will provide an update on microbes
currently described as B. cepacia, with particular
focus on clinical, taxonomic and ecological issues
(Table 1) associated with pulmonary infection in
patients with cystic fibrosis (CF).
The emergence of B. cepacia as a human
pathogen
Before the early 1980s, reports of human infections
caused by B. cepacia were sporadic and generally
restricted to hospitalised patients exposed to contami¬
nated disinfectant and anaesthetic solutions in which
this nutritionally adaptable saprophyte survives for long
periods. Infections included those of soft tissues and
the respiratory and urinary tracts, but bacteraemia also
occurred, sometimes associated with endocarditis and
septic shock [27-31]. A rising incidence of B. cepacia
infection was noted during the early 1980s and,
although in some cases culture of B. cepacia was
thought to reflect mere colonisation or contamination
rather than infection [11,32], extensive analyses of
USA databases of nosocomial infections confirmed a
significant increase in clinically significant B. cepacia
infections [33,34], The apparent propensity of B.
cepacia to cause fatal pulmonary infections, as
suggested by these analyses, is emphasised in patients
with chronic granulomatous disease (CGD)—in whom
B. cepacia pneumonia and septicaemia are life-
threatening [35, 36]—and in its emergence as a major
pathogen in patients with CF [37-39], By the 1990s,
disturbing reports also emerged of fatal cases of B.
cepacia pneumonia and septicaemia in previously
Table 1. Major issues associated with B. cepacia and cystic fibrosis (CF)
• Is there convincing evidence to confirm that B. cepacia has pathogenic potential and is not merely a marker of pulmonary disease?
• Based on the success, but unpopularity, of segregation and advances in clarifying the taxonomy of the genus Burkholderia, should all B.
cepacia be treated as equal? Can phenotypic or genomic markers be found which would identify highly transmissible or virulent clones?
• To what degree do natural environments represent a reservoir for B. cepacia and a hazard for CF patients? What hazards are associated
with the development and use of B. cepacia as a biological control agent?
• Could an improved understanding of the host immune response, including enhanced cytokine induction by bacterial surface components,
clarify the immunopathology of B. cepacia and lead to innovative forms of immunotherapy?
• At present, it is not possible to forecast the clinical outcome of B. cepacia colonisation. Can host and bacterial factors responsible for
initial colonisation and poor clinical outcome be identified?
• Recently, it has been demonstrated that CF airway epithelia contain bactericidal activity that is inhibited reversibly by high NaCl
concentrations. Does this killing potential include B. cepacia and is it host or strain specific?
• Ultimately, the identification of bacterial and host factors associated with transmission and virulence would assist greatly in the rational
design of an effective B. cepacia vaccine.
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healthy individuals [40,41], Community-acquired B.
cepacia infections are uncommon, but the organism's
pathogenic potential and the financial implications of
antimicrobial therapy were recently strikingly demon¬
strated when an offshore oil worker developed multiple
brain abscesses secondary to suppurative otitis media.
Therapy involved four neurosurgical operations, an
extensive period of hospitalisation and an antibiotic bill
of £10K [42],
The above case also demonstrated an interesting and
unexplained variability in antibiotic susceptibility
profiles that has been observed in serial B. cepacia
isolates from single patients and during epidemic
outbreaks [43-46], The mechanism responsible for
variable susceptibility is unclear, but may be asso¬
ciated with the observation that migration of insertion
sequences within the B. cepacia genome can affect the
expression of genes that modulate antibiotic resistance
[47],
B. cepacia and cystic fibrosis
During the last decade, the major clinical interest in B.
cepacia has focused on its addition to the relatively
narrow spectrum of microbial pathogens responsible for
debilitating and ultimately fatal pulmonary infections
in patients with CF [26,39,48,49], In the late 1980s,
surveillance studies in the UK indicated a maximum
prevalence of 7% [39, 50-52]; however, in some CF
centres this later increased to approach the prevalence
of 40% described in contemporary North American
studies [53], The three major issues concerning B.
cepacia can be summarised as follows: 1, the clinical
risk of rapid and fatal pulmonary decline, even in
patients with previously mild disease; 2, patient-to-
patient spread of epidemic strains within and between
regional CF centres and between centres in the UK and
North America; and 3, the innate multiresistance of
most B. cepacia isolates to available antibiotics—
which deprives patients of effective antimicrobial
therapy [46, 54]—combined with the failure to reduce
the bacterial population in sputum and a relatively poor
clinical response even when the colonising strain
exhibits in-vitro susceptibility.
The clinical significance of B. cepacia in CF patients
was first described in 1984 in a seminal report by
Isles et al. [37], In addition to noting the increased
prevalence of B. cepacia colonisation in patients
attending Toronto clinics, Isles et al. described a
rapid and unexpected clinical decline, including
necrotising pneumonia and bacteraemia, that occurred
in c. 20% of colonised patients. This acute clinical
decline is sometimes referred to as 'cepacia syn¬
drome' [37], It is important to note that acute clinical
deterioration and bacterial spread to sites other than
the lung is not observed with the other major CF
pathogens, Staphylococcus aureus, Haemophilus influ¬
enzae and P. aeruginosa.
The second major issue relating to B. cepacia arose in
the mid 1980s as an increasing—but scientifically
unproven—conviction held by some CF carers that the
clustering of cases in some large North American
clinics had arisen from cross-infection. At that time,
an alternative explanation for clustering was the
difficulty in culturing this relatively new pathogen
from CF sputa [48], As evidence, in a controlled study
involving 115 North American CF centres, only 36
(31%) cultured the organism successfully from a
seeded sputum specimen [55], However, by the early
1990s, the availability of selective culture media [48]
and awareness of the organism's cultural idiosyncrasies
[56] indicated that regional variation in the prevalence
of B. cepacia colonisation could not be explained
simply by laboratory methodology. Furthermore, the
development and use of bacterial fingerprinting
techniques—including multilocus enzyme electrophor¬
esis (MLEE), pyrolysis mass spectroscopy, PCR-
ribotyping and pulsed-field gel electrophoresis
(PFGE)—provided compelling evidence for person-
to-person spread of B. cepacia through nosocomial
and social contacts (Table 2) [25, 37, 46, 57-75] and,
occasionally, in the absence of proven sputum
colonisation [67]. Epidemiological data also provided
scientific justification for the introduction of guidelines
by national CF organisations to improve personal and
hospital hygiene and, more controversially, for the
implementation of segregation policies to limit contact
between colonised and non-colonised individuals [76],
Surveillance studies show that segregation undoubtedly
reduces the incidence of B. cepacia cross-infection
[38, 62, 71, 77], but the strategy has not eliminated
acquisition. Furthermore, the logistic and social
consequences of draconian infection control measures
reminiscent of mediaeval approaches to leprosy have
not been accepted universally. In particular, the need
for such measures has been questioned fiercely by
patients and care-givers in CF centres where intensive
surveillance has not revealed a high incidence or
prevalence of B. cepacia colonisation.
A pathogen or a marker of lung disease?
In the 1970s, some microbiologists and clinicians
considered S. aureus to be the only true microbial
pathogen in CF patients and viewed P. aeruginosa as
merely a marker of disease. A similar doubt has
accompanied the emergence of B. cepacia and has
exacerbated the controversy surrounding segregation of
colonised individuals. In discussions of any potential
opportunist pathogen, it is easy to find evidence of
asymptomatic carriage; even Salmonella typhi and
Vibrio cholerae do not invariably exhibit pathogenicity!
Clarification of the clinical relevance of B. cepacia is
also thwarted by the fact that the available scientific
evidence requires particularly careful analysis. There
is an inclination to link bacterial transmissibility and
virulence, and to categorise individual B. cepacia
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Table 2. Evidence for and against person-to-person transmission of B. cepacia
Reference Comments
A. Evidence in favour of
Isles et al. [37]
Thomassen el al. [57]
LiPuma el al. [58]
LiPuma et al. [59]
Anderson et al. [60]
Millar-Jones et al. [61]
Govan et al. [62]
Smith et al. [63]
Bingen et al. [64]
Corkill et al. [65]
Pegues et al. [66]
Johnson et al. [25]
LiPuma et al. [67]
Ryley et al. [68]
Sun et al. [69]
Revets et al. [70]
Whiteford et al. [71]
Pitt et al. [46]
person-to-person transmission
Seminal paper: noted rising incidence of B. cepacia and cepacia syndrome in Canadian clinics
Fall in incidence after segregation
Prevalence of one ribotype in individual clinics
Ribotyping demonstrates person-to-person spread between two patients at a CF camp
Nosocomial outbreak
UK nosocomial outbreak
Genotypic fingerprinting and extensive epidemiological data provides compelling evidence of
person-to-person spread through social contact in and between two UK CF centres
Further UK outbreak with transmission in clinical and social settings
International consensus confirming B. cepacia transmissibility
Highlights transmission particularly at UK CF events
Demonstration of transmission at USA CF camps
Intercontinental spread of Edinburgh/Toronto strain ET12
Inapparent transmission from culture-negative patient (?)
Further UK outbreak
Cable pili demonstrated on intercontinental strain (ET12)
Prevalent strain in Belgian clinic
Outbreak in UK paediatric clinic
Strain ET12 prevalent in UK clinics: accounting for 38% of cases
B. Cases with no evidence of person-to-person transmission
Glass and Govan [72] No transmission of pathogenic strain between siblings
Hardy et al. [73] No transmission to uncolonised patients during hospitalisation
Taylor et al. [74] No transmission in UK unit before segregation
Steinbach et al. [75] No transmission in large CF unit despite no segregation of hospitalised patients
strains as either transmissible and virulent, or non-
transmissible and avirulent. There is no scientific
justification for this view. In epidemic outbreaks in
which patients are colonised by the same strain, some
patients may remain asymptomatic whilst other
individuals succumb to rapid and unexpected fatal
deterioration [37,62], In the case of transmission,
epidemiological evidence has clearly identified
lineages with enhanced transmissibility [25, 46, 62,
69]; however, based on present knowledge, it cannot
be stated with confidence that a strain inherently lacks
the ability for epidemic spread. Furthermore, appar¬
ently 'non-transmissible' strains that have not spread
even to a patient's CF sibling have been responsible
for fatal infection [72], Finally, it could be argued that
transmission is not strain-dependent, but is associated
with nosocomial or social opportunities for transmis¬
sion. This hypothesis is certainly not supported by the
behaviour of the particular B. cepacia lineage with a
notorious ability to spread in CF centres in the UK
[46, 62] and North America [25, 69], referred to as the
Edinburgh/Toronto lineage [69] or ET12 interconti¬
nental clone (multilocus enzyme electrophoresis type
12) [25]. For convenience, this particular B. cepacia
lineage will be referred to as the ET12 lineage in the
remainder of this review.
Some CF carers who have experienced transmission of
B. cepacia amongst small numbers of their patients
have argued against segregation on the grounds that
no significant clinical deterioration was observed and
that implementation of such draconian measures
stigmatises patients and prevents valuable social
contacts with other CF patients [70]. However, the
hypothesis that B. cepacia is transmissible but merely
a marker of pulmonary deterioration can be chal¬
lenged. A recent retrospective study of the clinical
status of B. cepacia-colonised adults in the 24-month
period before colonisation found no difference in their
lung function, number of days in hospital or outpatient
visits [77], Furthermore, in numerous case-controlled
studies involving large numbers of patients, B. cepacia
colonisation has been associated in some but not all
patients with an accelerated decline in pulmonary
function and a poor prognosis [71,77-81]. Most
studies have reported that the risk of clinical
deterioration on acquisition of B. cepacia is increased
in adult patients with severe disease [78-80]. This
contrasts with an epidemic outbreak of B. cepacia
among children, in whom the dominant impact on
respiratory function was greater in patients with better
levels of respiratory function [71]. Explanations for
the range of clinical responses associated with B.
cepacia colonisation and inability to predict the
clinical outcome in individual patients could include:
1, differences in strain virulence; 2, the relatively low
20% 'strike rate' of cepacia syndrome; 3, the influ¬
ence of co-colonisation by other pathogens; 4, the age
at which colonisation occurs; 5, individual host
immune responses; and 6, the severity of underlying
CF disease.
The hypothesis that B. cepacia colonisation is merely
a marker of severe lung disease is also undermined by
the fact that fatalities have occurred in CF adults with
mild CF disease, including individuals not already
harbouring P. aeruginosa [62], Finally, one of the most
striking results from the first microbiological studies
in transgenic CF mice showed that 70% of CF mice
exposed to B. cepacia succumbed to more severe
broncho-pulmonary infection than control animals
[82],
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The Edinburgh/Toronto/ET12 epidemic lineage
In reviewing the emergence of B. cepacia in CF
populations in Europe and North America, it is
necessary to emphasise the influence of epidemic
lineages on the incidence and prevalence of B. cepacia
within CF centres. Evidence shows that the incidence
in a centre can be influenced greatly by the epidemic
spread of a single lineage, and that if such spread is
discounted then the prevalence of B. cepacia in most
CF centres remains relatively low at 5-10%. Transient
colonisation by B. cepacia also influences prevalence
and occurs in c. 5% of CF patients; however, transient
colonisation is observed very rarely with the ET12
lineage (authors' unpublished observations), perhaps
reflecting the high colonisation potential of this clone.
From a clinical, epidemiological and evolutionary
viewpoint, the influence of this single clone on the
CF community is considerable. In the UK alone, it has
been isolated in eight (50%) of 16 CF centres and from
68 (38%) of 178 B. cepac/a-colonised patients [46],
Attempts to identify its origins have been frustrated by
a lack of stored isolates; however, investigation of
available isolates allows several conclusions to be
reached. Based on evidence from MLEE and ribotyp-
ing [25] and PFGE [46,62], the first known isolates of
this epidemic lineage were cultured from Ontario
paediatric patients in the latter half of the 1980s [25],
In the UK, the first recorded isolate of the same lineage
was in August 1989 [62] from a patient who had never
been out of the UK nor shown any evidence of B.
cepacia colonisation during previous bacteriological
investigations. The patient had previous contacts with
other UK patients colonised by B. cepacia, but the
isolates from these patients were not available.
From the available evidence, it appears that the
Edinburgh/Toronto/ET12 lineage was established in
Canada before its appearance in the UK, and that at
some stage in the late 1980s, intercontinental spread
occurred between UK and Canadian patients whilst
attending summer camps in Ontario, followed by inter¬
regional spread in the UK during social contacts at
meetings [25,62]. It is tempting to conclude that this
highly transmissible strain is clonally related to the
isolates cultured during the first documented outbreak
of B. cepacia in CF patients in Ontario, reported in
1984 [37],
Potential pathogenic mechanisms of B. cepacia
Although B. cepacia produces several putative viru¬
lence determinants—including haemolysins, proteases,
lipases, siderophores and catalase—a major clinical
role for these factors has not been demonstrated
convincingly in CF [83,84], Flowever, catalase is
associated with the organism's ability to resist killing
by professional phagocytes and to produce serious
infection in patients with CGD [85].
Intracellular survival
Several puzzling clinical and scientific observations
have led to speculation that B. cepacia can survive and
grow within pulmonary phagocytes or respiratory
epithelial cells. First, clinical resistance to antimicro¬
bial therapy despite demonstration of an isolate's
susceptibility in vitro; second, isolation of serum-
sensitive isolates in bacteraemic infection [86]; third,
chronic pulmonary colonisation despite a pronounced
antibody response [87]; and fourth, the close taxonomic
relationship between B. cepacia and the intracellular
pathogen, B. pseudomallei. However, to date, the
scientific evidence for intracellular survival or growth
of B. cepacia is not convincing. Studies of intracellu-
larity in bacterial pathogens can be difficult and, in the
case of B. cepacia, are complicated further by the
organism's innate resistance to antibiotics, including
aminoglycosides, which are used commonly in intra¬
cellular assays to kill extracellular organisms. As it is
known that B. pseudomallei survives and multiplies
within professional phagocytes [88], studies within our
group have focused on monocytes, with Listeria
monocytogenes and P. aeruginosa as positive and
negative controls, respectively. However, it was not
possible to demonstrate either enhanced uptake or
survival of B. cepacia in monocytes. Previously, Burns
[89] reported the observation of B. cepacia within CF
post-mortem respiratory epithelial cells by electron
microscopy, but no further data have been published to
validate this important finding. Low-level invasion in
vitro of a respiratory epithelial cell line by the
epidemic ET12 lineage has been demonstrated [90],
but the significance of limited epithelial invasion by
bacteria remains unclear [91], A recent and potentially
seminal publication has even suggested that enhanced
uptake of CF pathogens by epithelial cells expressing
surface cystic fibrosis transmembrane conductance
regulator (CFTR), followed by epithelial desquamation,
may be an important host defence mechanism rather
than a bacterial virulence determinant [92].
Overall, the role of intracellularity in the pathogenesis
of B. cepacia infection in CF patients is still in doubt.
As a caveat, the demonstration of its intracellular
survival and growth within amoebae . raises the
possibility that these free-living protozoa may act as
an environmental reservoir from which CF patients
could acquire the organism [93].
B. cepacia and host immune responses
Colonisation with B. cepacia is associated with a
pronounced and specific humoral response, including
raised serum IgG and IgA and sputum IgA titres
against B. cepacia lipopolysaccharide (LPS) and outer-
membrane protein (OMP) components [87,94], Anti-5.
cepacia antibodies have also been detected in non-
colonised CF patients, and particularly in patients
colonised with P. aeruginosa [87, 95]. Studies with pre-
absorbed sera have failed to demonstrate an appreciable
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degree of cross-reactivity between the two species,
either for OMP or LPS components [87, 96], suggesting
that the response to P. aeruginosa is not the source of
pre-colonisation anti-5. cepacia antibody. Generally,
levels of anti-5. cepacia immunoglobulin in non-
colonised patients are low, but the demonstration of
substantially raised titres in a subset of patients may
reflect previous exposure to B. cepacia where an
appropriate antibody response has prevented the
occurrence of colonisation. On the other hand, the
demonstration of antibody in stored pre-colonisation
sera from patients who subsequently became colonised,
indicates that antibody does not always play a
preventative role. Similarly, the role of antibody in
patients once they are colonised is unclear; for
example, clinical outcome is independent of the
magnitude of anti-S. cepacia responses [87], A recent
study [97] with immunoblotting techniques has sug¬
gested that IgG antibodies against a 30-kDa OMP,
identified presumptively as the major immunodominant
porin, OMP D [95, 98], are associated with a better
prognosis in colonised patients. If these results are
confirmed, it raises the possibility of using this OMP as
a target for immunotherapy.
The association of B. cepacia with CGD, an inherited
defect in neutrophil oxidative killing pathways, and
the role of neutrophils as the predominant immune
effector cell in the CF lung [99], have led to
speculation that the interaction between B. cepacia
and neutrophils may be important in the evasion of
host defences by this organism. Speert et al. [85]
demonstrated that, unlike P. aeruginosa, B. cepacia is
resistant to non-oxidative neutrophil killing mechan¬
isms; hence the role of B. cepacia in CGD. Evasion of
the normal neutrophil oxidative burst would aid the
survival of B. cepacia in the presence of a pronounced
immune response. Within the CF lung, normal
opsonisation processes are compromised severely
through the disruption of immune effector molecules
by bacterial and host proteases [100, 101]. In parti¬
cular, cleavage of complement receptors and immuno¬
globulin molecules within the respiratory tract may
neutralise the humoral immune response to B. cepacia
and enable the organism to persist in the lungs of
colonised patients. However, this observation does not
explain the ability of rough, LPS-deficient, serum-
sensitive B. cepacia to cause invasive pneumonitis and
septicaemia in patients with elevated anti-fi. cepacia
immunoglobulin titres [86].
Inflammatory damage
Increasing evidence has emerged to suggest that host
immune responses are important in the pathogenesis of
B. cepacia infection. A UK multicentre study has
shown that levels of the inflammatory markers, C-
reactive protein and neutrophil elastase al-antiprotein-
ase complex, are significantly higher during B.
ce/wc/a-associated exacerbations than in exacerbations
caused by P. aeruginosa alone. Aggressive antibiotic
treatment with the most active agents available did not
eliminate B. cepacia, but in most cases was associated
with a decline in inflammatory markers to pre-
exacerbation levels [102], In addition, anecdotal
evidence indicates that patients who exhibit rapid
pulmonary decline and pronounced inflammatory
symptoms, but who do not respond to antibiotic
therapy, nevertheless respond to treatment with com¬
mercial preparations of immunoglobulin. The relative
absence of B. cepacia antibodies in healthy human
donors [87], from whom these immunoglobulins are
obtained, suggests that such preparations contain
potentially useful anti-inflammatory activity.
An unexpected but informative result from our own
studies has demonstrated that LPS from clinical and
environmental isolates of B. cepacia induces pro¬
inflammatory cytokines, including the major cytokine
tumour necrosis factor a (TNFa), to a level 10-fold
that induced by P. aeruginosa LPS and matching the
inflammatory power of Escherichia coli endotoxin
[103, 104], The mechanism involved in B. cepacia
cytokine stimulation is unclear, but is independent of
CD 14 receptors. Of interest, induction of TNFa by B.
cepacia LPS is reduced in the presence of P.
aeruginosa LPS, suggesting that the diversity of
clinical outcomes in patients colonised with B.
cepacia may be influenced in part by the presence
or absence of P. aeruginosa and other CF pathogens
[105],
What is a true B. cepacia?
Further research to establish a gold standard for
laboratory identification of B. cepacia has assumed
high priority. Reliable identification is important not
only in attempts to clarify the organism's pathogenic
potential, but also because of the clinical, social,
psychological and potentially litigious consequences for
patients, carers and diagnostic laboratories associated
with the organism's acquisition and transmission.
Selective media and laboratory protocols for culture
and presumptive identification of B. cepacia from
clinical or environmental sources have been described
and their value in microbiological surveillance estab¬
lished [14, 48, 56, 106]. However, existing selective
media also support the growth of other gram-negative
non-fermenting bacilli [46,48,56] and unequivocal
identification of B. cepacia by nrultitest commercial
systems can present difficulties [44, 56, 106, 107].
There is increasing evidence that organisms presently
identified as B. cepacia by standard laboratory
procedures exhibit such diverse genotypic and pheno-
typic properties that attempts to generalise on
virulence, transmission and antibiotic susceptibility
are ill-founded. Simpson et al. [44] speculated that
epidemic strains may represent a B. cepacia sub-
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population, arising as bacterial hybrids or through
horizontal transfer of virulence genes from the closely
related pseudomonads B. gladioli and the highly
dangerous intracellular pathogen B. pseudomallei.
Recently, isolates identified as B. cepacia were
characterised further by analysis of cellular proteins
and fatty acid components and clustered by means of
computer-assisted numerical comparison of the pro¬
files. Representative isolates from individual clusters
were selected to determine genotypic relatedness
within and between clusters by means of DNA-
DNA and DNA-rRNA hybridisation assays. These
molecular phylogenetic studies revealed that organisms
identified by conventional tests as B. cepacia com¬
prised several new Burkholderia spp. [108].
According to taxonomic conventions, new species
names should not be given to bacteria that cannot be
identified reliably by phenotypic characteristics;
instead, such groups can be described by the terms
genomovar I, II, etc. [109]. Following this convention,
isolates identified as B. cepacia by conventional
multitest systems such as the API 20NE system
(API-bioMerieux, Marcyl'Etoile, France) constitute at
least four different genomovars of B. cepacia; other
presumed B. cepacia strains are identified as the
nitrogen-fixing organism B. vietnamiensis. Preliminary
studies on a small number of isolates have indicated
that the majority of CF isolates from Belgium and
the UK tend to cluster in genomovar III [70, 108].
Subsequent ongoing analyses of a larger collection of
environmental, phytopathogenic and clinical isolates
in our laboratories have confirmed the potential
importance of genomovar identification. For example,
the isolate responsible for the first UK report of
cepacia syndrome [72], and three individual epidemic
clones including the highly transmissible ET12 line¬
age [25, 44, 62, 69] each belong to genomovar III. It
should be stressed that B. vietnamiensis and the
remaining B. cepacia genomovars were also identified
amongst isolates from CF patients, and that genomo¬
var III status is not synonymous with high trans-
missibility [72], Of the 150 ' B. cepacia'' isolates
studied to date, most environmental isolates (includ¬
ing the phytopathogenic type strain ATCC 25416)
belong to genomovar I; in contrast, isolates associated
with acute clinical decline in CF patients are
restricted to genomovar III. These results confirm
the complex taxonomic heterogeneity within the
genus Burkholderia and have important diagnostic
implications for infection control in the CF
community.
Unique bacterial clones and B. cepacia
transmission factors
Epidemiological data and genomic fingerprinting sug¬
gest that the variable incidence of B. cepacia—in
particular, the lack of cross-infection in some centres
[75,81], and the contrasting epidemic spread in
others—reflects the behaviour of a relatively small
number of highly transmissible clones [46, 69, 110-
112].
It seems reasonable to speculate that B. cepacia
strains responsible for epidemic spread may harbour a
common colonising factor whose identification could
be exploited for diagnostic and therapeutic purposes.
At present, the most significant of these factors is
adhesion to respiratory mucin [53,113-115], asso¬
ciated with giant intertwined fibres referred to as cable
pili [53, 114], The gene responsible for cable pili, cbl,
has been detected in the highly transmissible ET12
lineage, represented by the Edinburgh isolate CF5610
(J2315) [16, 25, 62, 69, 115], and responsible for B.
cepacia colonisation in 38% of UK patients [46], In a
slightly different form, cbl has also been associated
with epidemic transfer of B. cepacia from CF to non-
CF patients in a Mississippi outbreak [16,69,115].
However, studies with a cbl DNA probe indicated that
cbl is not present in all epidemic clones, suggesting
that other bacterial and host factors need to be
identified [69], Interestingly, a recent study [116] has
described enhanced binding of the ET12 lineage to
lipid receptors, particularly the galactolipid globotrio-
sylceramide (GB3), and led to speculation that
upregulation of GB3, mediated through the infection
process and TNF stimulation within the lung, may
provide an alternative receptor for isolates in which
cable pili are poorly expressed and a second receptor
system for the epithelial attachment of bacteria that
have migrated through the mucosal blanket.
Experimental proof of direct or indirect transmission
of epidemic B. cepacia is not feasible and can be
judged only by circumstantial evidence. However,
epidemiological data has strikingly demonstrated such
potential. Colonisation with more than one strain of B.
cepacia is unusual and has been reported in <10% of
patients [46]. During the Edinburgh outbreak, PFGE
fingerprinting showed that one patient harboured two
B. cepacia strains in his respiratory secretions,
including the ET12 clone; however, only the epidemic
strain was transmitted subsequently to his girlfriend
[62].
Modes of transmission and the risks of
acquisition
The potential risks of B. cepacia transmission, either
directly by person-to-person spread or indirectly from
contaminated fomites, continue to be a major concern
to the CF community. Table 2 summarises the
extensive documented evidence for direct transmission
of B. cepacia between CF patients during close
contacts within hospitals [61,63,65], at educational
or summer camps [59,66] and through other social
contacts [62,63]; in contrast, several reliable studies
have found no evidence of cross-infection [72-75], In
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their initial report, LiPuma et al. [59] cited previous
failures to culture B. cepacia from respiratory equip¬
ment and environmental surfaces as circumstantial
evidence that direct person-to-person spread might be
the primary means of transmission. However, a
subsequent prospective study [117] with selective
culture and DNA-based typing of isolates showed that
colonised patients can contaminate their environment;
thus indirect transmission might occur via contami¬
nated surfaces. The intrinsic resistance of B. cepacia to
many antibiotics also raised justifiable concern that the
use of contaminated home-use nebulisers might present
a special hazard for B. cepacia acquisition. Currently,
evidence for nebuliser-associated transmission is scanty
and equivocal. A case-controlled retrospective study of
five CF patients undergoing treatment in a CF centre
[118] showed a significant association between out¬
patient nebuliser use and B. cepacia colonisation. B.
cepacia was also cultured from nebulisers used by
colonised patients. Unfortunately, no bacterial typing
was performed to confirm the clonal relationships of
the human and nebuliser isolates. Recently, in a
prospective study [119], B. cepacia was cultured from
three of 35 home-use nebulisers. DNA macrorestriction
analysis by PFGE revealed that one of two strains of B.
cepacia recovered from the nebuliser of one patient
was also present in the patient's sputum. However,
sputum cultures from the two other patients whose
nebulisers harboured B. cepacia did not yield the
organism, suggesting an environmental origin for the
B. cepacia strain isolated from the nebuliser. Other
studies of nosocomial acquisition of B. cepacia in non-
CF patients have suggested that respiratory infection
probably occurred by indirect transmission following
use of contaminated nebuliser devices [31, 120]. Air¬
borne dissemination may also present a small risk of B.
cepacia acquisition. In a prospective study, B. cepacia
was recovered from the room air during occupation by
five of six patients, but to only a limited extent, with
the number of bacteria ranging from 1 to 158cfu/m3
[121]. Maximum yields were associated with episodes
of coughing and, after a patient left the room, the
organism persisted in room air for up to 45 min.
To conclude, ethical considerations prevent experi¬
ments that could provide scientific data to assess the
risks of B. cepacia acquisition, including clarification
of the frequency of contact and the infectious dose
required. Based on accumulated evidence (Tables 2
and 3), skin contact, respiratory aerosols, sharing food,
contaminated equipment, co-habitation or undergoing
physiotherapy in the same room as a B. cepacia-
positive individual present reasonable risks of acquisi¬
tion. However, epidemiological evidence [38,62],
including the high numbers (typically >108cfu/ml)
of B. cepacia present in the saliva of colonised
patients, suggests that the close and frequent social
contact that occurs between siblings, the direct
exchange of respiratory secretions associated with
kissing, and the involvement of a highly transmissible
B. cepacia lineage arguably present the greatest risks
of acquisition.
Environmental release of B. cepacia as a
biological control agent
Whilst the CF community debates the clinical issues of
B. cepacia colonisation and transmission, agricultural
microbiologists continue to develop the organism as a
biological control agent to exploit its antifungal activity
(Fig. 1) for the enhancement of crop yields [122, 123]
and its nutritional adaptability in the bioremediation of
landfill sites, contaminated soils and ground water
aquifers [124-126], Deliberate environmental distribu¬
tion of B. cepacia as field inoculants raises the issue of
the phylogenetic relationship between B. cepacia of
environmental and clinical origin and the potential
hazard for human infection. The debate on this
relationship has revealed the gulf that exists between
different areas of interest and microbiological expertise
and, as stated recently in an editorial comment on
another contentious issue, bovine spongiform encepha¬
lopathy, 'underscores the weakness of separating
agricultural and medical science' [127].
We have stated previously that the scientific evidence
that environmental strains of B. cepacia present little
hazard to man is weak [14] and is based on
examination of only a few bacterial isolates and
Table 3. Factors that may influence acquisition of B. cepacia
• In colonised individuals. B. cepacia saliva counts can exceed 108 cfu/ml, suggesting that the highest risk of patient-to-patient spread is
transmission of respiratory secretions during kissing or through sharing of eating or drinking utensils.
• Spirometer mouthpieces become heavily contaminated during lung function tests. Risk avoided by use of disposable mouthpieces.
Recovery from the surface of lung function equipment is low.
• Recovery from antibiotic reservoirs of nebulisers has been reported, but incidence is low and the degree of risk appears secondary to the
preceding factors.
• Aerosol recovery is low, suggesting low risk of aerosol transmission.
• Hands become contaminated after coughing and the organism can be transmitted by handshake. Survival on hands reduced to 10% after
30 min; this varies in different individuals and may account for variable recovery in surveillance studies.
• Gastrointestinal carriage has not been demonstrated, even in colonised individuals, suggesting that the risk of faecal-oral spread is
minimal.
• After surface contamination with B. cepacia-containing sputum, viable bacteria can be recovered for several weeks.
• Surface contamination by B. cepacia sputum is eliminated by treatment with UV irradiation and with common hospital disinfectants,
including Milton, Dettol, alcohol 70%, phenols, iodine and cetrimide. Careful drying is important after washing or disinfection.
• Recovery of B. cepacia from soil, plants, drains, lakes and surface waters is low, suggesting that natural environments present a possible
but low risk for acquisition.
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Fig. 1. Inhibition of the phytopathogenic fungus Rhizoc-
tonia solani by five isolates of B. cepacia. The fungus
was inoculated in the centre of the plate and bacteria
around the perimeter. Cultures were photographed after
incubation for 14 days at room temperature.
inappropriate bacterial properties [24], Although some
studies have indicated that environmental and clinical
isolates are distinct, no reliable phenotypic markers
have been identified [25,45, 108], The suggestion that
clinical isolates can be distinguished from soil isolates
based on the former's lack of plant pathogenicity [45]
is discounted by the fact that CF isolates of B.
cepacia will readily macerate onion tissue (Fig. 2)
[14], In addition, the invasive B. cepacia foot lesions
known as swamp foot [128], acquired by military
personnel during jungle training, confirm the patho¬
genic potential of environmental strains of B. cepacia
for man.
The potential hazard that some or all environmental B.
cepacia strains present to the CF community is
unclear and requires investigation. The fact that new
cases of B. cepacia colonisation continue to occur
with strains that show no genotypic relationship to
other isolates within the same CF centre, points to the
environment as a potential source. However, the extent
of this risk is difficult to assess. Extensive microbio¬
logical safaris into supermarkets and domestic homes
[15], and a range of botanical soils and cultivars [14],
indicate that B. cepacia can be cultured from up to
20% of warm moist environmental sites, particularly
soils, but that it is not as ubiquitous as other
pseudomonads. Interestingly, in our studies to date,
none of the environmental isolates of B. cepacia have
been identified as belonging to genomovar III.
Conclusions and future prospects
B. cepacia is a striking example of a multiresistant soil
saprophyte and phytopathogen that has emerged as an
important threat to susceptible human hosts. In the CF
community, the degree to which infection control
measures should be implemented continues to arouse
strong scientific and social debate. The validity of strict
control is supported by circumstantial, but nevertheless
compelling, evidence for direct person-to-person trans¬
mission of epidemic strains through nosocomial and
social contact. In contrast, although the risk of indirect
iatrogenic spread from contaminated fomites remains
Fig. 2. Soft rot of a segmented 'compromised' onion inoculated with a clinical B. cepacia isolate of the epidemic ET12
lineage (left) and an uninoculated control (right), both incubated at 30°C for 72 h. Reproduced with permission from
Butler et al. [14],
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unclear, available evidence suggests that this route is
less important than direct transfer. An important caveat
in attempts to generalise on B. cepacia transmission is
evidence that the major epidemics of B. cepacia
involve a subpopulation of highly epidemic lineages
which might be re-allocated ultimately to new species;
' Burkholderia cfeV might be an appropriate but
probably controversial choice! Ongoing microbiological
surveillance in CF centres indicates that sporadic
acquisition of epidemic lineages continues to occur
when there is a failure to comply with infection control
measures. For example, a striking demonstration of the
continued potential for transmission of the ET12
lineage was its recent acquisition by an Edinburgh
CF adult; extensive inquiries suggested that this patient
had social contact for only lOmin whilst visiting
another CF male who was hospitalised during an
episode of B. cepacia septicaemia. Even when infec¬
tion control appears effective in preventing spread of
epidemic lineages, new cases of B. cepacia colonisa¬
tion continue to occur with isolates that exhibit unique
PCR ribotyping or PFGE profiles. Such sporadic
acquisitions raise a fundamental question concerning
the source and colonising potential of individual B.
cepacia strains. For example, does the environment
contain a subpopulation of B. cepacia clones that are
innately primed for human colonisation, or does
colonisation and virulence in man require in-vivo
adaptation? Future improvements in laboratory identi¬
fication of B. cepacia subpopulations associated with
CF disease and identification of transmission factors, in
addition to cable pili, may provide scientific justifica¬
tion for relaxation of segregation in the absence of
known epidemic and potentially virulent lineages.
Turning our attention to CF patients, we need to
clarify why colonisation by the same strain of B.
cepacia leads to variable clinical responses, ranging
from asymptomatic colonisation to rapid fatal pulmon¬
ary deterioration. It could be argued that this particular
problem is not unique to B. cepacia, and that applying
Koch's postulates in an attempt to distinguish between
sycophancy and pathogenic potential is difficult when
dealing with any opportunist pathogen. Certainly, host
factors cannot be ignored in attempts to understand the
pathogenic processes involved in CF lung infections.
During the final preparation of this review, a
deceptively simple and elegant study has illustrated
how CFTR-associated defective Cl~ transport across
airway epithelia might lead to bacterial colonisation in
CF patients. Smith et al. [129] showed that the normal
human apical epithelial surface is bactericidal for P.
aeruginosa and S. aureus; in contrast, the bactericidal
activity was inhibited reversibly in CF epithelia
because of a high NaCl concentration. If this
phenomenon varies in individual CF patients—or if
individual B. cepacia strains differ in susceptibility to
the defensin-like bactericidal agent—it might explain
some of the host- and pathogen-specific anomalies
associated with B. cepacia pulmonary infection and
suggest novel strategies for infection control and
therapy of this unusual and challenging opportunist
pathogen.
It is difficult to avoid a final comment on the irony
that whilst B. cepacia continues to hold the CF
community to ransom, agricultural microbiologists
seek to develop the commercial and beneficial
potential of this microbial Jekyll and Hyde in their
search for biological control agents. This situation
demonstrates the diversity of microbiology, but should
also encourage attempts to reduce the present gulf
between agricultural and medical science.
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Note added in proof
Following submission of this review, the results of an
epidemiological study of B. cepecia in a large series of
CF patients attending the CF centre in Verona were
published. Cazzola et al. concluded that their results
are difficult to interpret. Nevertheless, data are essential
if progress is to be made in unravelling B. cepacia
epidemiology, and the results of this study are
particularly relevant to the major issues discussed in
our review.
Between Nov. 1991 and Dec. 1994, B. cepacia was
cultured from 85 (11.0%) of 769 CF patients attending
the Verona centre. Based on genomic fingerprinting,
32 (53.3%) patients were colonised by individual B.
cepacia strains; the remaining 28 (46.7%) patients
were divided into 10 subgroups, each colonised by a
distinct strain. As previously encountered with the
ET12 lineage, the outcome of B. cepacia colonisation
in the Verona study varied from rapidly fatal
septicaemia to maintenance of reasonably stable
respiratory function, even in patients colonised by
the same strain. Cazzola et al. provide further
evidence for hypotheses discussed in our review that
some B. cepacia strains exhibit and low transmissi-
bility that the environment is a likely source of
sporadic new cases: e.g., transmission was observed in
only three of eight pairs of CF siblings; in unrelated
patients, direct person-to-person transmission was
evident in only 10 cases (16.7%); despite a strict
segregation policy, whether as in- or out-patients, 15
new colonised patients were identified during 1993.
Considering social implications and the paucity of
previous data, it was particularly interesting to note
that transmission was demonstrated between two
unrelated CF schoolmates.
Cazzola G, Amalfitano G, Tonelli E, Perazzoli C, Piacentini I,
Mastella G. Burkholderia (Pseudomonas) cepacia epidemiology in a
cystic fibrosis population: a genome finger-printing study. Acta
Paediatr 1996; 85: 554-557.
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BACTERIAL CHARACTERISATION
Biochemical characteristics of clinical and
environmental isolates of Burkholderia
pseudomallei
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and N. J. WHITE
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The biochemical characteristics of 213 isolates of Burkholderia pseudomallei from
patients with melioidosis and 140 isolates from the soil in central and northeastern
Thailand were compared. Whereas the biochemical profiles of all the clinical isolates
were similar, all soil isolates from the central area and 25% of isolates from
northeastern Thailand comprised a different phenotype. This was characterised by the
ability to assimilate L-arabinose (100%), adonitol (100%), 5-keto-gluconate (90%) and
D-xylose (84%), but failure to assimilate dulcitol (0%), erythritol (0%) and trehalose
(10%). Compared with clinical isolates, these organisms had similar antibiotic
susceptibility profiles and were also recognised by a specific polyclonal antibody
against B. pseudomallei. As melioidosis is rare in central Thailand, but common in the
northeast, this raises the possibility that this biochemical phenotype may be less
virulent, or may even represent a different species.
Introduction
Burkholderia (formerly Pseudomonas) pseudomallei is
an environmental saprophyte capable of causing
devastating systemic infections in many species of
mammals and birds. Although B. pseudomallei has
been isolated from environmental samples across the
tropical world, the disease in man is confined to the
endemic areas of eastern Asia and northern Australia
[1], In northeastern Thailand B. pseudomallei is a
major cause of morbidity and mortality, causing one-
fifth of all community-acqpired septicaemias [2],
However, B. pseudomallei is also isolated readily from
soil samples in the southern and central regions of
Thailand, where clinical disease is rare [3,4], To
investigate this discrepancy between the distribution of
disease and the distribution of the organism in the
environment, this study compared the biochemical and
antigenic features, and antibiotic susceptibilities, of
clinical and environmental isolates of B. pseudomallei.
Received 25 Jan. 1996; accepted 26 March 1996.
Corresponding author: Dr N. J. White.
Materials and methods
Bacterial isolates
Clinical and laboratory studies on melioidosis have
been conducted in Ubon Ratchatani, northeast Thai¬
land, since 1986. More than 1100 patients with culture-
proven melioidosis have been seen during this time.
Single isolates of B. pseudomallei from 213 of these
patients were used for this study.
The soil isolates of B. pseudomallei were selected
from those collected in a survey of rice paddies in
northeastern Thailand [5] and in a quantitative
comparison of the isolation of the organism from soil
in central and northeastern Thailand [4], A maximum
of two isolates was selected from each site sampled,
giving a total of 140 isolates, 115 from the northeast
and 25 from the central region.
Organism identification
All isolates were identified initially by their character¬
istic colonial morphology on a differential agar
medium [6], positive oxidase reaction, and resistance
to colistin and gentamicin [7].
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Priming of Neutrophil Respiratory Burst Activity by
Lipopolysaccharide from Burkholderia cepacia
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Neutrophil activation may play an important role in the pathogenesis of respiratory disease in Burkholderia
cepacia-colonized cystic fibrosis (CF) patients. As bacterial lipopolysaccharides (LPS) are potent immuno-
stimulatory molecules, we investigated the role of B. cepacia LPS in neutrophil activation processes. LPS
extracted from a highly transmissible and virulent strain of B. cepacia (J2315) was found to increase neutrophil
surface expression of the p2 integrin, complement receptor 3, and to prime neutrophil respiratory burst
responses to the neutrophil-activating agent fMet-Leu-Phe. By contrast, LPS extracted from a nonmucoid
Pseudotnonas aeruginosa strain isolated from a patient with CF showed little or no priming activity. As B.
cepacia is currently being developed as a biocontrol agent for large-scale agricultural release, we compared LPS
molecules from a range of bacterial strains for their proinflammatory ability. Priming activity was demon¬
strated in LPS extracts from all B. cepacia strains tested, with one environmental strain, J2552, showing the
highest activity. These findings indicate (i) that B. cepacia LPS may contribute to the inflammatory nature of
B. cepacia infection in CF patients, both by promoting increased neutrophil recruitment and by priming
neutrophil respiratory burst responses, and (ii) that environmental strains of B. cepacia may have considerable
inflammatory potential in susceptible individuals.
During the last 15 years, Burkholderia cepacia has emerged
s a serious respiratory pathogen in cystic fibrosis (CF) (16).
Epidemic spread of B. cepacia between CF patients has been
ssociated with a subset of highly transmissible strains, includ-
tg the Edinburgh/Toronto or electrophoretic type ET12
:rain, which has been implicated in numerous outbreaks in
oth North American and United Kingdom CF centers and
as been isolated from up to 40% of B. cepacia-colonized
atients in the United Kingdom (23, 34). Recently, investiga-
)rs have identified putative transmissibility markers, including
dhesion to mucin and respiratory epithelium mediated via
able pili (39); enhanced adhesion to the cell surface glyco-
pid, globotriosylceramide (40); and a genomic marker termed
te Burkholderia cepacia epidemic strain marker (30). In con-
ast, little is known of the pathogenic mechanisms responsible
tr severe B. cepacia infection. For example, it is not clear why
)me patients appear unaffected by B. cepacia colonization
hile others succumb to rapidly fatal necrotizing pneumonia
nd septicemia, the so-called cepacia syndrome.
There is increasing evidence that acute pulmonary deterio-
ttion associated with B. cepacia infection is due to a marked
lflammatory response induced by this organism. In a case-
Dntrolled study, raised serum levels of the inflammatory
larkers C-reactive protein and neutrophil elastase were found
uring exacerbations with B. cepacia (11). In addition, anec-
otal evidence has suggested that severe B. cepacia infection
an be treated with anti-inflammatory therapy, in particular
te use of hypergammaglobulin preparations (16). Shaw et al.
57) described the in vitro induction of the proinflammatory
ffokine tumor necrosis factor alpha (TNF-a) from monocytes
imulated by lipopolysaccharides (LPS) extracted from clini¬
* Corresponding author. Mailing address: Cystic Fibrosis Labora-
iry, Department of Medical Microbiology, Edinburgh University
ledical School, Edinburgh EH8 9AG, United Kingdom. Phone: 0044
1)131 650 3162. Fax: 0044 (0)131 650 6351. E-mail: Jayne.Flughes@ed
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cal strains of B. cepacia, including a representative of the ET12
lineage (C1359). Interestingly, levels of TNF-a induced were
over nine times greater than levels induced by LPS from
Pseudomonas aeruginosa, the major respiratory pathogen in
CF. Recently Palfreyman et al. (33) have described the induc¬
tion of biologically active interleukin-8 from lung epithelial
cells and human monocytes by a B. cepacia extracellular factor
distinct from LPS.
Neutrophils have been implicated in immunologically medi¬
ated lung damage in CF through the release of reactive oxygen
species (ROS) and proteolytic enzymes during activation pro¬
cesses (6, 9, 26). Chronic colonization with mucoid P. aerugi¬
nosa is believed to exacerbate neutrophil-mediated damage
through "frustrated phagocytosis," as neutrophils attempt to
engulf P. aeruginosa microcolonies embedded in a protective
layer of alginate and release their granule contents in the
process (14, 15). Similarly, bacterial extracellular products
from B. cepacia or P. aeniginosa may also act directly on neu¬
trophils either by inducing end stage activation with the release
of granule contents or by priming responses to other immuno-
stimulatory agents. Colonization with both P. aeruginosa and B.
cepacia is associated with high bacterial counts in sputum,
typically 109 CFU/ml, suggesting that high concentrations of
LPS shed from both viable and nonviable bacteria will also be
present. As LPS molecules from a number of bacterial species
have been recognized as neutrophil-priming agents (1, 21, 24,
25, 32), we investigated the interaction of B. cepacia LPS with
neutrophils. Our results indicate the potent priming activity of
B. cepacia LPS and confirm the proinflammatory capabilities
of this unusual and challenging pathogen.
MATERIALS AND METHODS
Materials and equipment. Bacterial strains used in this study are from the
collection held in the Cystic Fibrosis Laboratory, Department of Medical Mi¬
crobiology, Edinburgh University, and are described in Table 1. Strains were
stored at -70°C in 5% skim milk (Oxoid, Basingstoke, United Kingdom) and
were recovered onto nutrient agar (Oxoid) before use. Fluorescence-activated
cell sorter lysing solution and CellFIX were supplied by Becton Dickinson UK
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E. coli 018K- 31
" Representative strain of the transcontinental ET12 lineage (23).
b Based on polyacrylamide gel electrophoresis of whole-cell proteins and
DNA-DNA hybridization of selected B. cepacia strains.
c Identified as CF5610 in this reference.
d Pyocin type 1/b (4, 8, b) s.
Ltd., Oxford, United Kingdom. Monoclonal antibodies (mouse anti-human
CDllb and mouse isotype control antibody) conjugated with fluorescein isothio-
cyanate were obtained from Serotec, Oxford, United Kingdom. Dihydrorhoda-
mine (DHR; Cambridge Biosciences, Cambridge, United Kingdom) was stored
at — 20°C as a 10-mg/ml stock solution in dimethyl sulfoxide and was diluted to
a 200-fig/ml solution in 20% (vol/vol) dimethyl sulfoxide in Hanks balanced salt
solution (HBSS) with 0.1% (wt/vol) glucose (mHBSS) immediately prior to use.
All other reagents were provided by Sigma Chemical Corporation (Poole, United
Kingdom). Flow cytometry was carried out on a Becton Dickinson FACSort, and
results were analyzed by using CellQuest 1.2.2 (Becton Dickinson).
LPS extraction. Bacteria were grown for 48 h in an orbital incubator (140 rpm)
at 37°C in nutrient broth no. 2 (Oxoid) containing 0.5% yeast extract (Difco
Laboratories, Detroit, Mich.). LPS was extracted by a modification of the aque¬
ous phenol method of Westphal and Luderitz (44) as described by Hancock and
Poxton (19). LPS samples were resuspended in pyrogen-free water at a concen¬
tration of 2 mg/ml. Samples were sonicated at an amplitude of 10 |xm for three
to eight 30-s pulses to ensure adequate solubilization. Protein concentration was
determined by using the Coomassie brilliant blue protein assay of Bradford (5),
with bovine serum albumin as the standard. For all LPS samples, protein content
was less than 0.5% of the total dry weight of LPS. LPS characterization was
carried out by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using
the buffer system of Laemmli (28), and silver staining was done by a modification
of the method of Tsai and Frasch (42) as described by Hancock and Poxton (19).
Samples from Escherichia coli 018K-, P. aeruginosa PAOl, and B. cepacia
J2540, J2552, and J2505 were found to be smooth in character, while samples
from P. aeruginosa J1385 and C1250 and B. cepacia J2315 and C1504 were rough
in character. All samples were stored at -20°C.
Preparation of plasma-free whole blood cells. Fresh heparinized blood was
collected from healthy volunteers. As we have observed low levels of anti-2?.
cepacia LPS antibodies in healthy individuals (22a), plasma was removed from
blood samples to prevent any opsonic neutrophil responses. Blood was trans¬
ferred to Eppendorf tubes and spun at 6,500 rpm for 30 s in a Micro Centaur
microcentrifuge (MSE, Loughborough, United Kingdom). Following the re¬
moval of plasma, the cell pellet was washed four times in HBSS. Finally, the cell
pellet was resuspended in a volume of mHBSS equivalent to the initial volume
of plasma removed. The resultant washed blood was kept on ice until use. All
experiments were initiated within 1 h of blood collection. Polymorphonuclear
cell viability was determined by trypan blue exclusion and was found to be greater
than 95%. Comparison of washed whole blood neutrophils with untreated blood
showed no differences in size, granularity, or baseline CDllb expression, indi¬
cating that little neutrophil activation had occurred during plasma removal.
Detection of surface CDllb following neutrophil exposure to LPS. All exper¬
iments were carried out with 100-p.l aliquots of washed blood in 5-ml polystyrene
tubes (Greiner, Stonehouse, Gloucestershire, United Kingdom), to which was
added an equal volume of mHBSS or LPS diluted in mHBSS. The tubes were
incubated for the desired time period at 37°C with gentle shaking. Reactions
were stopped by transferring the sample tubes onto ice. After the addition of
anti-CDllb-fluorescein isothiocyanate (5 jxl) or control antibody (5 pi) to each
sample, the tubes were mixed and incubated for 20 min on ice. Then erythrocytes
were lysed by the addition of 2 ml of lysing solution for 30 min. Neutrophils were
pelleted by centrifugation at 500 X g, washed once in phosphate-buffered saline
and resuspended in 500 pi of CellFIX. Samples were stored at 4°C until flow
cytometric analysis on the same day as the experiment. Neutrophils were gated
on forward and side scatter characteristics by using CellQuest 1.2.2 software.
CDllb expression was determined as the mean channel fluorescence (MCF) of
the neutrophil population, using the green channel (FL1). As considerable ir
terdonor variation in the magnitude of neutrophil responses was noted, MC
values were standardized by expression as a percentage of the MCF of neutrt
phils treated with buffer alone. Each complete experiment was conducted at lea:
four times, using blood from a different donor on each occasion.
Intracellular H202 production following neutrophil priming and stimulatioi
All experiments were carried out with an initial aliquot of 100 jxl of washe
blood. Where required, samples were preincubated with mHBSS or LPS at th
desired concentration at 37°C. Samples were then stimulated with mHBSS c
fMet-Leu-Phe (FMLP; 5 X 10-7 M) for 15 min at 37°C in the presence of 30 mP
DHR (4, 43). Reactions were stopped by transferring the sample tubes onto io
erythrocytes were lysed by the addition of 2 ml of lysing solution for 30 min, an
the remaining neutrophils were processed as described above. As H202 oxidize
DHR to fluorescent rhodamine, intracellular H202 production was determine
as the MCF of the neutrophil population, using the red channel (FL2) (43
Results were analyzed by using CellQuest and expressed as the MCF of the tot;
neutrophil population. Each complete experiment was conducted at least foi
times, using blood from a different donor on each occasion.
Statistical analysis. Statistical analysis was carried out by using Student's t te
to compare the means of two populations. For comparison of B. cepacia and l
aeruginosa populations, data were transformed by conversion to logarithms, an
analysis of variance was performed.
RESULTS
Induction of CDllb on neutrophils stimulated with LP
from representative strains. Neutrophils were exposed to ir
creasing concentrations of LPS from representative strains c
B. cepacia, P. aeruginosa, and E. coli for a 2-h period at 37°(
Both E. coli and B. cepacia LPS increased CDllb expressio
on neutrophils, although responses to E. coli LPS could b
demonstrated at a lower concentration (1 ng/ml) than for L
cepacia LPS (10 ng/ml). The greatest effect was seen wit
E. coli LPS at 100 ng/ml, where CD1 lb expression reached 2.
times levels on neutrophils incubated with buffer alone (Fig. 1
At all LPS concentrations, CDllb levels induced by E. co
tended to be greater than those induced by B. cepacia. How
ever, for both organisms, raised CDllb levels above baselin
became statistically significant only at concentrations of 10
ng/ml and above (P < 0.02). LPS from a nonmucoid CF strai
of P. aeruginosa, J1385, had no effect on neutrophil CD 11
expression at all concentrations tested.
Preliminary time course experiments indicated that at a lo'
concentration (1 ng/ml), B. cepacia LPS was associated with
late rise in neutrophil CDllb expression, occurring after 3 h c
incubation. By contrast, higher LPS concentrations induced
rise in CDllb expression to maximal levels in less than 2 h c










FIG. 1. Induction of CDllb on neutrophils following stimulation with vai
ous concentrations of LPS from E. coli 018K— (■), B. cepacia J2315 (A), ar
P. aeruginosa J1385 (♦). Results are expressed as a percentage of the MCF 1
neutrophils treated with buffer alone for 2 h (mean of four experiments
standard error of the mean).
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time (min)
FIG. 2. Time course of induction of CD1 lb on neutrophils following stimu-
ition with buffer alone (O) or LPS (100 ng/ml) from E. coli 018K- (■),
'. cepacia J2315 (A), and P. aeruginosa J1385 (♦) at 37°C. Results are expressed
s a percentage of the MCF of neutrophils treated with buffer alone at time zero
mean of four experiments ± standard error of the mean).
ig LPS from B. cepacia, P. aeruginosa, and E. coli were carried
nit with an LPS concentration of 100 ng/ml (Fig. 2). Incuba-
ion with buffer alone was associated with a slight elevation in
ID lib expression between 60 and 120 min, returning to base-
ne levels by 150 min. E. coli LPS was found to induce statis-
ically significant levels of CDllb by 60 min (P < 0.01), peak-
ig at 90 min (P < 0.001) with levels 2.3 times greater than
hose on neutrophils treated with buffer alone. Responses to B.
epacia LPS were slower to develop, rising to 1.8 times the
jvels on neutrophils treated with buffer alone by 90 min and
eaching statistical significance after 120 min (P < 0.01). In-
ubation with P. aeruginosa LPS had little effect on CDllb
xpression over the entire incubation period.
Priming of FMLP-induced respiratory burst activity by LPS
rom H. cepacia and E. coli. DHR was used to detect the pres-
nce of intracellular H202 as a measure of neutrophil respira-
ary burst activity. Unstimulated neutrophils and unprimed
eutrophils stimulated with FMLP fell within the R1 region
Fig. 3A) on the basis of size and granularity. Stimulation
f LPS-primed neutrophils with FMLP was associated with
hanges in the forward and side scatter characteristics of a
ubpopulation of neutrophils (Fig. 3B and C, R2). By contrast,
either LPS priming alone nor stimulation of unprimed neu-
'ophils with FMLP was associated with a shift in neutrophils
om the R1 to the R2 population (Fig. 3A). In all instances,
1CF for R2 populations was greater than MCF for R1 pop-
lations (Fig. 3D to F). However, as the patterns of change in
1CF within each individual experiment were identical for both
11 and R2 neutrophils, respiratory burst activity was generally
xpressed as the MCF of the total neutrophil population (R1
lus R2).
Both E. coli 018K— and B. cepacia J2315 LPS primed for
:sponses to FMLP in a dose-dependent manner. By contrast,
1 aeruginosa J1385 LPS had no priming effect on neutrophils,
riming effects of E. coli LPS could be detected at lower
ancentrations (1 ng/ml) than for B. cepacia LPS (10 ng/ml)
nd were greater in magnitude at all concentrations tested
lata not shown). Subsequent time course experiments were
rrried out with 100 ng of LPS per ml as standard. Neutrophils
■om individual donors varied considerably in both the magni-
lde and timing of priming responses (Fig. 4), but several
eneral trends could be observed. None of the LPS prepara-
ons induced a respiratory burst in the absence of stimulation
with FMLP (data not shown). Preincubation with buffer alone
was associated with little or no priming of responses to FMLP.
However, both E. coli LPS and B. cepacia LPS were potent
priming agents of a respiratory burst response, with priming
occurring after as little as 30 min of incubation. In assays using
neutrophils from three of four donors, priming responses oc¬
curred more rapidly and displayed greater peak activity follow¬
ing stimulation with E. coli LPS rather than B. cepacia LPS
(Fig. 4A to C). However, for one individual, little difference
was observed between E. coli and B. cepacia LPS in both the
speed and magnitude of priming responses (Fig. 4D).
In selected experiments, R1 and R2 populations were ana¬
lyzed individually with respect to both MCF and the number of
neutrophils in each population. In all instances, MCF activity
was greatest within the R2 population, although considerable
overlap in results for individual neutrophils occurred (Fig. 3D
to F). Priming with both E. coli and B. cepacia LPS increased
FMLP-induced respiratory burst responses in both R1 and R2
populations in a dose-dependent manner. Furthermore, LPS
was associated with a shift of neutrophils from the R1 to the
R2 population on stimulation with FMLP, so that the increase
in MCF within R2 correlated in a linear fashion with an in¬
crease in the percentage of total neutrophils within the R2
population (r2 = 0.94), while an increase of MCF within R1
correlated with a decrease in the percentage of neutrophils
within the R1 population (r2 = 0.94). Thus, LPS priming ap¬
peared to have a dual effect by first increasing the magnitude
of responses in both R1 and R2 neutrophils and second shift¬
ing neutrophils into the highly responsive R2 population.
Neutrophil activation by LPS from a range off}, cepacia and
P. aeruginosa strains. LPS from representative strains of B.
cepacia and P. aeruginosa (Table 1) were investigated for the
ability to induce CDllb and to prime FMLP-induced respira¬
tory burst responses. LPS from E. coli 018K— was included as
a positive control and induced maximal CDllb expression at
2.7 times the levels induced by buffer alone (Fig. 5). LPS from
all B. cepacia strains, except the environmental strain J2540,
induced levels of CDllb expression comparable to those in¬
duced by E. coli LPS. Furthermore, LPS from all B. cepacia
strains, including J2540, induced CDllb levels which were
higher than those induced by all P. aeruginosa LPS prepara¬
tions. Of the P. aeruginosa strains tested, only LPS from strain
PAOl, the classic laboratory strain, increased CDllb expres¬
sion above that of unprimed neutrophils, while LPS from both
a nonmucoid (J1385) and a mucoid (C1250) CF strain had no
effect. Direct comparison of individual P. aeruginosa with B.
cepacia strains by Student's t test found a significant difference
(P < 0.05) for all combinations except PAOl and J2540. Fi¬
nally, analysis of variance between mean results for P. aerugi¬
nosa and B. cepacia strains indicated a significant difference
between these populations for CDllb induction (P < 0.001).
Similar trends were observed for the priming effect of LPS
on an FMLP-induced respiratory burst (Fig. 6). LPS from B.
cepacia J2552 and E. coli 018K— primed intracellular H202
production to the greatest degree, with an approximately 10-
fold increase in responses to FMLP following incubation with
both LPS compared to neutrophils stimulated with buffer
alone. LPS from all B. cepacia strains primed responses to
levels greater than for all P. aeruginosa strains tested, and these
observations were significant for all combinations of strains
except PAOl and J2540 (Student's t test, P < 0.05). Although
slight neutrophil-priming effects were observed for LPS prep¬
arations from both P. aeruginosa PAOl and P. aeniginosa
C1250, these results were not statistically significant. LPS from
P. aeruginosa J1385 had almost no effect on FMLP-induced
respiratory burst activity compared to buffer controls. Again,





FIG. 3. Size, granularity, and intracellular H202 production of neutrophils stimulated with FMLP following preincubation with E. coli LPS. (A to C) In the dot plo
of side versus forward scatter, neutrophils are gated as two populations, R1 and R2. (D to F) Histograms showing fluorescence of neutrophils in populations R1 ar
R2 in the presence of DHR. Neutrophils were preincubated for 90 min with buffer alone (A and D) or LPS at 1 (B and E) or 100 (C and F) ng/ml.
analysis of variance confirmed a significant difference between
LPS from the P. aeruginosa and B. cepacia populations tested
(P < 0.001).
DISCUSSION
Neutrophil activation in response to bacterial colonization
has been implicated in the pathogenesis of CF lung disease by
initiating and sustaining a cycle of increasing lung damage and
bacterial colonization (9, 26). In this study, we investigated the
role of B. cepacia LPS in two aspects of neutrophil activation:
first, the up-regulation of surface CD lib; and second, the
priming of neutrophil respiratory burst responses. We used
flow cytometry to analyze neutrophils within a whole blood cell
population from which plasma had been removed. Comparison
of neutrophil size, granularity, and CD lib expression ind
cated that this procedure did not activate neutrophils to ar
significant degree.
CDllb associates with CD18 to form the (32 integrin con
plement receptor 3 (CR3), which is expressed on the cell su
face of granulocytes and macrophages/monocytes and is ii
volved in numerous neutrophil functions, including adhesioi
transmigration, phagocytosis, and activation (10). Increase
surface expression of CR3 is a prerequisite for neutroph
transmigration from the pulmonary circulation to the alveol;
spaces; thus, up-regulation is seen early in neutrophil activ;
tion processes (2, 38). In the present study, we have demoi
strated that LPS from both clinical and environmental strait
of B. cepacia induced a marked increase in neutrophil CB
expression. By contrast, LPS from three representative i
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FIG. 4. Priming of FMLP-induced neutrophil respiratory burst responses by
preincubation with buffer alone (O) or LPS (100 ng/ml) from E. coli 018K— (■)
or B. cepacia J2315 (A) for up to 3 h. Charts show results from studies on four
individual donors. Intracellular H202 production is expressed as the MCF of the
total neutrophil population stimulated with FMLP in the presence of DHR.
aeruginosa strains had little effect on CR3 expression. These
results are consistent with those of Shaw et al. (37), who first
reported that B. cepacia LPS induced a TNF-a response from
circulating blood monocytes which was ninefold greater than
that induced by P. aeruginosa LPS. TNF-a was detectable be¬
tween 2.5 and 4.5 h after the addition of B. cepacia LPS, and
levels peaked at approximately 3.5 h. As the assays in the
present study were carried out on a whole blood cell popula¬
tion, it is possible that the increase in CR3 expression was due
to secondary stimulation of neutrophils following the release of
cytokines from the monocyte population. Indeed, at low LPS
concentrations, an increase in neutrophil CDllb expression
occurred after 3 h, possibly through stimulation by monocyte-
















FIG. 5. Induction of CDllb on neutrophils following 90 min of incubation at
37°C with buffer alone (E3) or LPS (100 ng/ml) from strains of P. aeruginosa (il),
B. cepacia (□), and E. coli (■). Results are shown as the log10 MCF of the





















FIG. 6. Priming of FMLP-induced intracellular H202 production in neutro¬
phils following 90 min of incubation at 37°C with buffer alone (13) or LPS (100
ng/ml) from strains of P. aeruginosa (^), B. cepacia (□), and E. coli (■). Results
are shown as the log1() MCF of the total neutrophil population in the presence
of DHR (mean of five experiments ± standard error of the mean).
higher concentrations of LPS (<2 h) suggests a direct effect of
LPS on neutrophils.
Respiratory burst activity occurs late in neutrophil activation
processes and may be increased by prior exposure of neutro¬
phils to priming agents, including LPS (1, 18, 21, 24, 25, 32).
The bacterially derived peptide FMLP triggers respiratory
burst activity in primed neutrophils. In the present study, little
or no respiratory burst response was observed in unprimed
neutrophils stimulated with FMLP. This is in agreement with
the observations of previous investigators (8, 45) and confirms
the low activation state of neutrophils in the whole blood cell
preparations used. E. coli LPS has been demonstrated to prime
FMLP-induced respiratory burst responses in neutrophils (24).
Comparison of B. cepacia and P. aeruginosa LPS with E. coli
LPS in the present study indicates that while B. cepacia LPS
molecules were potent neutrophil-priming agents, little prim¬
ing activity was induced by P. aeruginosa LPS. Of the B. cepacia
strains tested, only J2540, an environmental strain, failed to
induce priming significantly above the levels of all of the P.
aeruginosa strains tested. In time course experiments using
LPS from B. cepacia J2315 and E. coli 018K—, priming was
observed after as little as 30 and 45 min, respectively, suggest¬
ing that neutrophil-priming responses were not secondary to
LPS-induced cytokine release from circulating monocytes. LPS
from two P. aeruginosa strains, PAOl, a well-characterized
laboratory strain, and CI 250, a mucoid strain isolated from a
CF patient, primed neutrophils to a low degree. However, LPS
from a nonmucoid CF strain, J1385, had no priming effect.
Interestingly in a study of LPS extracted from five CF strains of
P. aeruginosa, Kharazmi et al. (25) observed similar variation in
neutrophil priming, with LPS from two mucoid strains showing
the greatest overall activity.
Our observation of a high degree of correlation between
mean CR3 surface expression and mean FMLP-induced respi¬
ratory burst activity agrees with recently published studies (8).
Unlike increased CR3 expression, however, priming responses
were not uniform throughout the neutrophil population, and a
subpopulation of highly responsive neutrophils was identified
by changes in size (forward scatter) and granularity (side scat¬
ter) on stimulation with FMLP (Fig. 3, R2). These results
correspond to those of Yee and Christou (45), who observed
that the FMLP-induced elevation of intracellular Ca2+ levels
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in neutrophils primed with LPS was due to raised levels in a
subpopulation of responsive cells. In the present study, highly
responsive cells were virtually absent in unprimed populations
but appeared in samples primed with LPS from both B. cepacia
and E. coli. The observed changes in forward and side scatter
for R2 neutrophils may simply reflect the activation of these
cells following FMLP stimulation. However, since respiratory
burst responses also increased among R1 neutrophils, and
since a considerable overlap in individual responses for neu¬
trophils in R1 and R2 populations was observed, it seems more
probable that LPS is associated with a significant phenotypic
change in R2 neutrophils prior to stimulation with FMLP. The
nature of such a phenotypic change remains unclear but could
involve changes in receptor expression. However, comparison
of histogram distributions of CDllb expression and FMLP-
induced intracellular H202 production indicated that the
highly responsive subpopulation of neutrophils could not be
identified on the basis of increased CR3 expression. FMLP
receptors were not measured in the present study; however,
previous investigators have found that both CR3 and FMLP
receptors are up-regulated on LPS-treated neutrophils in a
unimodal fashion, with no evidence of neutrophil subpopula-
tions (45), suggesting that increased receptor expression is not
the mechanism underlying the highly responsive phenotype.
The data presented here indicate that B. cepacia LPS may be
an important virulence determinant in the development of
inflammation in response to B. cepacia infection. The demon¬
stration of neutrophil-priming activity even in the absence of
plasma is particularly relevant to the CF lung, where concen¬
trations of plasma factors are likely to be low, due both to poor
diffusion into bronchiectatic airways and to the presence of
high concentrations of proteolytic enzymes (9). The necrotiz¬
ing pneumonitis and bacteremia which are characteristic of
cepacia syndrome are unique to B. cepacia infection and have
never been described in CF infection caused by P. aeruginosa.
The up-regulation of CR3 expression in neutrophils exposed to
B. cepacia LPS may be involved in the increased recruitment of
neutrophils to the lung. At the same time, B. cepacia LPS may
prime neutrophil responses to increase the release of tissue-
damaging enzymes and reactive oxygen species from activated
neutrophils. It is tempting to speculate that cepacia syndrome
develops whenever the burden of activated neutrophils within
the lung becomes too great for overstretched regulatory mech¬
anisms, increasing the rate of inflammatory damage and per¬
mitting the bacteremic spread of B. cepacia beyond the lung
parenchyma.
Environmental B. cepacia strains are currently being devel¬
oped as biological control agents, both in the control of fungal
plant pathogens and in the bioremediation of contaminated
landfill sites (3, 12, 20, 22, 27, 36). Identification of strains
which may represent a human hazard is therefore of para¬
mount importance if B. cepacia is to be released on a large
scale, particularly in agricultural programs. Recently, taxo-
nomic analyses have revealed that bacterial strains currently
identified as B. cepacia consist of at least four distinct species
or "genomovars" (16, 35). Although numbers were small, in¬
vestigation of a panel of CF, non-CF clinical, and non-CF
environmental isolates suggested that strains belonging to
genomovars II and III were associated with colonization and,
in some cases, transmissibility in CF, while strains belonging to
genomovar III were associated with severe disease and cepacia
syndrome in CF patients (16). By contrast, most environmental
isolates, including the B. cepacia phytopathogenic type strain
ATCC 25416, belonged to genomovar I, which is less common
in CF patients. A survey of Belgian CF patients identified
genomovars II, III, and IV among B. cepacia-co\onized pa¬
tients but no genomovar I isolates (35). Comparison of a geno¬
movar III strain (J2315) with two genomovar I strains (J2540
and J2552) in the present study has shown, however, the in¬
flammatory potential of LPS from strains of both genomovars.
Thus, the rarity of genomovar I isolates in CF may reflect the
poor colonizing ability of these strains rather than any intrinsic
lack of pathogenicity. As it is currently impossible to predict
the effect of increased exposure on the risk of a CF patient
acquiring a genomovar I strain, we believe that the use of
environmental B. cepacia strains in large-scale agricultural re¬
lease programs must be carefully reviewed and monitored.
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